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In  the  last  few  years  the  knowledge  about  liver  tumors  has  progressed  rapidly 
involving  many  fields  of  science  such  as  molecular  biology  and  genetics, 
pharmacology,  imaging  techniques,  invasive radiology and surgery, etc. That  is why 
the above Billroth’s sentence is becoming more actual than ever. 
The  overriding  goal  in  development  of  this  book  has  been  the  mobilization  of 
information  related  to  the  very  selected  key  topics  in  the  biology,  diagnosis  and 
management of  liver  tumors. Experts  from  clinics and  laboratories  from around  the 
world,  including  Europe,  North  America  and  Asia  shared  their  knowledge  and 
experience gained  in  the understanding and management of primary and metastatic 

















Molecular Genetics and  
Genomics of Hepatocellular Carcinoma 
Dilek Colak1 and Namik Kaya2 
1Department of Biostatistics, Epidemiology and Scientific Computing,  
King Faisal Specialist Hospital and Research Centre, Riyadh,  
2Department of Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh,  
Saudi Arabia  
1. Introduction 
Hepatocellular carcinoma (HCC) is a major type of liver cancer and third leading cause of 
cancer-related deaths worldwide. It is often diagnosed at an advanced stage, and hence 
typically has a poor prognosis. The advances in high-throughput “omics” technologies 
(genomics, transcriptomics, proteomics) parallel to the availability of high-density 
microarrays and next-generation sequencing technologies feature important advances in 
understanding of the complex biological processes underlying tumorigenesis and metastasis 
of HCC, and uncovering promising biomarkers with clinical potential.  Ultimately, the trend 
will be toward a personalized medicine that will improve diagnosis, treatment and 
prevention of primary liver cancer. In this chapter, we present an overview of most up-to-
date developments regarding these approaches toward an understanding of molecular 
mechanisms of HCC and for the development of novel biomarkers and cancer therapeutics 
targets. 
2. Background  
Hepatocellular carcinoma (HCC) is the most common primary cancer originating in the 
liver, the fifth most common cancer type, and is the third leading cause of cancer mortality 
worldwide [1-2]. It is often diagnosed at an advanced stage, leading to poor prognosis. 
Recent reports show that HCC is becoming more widespread and has dramatically 
increased in North America, Western Europe and Japan [2-4].  Early detection of HCC, 
especially detection of early/small HCC, followed by the appropriate treatment would 
significantly alter the prognosis and reduce the number of tumor-related deaths. Though 
inspiring progress has been made in understanding the molecular mechanisms of HCC, 
there is still lack of complete understanding of the disease perhaps due to complexities 
associated with the HCC such as intricacy of liver transcriptome, viral infection, liver 
regeneration, and other confounding factors, that have been major limitations for 
developing useful biomarkers for the detection and early diagnosis as well as identification 
of novel therapeutic targets for HCC. 
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The advances in high-throughput “omics” technologies such as genomics, 
transcriptomics, proteomics, and metabolomics combined with the availability of high-
density microarrays and low-cost high-throughput parallel sequencing technologies and 
their analyses using different bioinformatics tools and algorithms are providing 
unprecedented biological insights related to HCC. Global molecular profiling studies of 
HCC are providing a comprehensive view of genomic aberrations and expression changes 
that occur during the carcinogenic process. Hence, the knowledge gained from continuing 
research efforts on HCC undoubtedly facilitates the understanding of molecular 
mechanism of HCC pathogenesis, and to provide the best therapy for each cancer patient 
and to improve patient management. This approach will create a foundation for 
personalized therapeutics and treatments and expectantly will be available in the near 
future alongside the unprecedented advancement of next-generation sequencing 
technologies. These technologies already began to identify novel genes that may have a 
driver force for HCC pathobiology [5]. Identification of such driver genes within each 
tumor will highly likely be a source for the development of novel therapeutic targets for 
the malignancies for each HCC-affected individual.  
Our aim in this chapter is to focus on the current advances in the genomics field of HCC as 
well as recent progress using next-generation deep sequencing technologies, and the current 
shift towards integrative approaches using data from these advanced technologies that will 
help better understanding of HCC and for the development of novel biomarkers and cancer 
therapeutics targets. 
3. Genomic alterations in liver cancer  
Current advances in microarray technologies has resulted in high-dimensional genomic data 
sets and profoundly improved our understanding of genomic imbalances in the context of 
its role in carcinogenesis; first, with the introduction of copy number variation (CNV) 
concept in addition to single nucleotide polymorphisms (SNP), and second, with the 
improved mapping of such CNVs throughout the whole genome of patients versus normal 
individuals. While very early observations have identified CNVs as “chromosomal 
polymorphisms” that are several megabases in size, the lower end of the size range of CNVs 
continues to drop that is consistent with the pace of technological advancement [6]. With 
their inclusion of coding genes, it is hardly surprising that CNVs play a role in human 
health and disease, although their role is only recently being recognized, first in the context 
of Mendelian disorders and more recently in complex diseases [7-8]. The presence of these 
polymorphisms, either at small (SNPs or mutations) or large (CNVs and CNAs) scale as well 
as regions comprising loss of heterozygosity (LOH) blocks are, therefore, likely to contribute 
to cancer formation [9-11]. The genomic modifications in a tumor represents a structural 
fingerprint that may include the transcriptional control mechanisms and locally impact gene 
expression levels [10, 12].  
Initial array platforms utilizing either spotted clones inserted in bacterial artificial 
chromosomes (BACs) or in situ synthesized oligos on chip surfaces have been applied to 
HCC samples to better understand the role of genomic aberrations at the DNA level. These 
microarray-based assays are called array comparative genomic hybridization (aCGH) 
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technique since they are a modified version of the comparative genomic hybridization 
(CGH) approach applied to microarrays. Numerous studies have investigated chromosomal 
alterations associated with HCC using both CGH and aCGH techniques (as reviewed by 
Moinzadeh et al. [9]). Moreover, two leading microarray companies have developed similar 
assays containing only SNP probes. This approach was initiated by Affymetrix Inc. then 
later applied by Illumina Inc. Both companies have come up with different SNP assays 
comprising different numbers of unique SNP probe sets. While the aCGH approach 
provides much higher resolution over standard microscope-based banding techniques in 
terms of cytogenetics analysis, SNP arrays bring two main advantages over the other 
techniques including aCGH: LOH and uniparental disomy detection, and more diverse 
applications, such as utilization in association studies based on both SNP as well as CNV 
calls.  
Later, higher density arrays having hundreds of thousands or even currently more than a 
million unique probe sets targeting CNVs and SNPs have been employed in HCC research 
and identified critical regions of the genome likely to be involved in molecular 
carcinogenesis of HCC. Such critical regions commonly exhibit either deletion or increased 
gene dosage, leading to changes in DNA copy number variations/polymorphisms 
(CNVs/CNPs), aberrations/abnormalities (CNAs) or contain LOH blocks in various 
cancers, including HCC [9, 13-15].  
It is plausible that such HCC-specific CNVs and LOH blocks spanning from several 
kilobases to megabases comprise critical driver genes that may play a leading role in 
hepatocarcinogenesis and contain the genetic factors involved in HCC [14, 16-17]. In one of 
those early studies, Luo et al. utilized an integrated approach of DNA and RNA level 
analyses for HCC, and investigated overlapping genome-wide transcriptomic and genomic 
alterations among hepatocellular carcinomas (HCC), hepatoblastomas (HPBL), tissue 
adjacent to HCC and normal liver tissue derived from normal livers and hepatic resections 
[14]. In their study, genomic imbalances between 27 HCC samples and matching normal 
controls were determined using low density oligonucleotide arrays. The results indicated 
that several regions on chromosome 7, 8, 10 and 12 harbor numerous genomic aberrations. 
Further investigations revealed that many of these changes do not cause remarkable gene 
expression alterations. However, among other genes, two genes, GPC3 and TIEG, were 
found to have significant correlation between their copy numbers and expression changes. 
Further investigations of these two genes in a larger cohort (484 hepatic tissue and normal 
samples) confirmed the expression differences in HCC samples. Additional studies 
investigating the role of GPC3 expression in poorer clinical outcome revealed this gene may 
have a possible role on HCC aggressiveness and therefore may predict the HCC outcome 
[14].  
In a more recent study, Chen et al. employed Affymetrix’s 500K SNP arrays with an 
average of 6 kb distance between its unique SNP probes to examine 13 different HCC cell 
lines in addition to some other cancer cell lines as well as 45 archived primary HCCs [18]. 
Numerous common and novel aberrations were observed in multiple cancer lines 
confirming previously known HCC-related cytogenetic regions detected by low-
resolution methods and refining their breakpoints and boundaries, and also introducing 
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previously unknown critical genomic regions associated with HCC. Among 653 
amplicons and 57 homozygous deletions (HDs) detected by the arrays using different cell 
lines, 126 amplicons and 6 HDs were selected and tested to identify novel HCC-related 
genes.  Further analysis of such aberrant regions yielded two genes, FNDC3BB and 
SLC29A2, consistently up-regulated in multiple HCC data sets. Knock-down studies 
using short hairpin RNAs targeting both genes showed decreased cell proliferation, tumor 
formation, and anchorage-independent growth in xenograft models in nude mice 
confirmed a possible pivotal role of these genes in growth and tumor formation in subsets 
of HCC samples. Up-regulation of either gene is proposed to be activated through STAT3 
signaling pathway which is a well-known phenomenon in HCC progression usually 
triggered by cytokines such as interleukin-6 [19-22].  
In another study, Clifford et al. used Affymetrix SNP 6.0 assay comprising probes for 
detection of CNVs and SNPs, each has more than 900,000 unique oligos, totaling nearly 1.9 
million probe sets [23]. In their study, a large number of samples exceeding 1100 cases 
including histopathologically confirmed HCC and liver cirrhosis (LC) samples as well as 
normal controls with Korean and Chinese ethnicity were analyzed in two stages; each 
having different subsets of patients and controls. Based on their analysis, two SNPs were 
found to diverge significantly between HCC versus LC group and therefore considered a 
likely factor influencing transitional events from cirrhosis to hepatocellular carcinogenesis. 
Interestingly, the first SNP, rs2551677, is not within close proximity of any known gene, the 
closest gene DDX18 being 175 kb upstream of the SNP. The second SNP, rs2880301, is 
positioned on intron 1 of TPTE2 encoding a homolog of PTEN tumor suppressor gene and is 
the first time reported to be associated with carcinogenesis [23]. Additionally, three SNPs 
(rs9267673, rs2647073, and rs3997872) were found to be strongly associated with HCC only 
and were not presenting any additive/multiplicative effect. The first SNP, rs9267673, is in 
close proximity of C2 gene unlike the other two SNPs, rs2647073 and rs3997872, associated 
with SNPs falling into linkage disequilibrium of two different HLA group genes: The 
rs2647073 with HLA-DRB1, HLA-DRB6, HLA-DRB5, and HLA-DRA whereas the rs3997872 
with HLA-DQA1, HLA-DQB1, HLA-DQA2, and HLA-DQB2 loci. The associations were 
independently confirmed using TAGMAN assays indicating the validity of the SNP study. 
When they analyzed probes targeting copy number polymorphisms, eight CNV loci 
including six germline CNVs were identified to be significantly associated with liver 
carcinogenesis. One of the germline CNVs showing a high level of association with HCC is 
located on a small region on p arm of chromosome 1 where no gene is known. Five other 
CNVs found to be linked to HCC involving KNG1, C4orf29, LARP2, ALDH7A1, PHAX, 
C5orf48, LMNB1, SRPK2, PUS7, and TMPO genes. Among these CNVs, two involving TRG@ 
and TRA@ had the strongest association to HCC. Moreover, a functional pathway and 
network analyses carried out using 1000 most significant SNPs associated with HCC. 
Among the critical pathways “antigen processing and presentation” is found the most 
significantly overrepresented pathway with p-value of 1x10-11 indicating the strongest 
association to HCC. Overall, these observations indicate involvement of immune system in 
constitutional susceptibility to HCC and HCC carcinogenesis which was suggested by 
clinical observations and animals models previously.  
In a recent study, Jia et al. searched for critical somatic CNVs in 58 HCC tumor samples with 
adjacent non-tumor samples using Affymetrix 6.0 assay and identified 1241 regions [24]. 
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These regions were then interrogated in search of dysregulated genes and 362 differentially 
expressed genes were identified. Among these, 20 genes were further evaluated functionally 
and TRIM35, HEY1, and SNRPE were confirmed to be involved in HCC by various 
functional experiments. Involvement of these genes, TRIM35 as tumor suppressor, and 
HEY1 and SNRPE as potential oncogenes, in HCC is novel. 
4. Global gene expression profiling of liver cancer 
During the past two decades, discoveries on the global gene expression profiling 
technologies emerged one after the other. Subtractive hybridization, differential display, 
SAGE, microarrays and more recently next generation sequencing techniques appeared as 
cutting-edge tools to study genome-wide transcriptional profiling differences in nearly all 
different types of tissues. With the rapid advances in these technologies, the medicine, 
particularly cancer genomics, is evolving into numerous dimensions.  
The microarrays had a great impact from the way we look at the transcriptome and the way 
we understand the biology and complexity of it. Microarray expression technologies have 
allowed the simultaneous analysis of thousands of transcripts that cover nearly the entire 
genome [25]. Hence, gene expression microarrays, that are providing a comprehensive view 
of the transcriptional changes that occur during the carcinogenic process, have been applied 
with great success to the molecular profiling of HCC which has resulted in a much more 
detailed molecular classification scheme as well as in the identification of potential gene 
signature sets, molecular biomarkers, prediction of early recurrence and patient survival 
[26-29].   
Over the last decade, numerous studies have applied this technology, and identified a 
number of candidate genes useful as biomarkers in cancer staging, prediction of recurrence 
and prognosis, and treatment selection. Considering the complexity of the HCC 
carcinogenesis many genes may be involved in the initiation and progression of the cancer, 
and therefore a comprehensive expression analysis using microarray technology has great 
potential to discover new genes involved in carcinogenesis, as well as may highlight the 
functional modules and pathways altered in HCC. Indeed, some of the new target molecules 
that were identified using this technology have been used to develop new serum diagnostic 
markers and therapeutic targets against HCC to benefit patients. 
The first report of cDNA microarray analysis of hepatocellular carcinoma (HCC) by Lau et 
al. [30] studied the gene expression using about 4000 known human genes in 10 pairs of 
HCC and non-tumorous tissues. Since then numerous studies have been published to date 
in the context of genome-wide expression profiling of HCC liver. The microarray analyses of 
HCC highlighted activation of important pathways in liver carcinogenesis, such as wingless-
type (WNT), p53, transforming growth factor (TGF)-β, MAPK signalling pathways [31-34] as 
well as novel genes with altered expression, such as MARKL1, VANGL1, PEG10, BMAL2, 
HLA-DR, GPC3, and ROBO1.  
Over the past 10 years, the microarray-based gene expression profiling has been used to 
identify gene signatures associated with etiological factors, histological phenotypes, and 
clinical phenotypes, as well as unveiling novel subtypes of HCC previously unrecognized 
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by conventional methods [26, 35-36] . Most cases of HCC originate from chronic liver 
disease caused by hepatitis viral infection, including hepatitis B virus (HBV) and hepatitis 
C virus (HCV), exposure to aflatoxin B1 in mold, and alcohol abuse. In this context, gene 
signatures associated with different etiologies have also been reported [37-39].  
Microarray studies indicated that HBV and HCV viral infections lead to the development 
of liver cancer by different molecular mechanisms [32, 38-39].  Okabe et al. analyzed 
expression profiles of 20 primary HCCs by using cDNA microarrays consisting of 23,040 
genes, and compared HBV- with HCV-related HCC [32]. The authors identified a gene 
signature that is correlated with the infection status, and found that genes that are 
involved in drug metabolism and carcinogen detoxification were differentially regulated 
between HCV-based and HBV-based HCC. In another study, Iizuka et al. [38] performed 
genome-wide expression profiling 45 HCC (14 HBV- and 31-HCV-associated) and 
identified 83 genes whose expression significantly differed between the two types of 
HCCs.  The HBV-associated HCC showed significantly up-regulation of imprinted genes 
(H19 and IGF2) and genes related to signal transduction, transcription, and metastasis. On 
the other hand, HCV-associated HCC displayed up-regulation of genes related to 
detoxification and immune response. Delpuech et al. showed that HBV-associated HCC 
altered different cellular pathways, those controlling apoptosis, p53 signalling and G1/S 
transition, whereas the HCV-related HCC resulted in an over-expression of the TGF-beta 
induced gene [31]. 
Microarray gene expression profiling together with  prediction models have been used in 
numerous studies to identify gene signatures in tumor or surrounding non-tumorus tissues 
that can predict vascular invasion, metastasis, post-surgical recurrence, survival, and 
response to therapy. These signatures may aid in identifying patients most likely to benefit 
from surgery and chemotherapeutic treatment. 
Vascular invasion (VI) is an unfavorable prognostic factor for early HCC recurrence. There 
have been several microarray studies which identified gene signatures that correlated with 
VI. Ho et al. [40] identified 14 genes correlated with VI, which can classify patients with high 
or low risk of VI development and recurrence after curative hepatectomy. In another study, 
Budhu et al. reported a 17-gene signature expressed in noncancerous hepatic tissues with 
venous metastasis, capable of predicting recurrence after surgical hepatectomy, with 79% 
accuracy [41].  Similarly, Wang et al. identified a 57-gene signature to predict disease 
recurrence at diagnosis (84% sensitivity) [42].  
Using supervised machine learning methods on the gene expression data, Nam et al.  
identified 240 genes that classified samples into different histological grades, from low-
grade DNs to primary HCC [43].  Kim et al. reported 44 genes that can discriminate HBV-
positive HCC from non-tumor liver tissues [44].  Iizuka et al. [26] reported a gene signature 
of 12 genes that can predict HCC patients at high risk of early intra-hepatic recurrence (IHR) 
after curative surgery (93% sensitivity). Similarly, Kurokawa et al. [45] identified a 20-gene 
signature which could predict early IHR after curative resection. In another study, a 3-gene 
signature (HLA-DRA, DDX17, and LAPTM5) found to be predictor of recurrence after 
curative hepatectomy, which predicted early IHR with 81% accuracy in the validation group 
[46]. 
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after curative surgery (93% sensitivity). Similarly, Kurokawa et al. [45] identified a 20-gene 
signature which could predict early IHR after curative resection. In another study, a 3-gene 
signature (HLA-DRA, DDX17, and LAPTM5) found to be predictor of recurrence after 
curative hepatectomy, which predicted early IHR with 81% accuracy in the validation group 
[46]. 
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Researchers also used microarrays to identify gene signatures as predictors of survival after 
surgical resection. Lee et al. analyzed the gene expression profile of 91 HCC samples using 
unsupervised classification approach which divided the patients into two subclasses with 
significant differences in survival [29].  The authors also identified genes that accurately 
predicted the length of survival. Functional analyses indicated that genes related to cell 
proliferation, anti-apoptosis, and cell cycle regulators were found to be predictor of poor 
prognosis.  Other microarray studies reported c-Met- and TGF-beta regulated genes that are 
highly associated with the length of survival [47-48].  
HCC is a challenging malignancy; most cases of HCC are diagnosed in an advanced stage, 
and, therefore, treatment options are limited. Hence, it is important to diagnose it at early 
stage. DNA microarray studies attempted to identify markers for early HCC [27, 49]. 
Recently considerable attention has been placed on global gene expression studies as well as 
genomic aberrations in order to understand the pathogenesis of HCC, and to look for 
possible early markers of detection [14, 16-17, 28, 34, 49-51].  Furthermore, combining cross-
species comparative and/or functional genomics approaches from human and animal 
models of HCC along with genomic DNA copy number alterations enhances the ability to 
identify robust predictive markers for HCC [13, 36, 52-54]. Thus, characterization of diverse 
HCC subgroups using the array technologies  together with improved analytical approaches 
are crucial for better management of the disease, especially in the era of personalized 
medicine approach in HCC treatment. 
5. Global miRNA expression profiling of HCC  
One of the most important findings of the analysis on the human genome is identification of 
a significant number of sequences encoding non-coding RNA molecules such as small 
nucleolar RNAs and microRNAs also known as miRNAs [55-56]. MicroRNAs, single-
stranded RNAs typically 21-23 nucleotide long, are untranslated molecules that have 
capability to bind complementary sequences resulting in their silence, therefore, regulating 
the expression of their target genes. Some of these molecules have currently been intensely 
studied and their biogenesis, structure and function are now known and some other small 
regulatory RNAs are yet to be discovered. Among these different RNAs species, miRNAs 
holds special attention due to its properties and potential use as therapeutic targets for 
cancer. Currently around 6000 miRNAs from multiple species have been annotated in 
different databases. These miRNAs target and regulate around 30% of all protein coding 
genes in mammals. It has been shown that the miRNAs regulate processes essential to 
differentiation, apoptosis, cell growth, adhesion, and cell death [57-58]. Recently, due to its 
oncogenic and tumor suppression activities, these molecules exploited for various cancers, 
including HCC [59-63].  
The genomic instability, transcriptional regulation, and epigenetic alteration have been 
identified to contribute to the abnormal expression of miRNAs in HCC. Furthermore, the 
aberrant expression of certain miRNAs is correlated with clinical features of HCC, 
indicating their potential to serve as diagnostic and prognostic biomarkers of HCC [64-65].  
Some aberrantly expressed miRNAs may have a direct role in liver tumorigenesis, and 
could promote differentiation, cell cycle progression, angiogenesis and invasion, such as 
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mir-221 and mir-21 [59]. Murakami et al. identified eight miRNAs with altered expression in 
HCC, which discriminated HCC samples from non-tumor with 97.8% accuracy [66].  
Similarly, Huang et al. identified 24 abberrantly expressed miRNAs [67].  Toffanin	 et	 al.	
studied	 miRNA	 profiling	 of	 HCC	 samples	 that	 was	 previously	 profiled	 for	 mRNA	 and	 copy	
number	 (CN)	 changes	 [65].	 The	 authors	 identified	 three	 subclasses	 of	 HCC	 based	 on	miRNA	
profiles.	The other studies identified miRNA signatures that predicted metastasis potential, 
recurrence and survival [64, 68-69]. Since the miRNAs are stable in blood, more recently, the 
circulating miRNAs have been reported as diagnostic markers for various cancers, including 
the HCC [70-72].Therefore, identification of miRNAs and their protein-coding target genes 
is important to understand the mechanisms of hepatocarcinogenesis, and reveals new 
biomarkers for diagnosis, prognosis and therapeutic targets. 
6. Deep sequencing of HCC using next-generation sequencing technologies 
Current advances in genomics technologies have been first seen as revolution of 
microarrays and then recently appeared as high-throughput parallel sequencing 
techniques. The resolute advance of fluorescence-based standard Sanger technique 
seemingly stretched to its limits for technical enhancements. At the same time soaring 
demand for low-cost and high-output sequencing has driven the development of superior 
technologies that allow massively parallel sequencing processes, producing millions and 
billions of sequences at once [73-74]. Therefore, it was inevitable to see the replacement of 
standard sequencing methods to newly emerging advanced sequencing technologies 
called next generation sequencing technologies. These technologies initially appeared as 
relatively high-cost difficult techniques for practical use and believed to be useful for only 
whole genome sequencing of different species. But soon these perceptions were evaded 
radically.  Today, the state of DNA sequencing technologies is in a greater flux than ever 
before. With this foreseeable evolution, comes new possibilities not only in the field of 
large-scale genomic sciences from medicine to agriculture and plant sciences coupled with 
new challenges in data storage and analysis, but also for practical use such as clinical 
utilization for routine diagnostics[74-78]. Currently, several methods are already 
established, made significant impact on the field of genomics by having reputable track 
record for many different published applications and some are in the process of building 
confidence, some are yet to be tested and perfected[78-84].  
The first study of HCC using the next-generation sequencing technology for deep 
sequencing appeared most recently [5]. Using Illumina’s Genome Analyzer IIx system, also 
called GAIIx, Totoki et al. sequenced genomic libraries from a normal Japanese male and 
hepatitis C-positive HCC sample.  Both samples’ sequence reads had an almost complete 
match to a human reference sequence covering 99.79% and 99.69% for lymphocyte (normal 
male) and HCC sample genomes, respectively. Nearly ~3 million nucleotide variations were 
recorded from each genome, yielding 84,555 bases more variations in lymphocyte genome 
perhaps due to presence of chromosomal alterations in tumor genome and 11,731 of these 
changes in HCC were somatically acquired. There were several interesting results related to 
nucleotide changes in the study. First, it was found that occurrence of somatic substitutions 
was varied between genic and intergenic regions, significantly lower in the genic regions 
(consisting of coding and noncoding exons, and introns) in comparison to its counterpart 
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intergenic regions. This was explained either by negative selection of lethal mutations in the 
genic regions or by the existence of specific molecules responsible for the repair of 
transcribed region.  Second, presence of germline variations was significantly lesser in the 
coding regions relative to the non-coding regions. Third, the ratio of nonsynonymous to 
synonymous variations (N/NS) either somatic or germline origins differed in HCC and was 
significantly lower than that of somatically originated substitutions. To explain this, authors 
highlighted the influence of positive selections happening in exons causing survival of 
tumor cells or favored negative selection of somatic variations over germline substitutions 
on the coding exons. Fourth, the preferred somatic substitutions included T>C/A>G and 
C>T/G>A transitions. Fifth, in addition to 81 confirmed somatic substitutions common to 
both genomes (all in protein coding regions), 670 small deletions and insertions were 
identified and seven of which were validated. Among these variations, some of the changes 
seemed more critical  since they were located on the previously annotated tumor suppressor 
genes for HCC and other cancer types. Moreover, authors decided to resequence exons 
potentially harboring malignant changes in 96 HCC and control samples as well as 21 HCC 
cell lines. These efforts yielded two critical somatic mutations p.Phe190Leu and p.Gln212X 
in LRRC30.  
Besides the nucleotide changes, small deletions and insertions, 22 verified chromosomal 
rearrangements were identified. These rearrangements were mostly intra-chromosomal and in 
close proximity with some known copy number regions. These chromosomal rearrangements 
led four different fusion transcripts that involve transcriptional regulation of BCORL1-ELF4 
[5]. Then using the deep whole exome sequencing approach (76X or more coverage) a 
nonsense mutation in TSC1 gene was also identified in a subset of tumor cells.  
As demonstrated in this study, further next-generation sequencing studies have the 
potential to reveal novel genes/mutations and likely critical pathways that can be utilized 
for the biomarker discovery and identification of novel therapeutic targets for HCC. Besides, 
the next-generation technologies have already been proven to be useful for genomic studies 
on some cancers [85-94]. Moreover, once affordable prices are reached, such next generation 
sequencing techniques will create an amazing opportunity to look for genome-wide DNA 
and/or RNA level differences and methylation patterns in many cancer types at an 
affordable cost and will open doors for daily diagnostics and personalized medicine [86] 
[95-96]. 
7. Animal models and comparative genomics of HCC  
Developing animal models of HCC provide an experimental ground for dissecting the 
genetic and biological complexities of human cancer and contribute to our ability to 
identify and characterize pathogenic modifications relevant to various stages of cancer 
development and progression. [97-98]. Several models of constitutive, conditional and 
inducible models of HCC were developed inducing genetic manipulations and 
investigating the genetic changes. The results usually are comparable to that found in 
humans [99]. Each model appears to have its own advantages and disadvantages [100]. 
Recent studies, including our own, demonstrated the usefulness of modeling human 
cancer in diethylnitrosamine (DEN)-induced in rats [54] as well as in genetically 
engineered mice [97, 101]. 
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The recent studies have used cross-species comparative genomics approach, that identifies 
genes that are conserved in animal models of cancer and in human cancer, that would facilitate 
the identification of critical regulatory modules conserved across species in the expression 
profiles and to understand the molecular pathogenesis of various cancers, including HCC [36, 
54, 101-103]. The cross-species comparative analysis of animal models and human HCCs 
would provide new therapeutic strategies to maximize the efficiency of treatments.   
8. Integrative and comparative analyses of HCC for identification of novel 
therapeutic targets and biomarker discovery 
It has been shown that CNAs have clear impact on expression levels in a variety of tumors 
[9, 13, 15]. The presence of such CNAs and LOH may contribute to cancer formation [9-11]. 
Integrating the gene expression with the CNA data reveals the chromosomal regions with 
concordantly altered genomic and transcriptional status in tumors [12, 52, 104]. The pattern 
of genomic modifications in a tumor represents a structural fingerprint that may include the 
transcriptional control mechanisms and locally impact gene expression levels [10, 12]. 
Therefore, focusing on differentially-expressed genes with concomitant altered DNA copy 
number may identify novel early HCC markers of malignant transformation, progression 
and survival [17]. 
The studies using integrative analysis of genomic aberrations with the expression profiling 
demonstrated the usefulness of this approach to identify the likely drivers of cancer [105] 
and helped better understand the processes affected by the drivers/passenger factors and 
led to obtain novel insights into pathobiology of HCC [17, 54, 105].  
In this context, we performed cross-species and integrative genomic analysis to identify 
potential biomarker genes for early HCC [54]. In this study, we first developed a rat model 
of early HCC as well as liver regeneration post-hepatectomy and compared them to normal 
liver using a microarray approach. We then performed a cross-species comparative analysis 
coupled with CNAs of early human HCCs to identify the critical regulatory modules 
conserved across species. We identified 35 gene signature conserved across species, with 
more than 50% mapping to human CNA regions associated with HCC [54]. Combining 
cross-species comparative and/or functional genomics approaches from human and animal 
models of HCC along with genomic DNA copy number alterations enhances the ability to 
identify robust predictive markers for HCC [13, 36, 52-54]. 
9. Future directions 
Elucidating the molecular pathogenesis of HCC on human samples has been an onerous 
task due to certain limitations such as varying etiologies among studied patients, changes 
likely to arise during the different stages of the disease or progression of HCC, and 
heterogeneity of the disease. Moreover, the success of studies is hampered by the fact that 
hepatic transcriptome is among the most complex of any organ, and the study of tumor 
formation in liver can be thorny and complicated by the continuous change of the 
transcriptome during liver regeneration after hepatectomy. Besides, cancer progresses 
through a series of histopathological stages during which genetic alterations accumulate 
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and, in consequence, the pattern of genetic expression changes complicates the 
interpretation of the genetic changes in human HCC. These limitations have hampered 
development of proper therapeutics that was further complicated by recurrences even after 
aggressive local therapies.  
The advances in high-throughput “omics” and next-generation sequencing technologies 
have been providing unprecedented biological insights related to pathogenesis of HCC. 
Undoubtedly, comparative and integrative genomics approaches are promising to lead to 
novel and robust biomarkers for improved diagnosis, prognosis, and treatment of HCC. The 
systems approach via the integration of data reflecting alterations at genomic, 
transcriptomic, proteomic, and epigenomics levels will ultimately converge toward a 
personalized medicine that will improve diagnosis, treatment and prevention of liver 
cancer.  
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Genes that affect a person's chance of developing hepatocellular carcinoma (HCC), as 
BRCA1 and BRCA2 affect a person's chance of developing breast or ovarian cancer, have 
been difficult to detect. The vast majority of liver cancers can be attributed to Hepatitis B or 
C virus infection, aflatoxin exposure, or alcoholic cirrhosis, alone or in combination 
(Montalto et al., 2002). This high background of predisposing environmental factors makes 
identifying less penetrant genetic contributors more difficult. Familial patterns of 
susceptibility to liver cancer independent of environmental factors have helped identify a 
few monogenic metabolic syndromes (e.g., hemochromatosis; Dragani, 2010). However, the 
analysis of liver tumors points to a variety of other genes that affect liver tumor 
development. The patterns of chromosome gain and loss in liver cancers worldwide reveal 
several regions that are gained or lost in up to 86% of tumors, including  gains of 1q, 6p, 8q, 
and 20q, and losses of 1p, 4q, 6q, 8p, 13q, 16q, and 17p (Lau and Guan, 2005; Chochi et al., 
2009; Zhang et al., 2010). Chromosome analyses combined with genome-wide association 
studies have revealed candidate HCC modifier genes for some of these regions, such as 
PAPSS1 on chromosome 4q and HCAP1 on chromosome 17p (Wan et al., 2004; Shih et al., 
2009).  
Mice present an independent model of liver carcinogenesis for which external variables such 
as chemical exposure can be controlled and the genetics is manipulable. Different inbred 
strains of mice develop cancers at different frequencies. Because these differences are 
genetic, and the mice are homozygous due to inbreeding, causative genes can be identified 
through positional cloning.  
Inbred mouse strains differ dramatically in their susceptibility to both spontaneous and 
carcinogen-induced HCC. Females of the C57BR/cdJ strain, for example, develop up to 50-
fold more tumors after a single injection of N,N-diethylnitrosamine (DEN) than females of 
the related, relatively resistant C57BL/6J (B6) strain. We have recently mapped the 
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predominant locus responsible for this difference to a 6 Mb region on Chromosome 17 
(Peychal et al., 2009). This region corresponds to part of the chromosome 6p region 
amplified in the majority of late-stage HCC (Santos et al., 2007; Chochi et al., 2009). 
The C3H/HeJ strain (C3H), highly susceptible to both spontaneous and carcinogen-induced 
HCC, develops up to 50-fold more liver tumors than the B6 strain after a single carcinogen 
treatment (Drinkwater and Ginsler, 1986). We previously reported mapping the 
predominant locus responsible for this susceptibility, Hcs7, to distal Chromosome 1 (Bilger 
et al., 2004). This chromosomal region corresponds in part to the 1q21-24 chromosomal 
region amplified in up to 86% of human liver cancers (Lau and Guan, 2005; Chochi et al., 
2009; Zhang et al., 2010). C3H alleles on mouse Chromosome 1 confer a dominant 15-fold 
increased susceptibility to male mice and a semi-dominant 5-fold increased susceptibility to 
female mice carrying C3H alleles (Bilger et al., 2004). 
Here we analyze the effect of C3H Chromosome 1 alleles on spontaneous hepato-
carcinogenesis, on apoptosis and mitosis after DEN treatment, and on preneoplastic lesion 
growth. We have mapped the Hcs7 modifier to a 3.3 Mb region and used expression and 
CGH arrays to identify the Ifi202b gene as a strong candidate for this locus. 
2. Materials and methods 
2.1 Mice 
B6 and C3H mice were purchased from the Jackson Laboratory (Bar Harbor, Maine) and 
bred in our facilities. All mice were housed in plastic cages on corncob bedding (Bed 
O’Cobs, Anderson Cob Division, Maumee, OH), fed Purina 5020 diet (9% fat; St. Louis, MO), 
and given acidified tap water ad libitum. Mice were inspected daily and weighed monthly. 
Lines derived from the B6.C3H-Ch1 recombinant strain (Bilger et al., 2004) were generated 
as follows. B6 females were mated with B6.C3H-Ch1 males heterozygous for the congenic 
region. Markers between D1Mit285 and D1MIT17 were used to identify recombinants, and 
breakpoints were mapped more finely with additional markers. Males and females from a 
given recombinant line were then intercrossed to generate homozygotes. Heterozygous or 
homozygous mice were mated with B6 to generate heterozygous experimental progeny 
(Figures 1 and 3, and Table 3) or homozygotes were intercrossed to generate homozygous 
experimental progeny (Tables 1 and 2). Tested parental B6.C3H-Ch1 were homozygous. 
Lines derived from B6.BR-Ch1 were generated by mating B6 females with B6.BR-Ch1 males 
heterozygous for the congenic region. The markers D1Mit143, D1Mit17,  and two additional 
microsatellite markers at 172.9 and 176.9 Mb were used to identify recombinants. (The lack 
of SNPs or SSLPs between B6 and BR in this region prevented refinement of these 
breakpoints.)  Heterozygotes were intercrossed to generate homozygous lines. B6 females 
were then crossed with homozygous congenic males to generate experimental progeny.  
The C3H.B6-Ch1 line carrying B6 alleles for distal Chromosome 1 on a C3H genetic 
background was generated by crossing C3B6F1 (N1) mice with C3H mice and selecting 
C3H.B6 N2 mice carrying B6 alleles at D1Mit143, D1Mit15, D1Mit166, and D1Mit461. 
Backcrossing to C3H and selection of these B6 alleles was continued for eight additional 
generations to generate C3.B6(D1Mit143-D1Mit461)N10, or "C3H.B6-Ch1" (Figure 3) mice. 
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2.2 Genotyping 
DNA was prepared from spleen tissue by Proteinase K treatment/ammonium 
acetate/isopropyl alcohol precipitation as described (Bilger et al., 2004) or from spleen, tail, 
or toe tissue by alkaline lysis (modified from Truett et al., 2000). Approximately 2 mm3 of 
spleen or 10 mm3 of tail or toe tissue was incubated in 200 µl lysis solution (25 mM NaOH, 
0.2 mM EDTA) at 95°C for 20-60 minutes and then neutralized by the addition of 200 µl 40 
mM Tris (pH 8.0). After agitation for approximately 30 seconds and centrifugation for five 
minutes at 13.5 krpm, 0.25 to 2 µl of the supernatant was used directly for genotyping as 
described (Bilger et al., 2004). 
2.3 Tumor and preneoplastic lesion induction and assessment 
Tumors were induced by a single intraperitoneal injection of DEN (Eastman Kodak Co., 
Rochester NY; 0.1 mol/g body weight) dissolved in tricaprylin (a.k.a. trioctanoin; Sigma, 
St. Louis, MO) 12 ± 1 days after birth. Mice, all male, were sacrificed by CO2 asphyxiation. 
For prenoplastic lesion volume analysis, mice were sacrificed at 16 or 24 weeks of age (Table 
2) and representative sections of the liver were frozen immediately on dry ice and stained 
for glucose-6-phosphatase activity as described (Bugni et al., 2001). Glucose-6-phosphatase 
deficiency is a hallmark of the majority of preneoplastic lesions in DEN-treated mice (Bugni 
et al., 2001). For tumor analysis, mice were sacrificed at 32 weeks of age (Figure 1, Figure 3). 
Livers were removed and weighed, and all tumors larger than 1 mm in diameter were 
counted. Liver tumors were sampled at random, fixed in RNAlater (Qiagen, Valencia, CA) 
at 4°C, then drained of RNAlater and transferred to -80°C. Spleens were collected as a 
source of DNA and frozen on dry ice. All tumors were scored by a single observer blind to 
genotype. To assess spontaneous tumors (Table 1), mice were allowed to age to 15 months 
without undergoing any procedures. Tumors larger than 1 mm in diameter were counted. 
To assess apoptosis, mitosis, and RNA expression immediately following DEN injection, 
male mice were either left untreated or injected with DEN (0.1 mol/g body weight), at 12 
days of age between 11 a.m. and 3 p.m..  Mice were sacrificed one, two, or three days later 
between 3 and 6 p.m.. One half of each left lobe and half of each half of the medial lobe were 
placed in formalin at 4°C. Half of the remaining parts of the left and medial lobes were 
placed in RNAlater at 4°C. The remaining portions of the left and medial lobes were frozen 
in pre-chilled tubes on dry ice and transferred to -80°C. 
Formalin-fixed tissue was sectioned and stained with hematoxylin and eosin (H&E). 
Hepatocytes, apoptoses, and mitoses were counted under 600× magnification.  
2.4 Microarray analysis of gene expression   
RNA was purified from 20-70 mg liver or liver tumor tissue  fixed in RNAlater using an 
RNeasy MIDI kit (Qiagen, Valencia, CA) as directed, except 50% ethanol, rather than 70% 
ethanol, was added to the homogenized lysate. Fluorescently labeled cDNAs were 
generated using Agilent Quick-Amp Labeling kits and hybridized in competition with a 
mixed-sex, whole-tissue liver cDNA control to Agilent Whole Mouse Genome arrays (Item 
#G4122F, Agilent, Santa Clara, CA). Arrays were scanned using an Agilent DNA Microarray 
Scanner G2505C.  
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2.5 Comparative genomic hybridization 
Genomic DNA from male spleens was prepared using a standard Proteinase K/ammonium 
acetate/isopropyl alcohol precipitation protocol as described (Bilger et al., 2004), except 
DNA was treated with RNase A, which was then precipitated with ammonium acetate 
before the final DNA precipitation. Genomic DNA of either line 1R5 or inbred C3H mice 
was then labeled and mixed with control genomic B6 DNA, for dual-color CGH, and 
hybridized to the MM 8_WG_CGH_1of8 chip. This array has 50-75 nucleotide probes spaced 
at an average of 650 bp, covering all of Chr 1 and Chr 2 through position 123959568. Results 
were analyzed by Nimblegen CGH Services, using the CGH-segMNT algorithm (Roche 
Nimblegen, Madison, WI). 
2.6 Statistical analysis 
The significance of differences between tumor multiplicity data sets was determined by the 
Wilcoxon rank-sum test, using Mstat software (version 5.4, McArdle Laboratory for Cancer 
Research; URL, http://www.mcardle.wisc.edu/mstat). All P-values were calculated on the 
basis of a two-sided test, except in the case of spontaneous tumorigenesis, for which we 
were testing the one-sided hypothesis that C3H alleles that increase DEN-induced tumor 
multiplicity also increase spontaneous tumor multiplicity. Differences between RNA 
expression data sets were evaluated with the limma software package (Smyth, 2004), using a 
moderated t-statistic followed by FDR correction.  
3. Results 
3.1 A dominant modifier on Chr 1, Hcs7, maps to a 3.3 Mb region between 175.35 and 
178.64 Mb 
To map the Chromosome 1 modifier to a smaller region, we crossed B6 mice with B6.C3H-
Ch1 congenic mice carrying Hcs7 susceptibility alleles on Chromosome 1. Mice that had 
undergone recombination in the susceptibility region were selected and then bred again 
with B6 mice to generate heterozygous progeny cohorts for phenotyping. Male progeny 
were injected with DEN at 12 days and sacrificed at 32 weeks of age. The median number of 
tumors developed by males of each recombinant line is shown in Figure 1, below.  
Most of the susceptibility conferred by Hcs7 can be mapped to the distal end of the 
chromosome. Lines carrying C3H alleles only distal of D1Mit143 at 165 Mb developed 5- to 
12-fold more tumors than B6 (line 1R28:  P < 10-7; line 1R33:  P < 10-6; line 1R42:  P < 10-5). For 
lines 1R28 and 1R33, the number of tumors developed was not significantly different from 
the number developed by the homozygous B6.C3H-Ch1 parental congenic line (1R28:   
P > 0.30; line 1R33:  P > 0.11).  
Six of the seven recombinant lines that carry C3H from D1Mit15 at 170 Mb to D1Mit17 at  
191 Mb near the telomere were highly susceptible. These six lines developed an average of 
eight times as many tumors as B6. The exception, line 1R5, carries this susceptibility region 
but was resistant (1R5 vs B6:  P > 0.35). Comparative genomic hybridization revealed a 
potential explanation. In the distal susceptibility region, line 1R5 differs from C3H at the  
5' end of the Ifi202b gene (Figure 2). While line 1R5 and C3H both carry polymorphisms that 
suggest duplication of part of this region relative to B6, line 1R5 also carries polymorphisms 
that reduce hybridization to the CGH probes relative to B6 and C3H. This effect could be 
due to deletion, rearrangement, or novel sequences. 
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Fig. 1. C3H liver cancer susceptibility alleles map to distal Chromosome 1.  
Male mice carrying C3H alleles on Chromosome 1 on a B6 genetic background were injected 
with DEN and liver tumors were counted at 32 weeks. The line designated B6.C31 refers to 
B6.C3H-Ch1. Regions inherited from B6 are shown in white; C3H regions are shown in 
black. Regions carrying a breakpoint between B6 and C3H alleles are shown in grey. The 
median tumor multiplicity and number of mice tested are shown to the right of each line. 
Lines that were significantly more susceptible than B6 are marked with a "+."  The positions 
of markers along Chromosome 1 are shown as tics below the position axis at the top of the 
figure. 
Two additional lines, derived from the susceptible 1R14 and 1R33 lines during the breeding 
of experimental progeny, suggested that Hcs7 lies in a 6.4 Mb region carrying Ifi202b. 
Although few mice were phenotyped (five per line), the results for each line were 
significant. Line 33a, like its parent, was significantly more susceptible than B6 (P < 10-3) and 
not significantly different from B6.C3H-Ch1 (P > 0.55). The distal breakpoint for line 1R33a 
is proximal of 179.3 Mb, suggesting that the minimal susceptibility region lies proximal of 
179.3 Mb. Line 1R14a, unlike its parental line 1R14, was resistant to hepatocarcinogenesis. 
The difference between the lines is the distal breakpoint between 172.9 and 173.0 Mb in line 
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1R14a, suggesting that the minimal susceptibility region is distal of 172.9 Mb. Together, the 














Fig. 2. The homozygous line 1R5 genome differs from C3H at Ifi202b.  
Genomic DNA of either line 1R5 or inbred C3H was labeled and mixed with control 
genomic B6 DNA before hybridization to a chip carrying Chromosome 1 probes spaced  
650 bp apart. The log2 ratio of the mean of the intensity of the 1R5 or C3H signal (Test) 
relative to B6 is plotted. C3H is shown as a dashed grey line; the 1R5 recombinant is shown 
as a solid black line. 
Several other congenic lines that lacked the distal susceptibility region were significantly 
more susceptible than B6, developing three- to four-fold more tumors by 32 weeks (lines 
marked with plus signs, Figure 1; P < 10-3 for all). These lines and the closely related 
congenic lines that are as resistant as B6 reveal a complex pattern of possibly interacting 
modifiers along proximal Chromosome 1. Resistant line 1R50, for example, carries more 
C3H than sensitive line 1R12, but it carries less C3H than sensitive line 1R54 (1R50 vs B6:  
P > 0.06; vs R12: p < 10-2; vs 1R54:  p < 0.02). Similarly, the C3H region carried by resistant 
line 1R7 extends farther distally than the C3H region carried by sensitive line 1R43. 
However, the resistance of line 1R7 might be explained by a unique B6 genotype at the 
proximal end of Chromosome 1 (proximal of 74 Mb).  
To localize the distal Chromosome 1 liver cancer modifier further, we bred line 1R33 with B6 
and selected males with breakpoints in or near the region between 172.9 and 179.3 Mb 
(Figure 3). These mice were bred with B6 females to generate experimental progeny that 
were injected with DEN at 12 days; tumors were counted at 32 weeks.  
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Fig. 3. C3H liver cancer susceptibility alleles map to a 3.3 Mb region between 175.35 and 
178.64 Mb.  
Male mice were injected with DEN and liver tumors were counted at 32 weeks. "B6" and 
"C3" mice were inbred; lines beginning with a "1" or "2" were B6.C3 congenic mice carrying 
C3H Chromosome 1 alleles on a B6 genetic background; "B6.BR." lines carry BR Chromo-
some 1 alleles on a B6 genetic background; and the C3H.B6-Ch1 (C3.B6-Ch1) line carries B6 
Chromosome 1 alleles on a C3H background. Regions inherited from B6 are shown in white; 
C3H and BR regions are shown in black. Regions carrying a breakpoint between B6 and 
C3H alleles, or between B6 and BR alleles, are shown in grey. The median tumor 
multiplicity and number of mice tested are shown to the right of each line. Lines that were 
significantly more susceptible than B6 are marked with a "+."  The positions of markers 
along Chromosome 1 are shown as tics below the position axis at the top of the figure. 
Mice from line 2R16, which carries the smallest susceptibility region, developed 7-fold more 
tumors than B6 (P < 10-5; Figure 3). This line carries C3H from 172.9 to 178.64 Mb, 
confirming and narrowing the location of the distal modifier. Line 2R16 was derived from 
line 2R3, which carries an additional ~14 Mb of C3H alleles distal of 178.64 Mb. Like 2R16, 
2R3 was highly susceptible, developing 10-fold more tumors than B6 (line 2R3 vs. 2R16:  
P > 0.12; vs. B6:  P < 10-8). Line 2R8 has a larger congenic region than 2R16, extending up to 
7.5 Mb farther proximally and ~ 700kb farther distally. This line was also highly susceptible, 
developing more than 8-fold more tumors than B6 (P < 10-5). Together with the parental line 
1R33 (again highly significantly different from B6), these lines establish that the Hcs7 locus 
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confers a 7- to 10-fold increase in tumor multiplicity and lies between 172.9 and 178.64 Mb. 
This region carries 132 genes (www.ensembl.org; 8/2011). Line 2R7, which extends distally 
from 175.35 Mb, was also highly susceptible relative to B6, developing almost 9-fold more 
tumors (P < 10-5). In addition, line 2R7 is approximately 3-fold more susceptible than line 
2R5, which carries C3H alleles distal of 178.9 Mb (P < 0.02). Together with the 2R16 results 
that place Hcs7 between 172.9 and 178.64 Mb, these data suggest that Hcs7 lies in the 3.3 Mb 
between 175.35 and 178.64 Mb. This region carries 44 genes (www.ensembl.org; 8/2011). 
Again, the remaining lines suggest that the pattern of modifiers along the chromosome is 
complex. Lines 2R9 and 2R7 both carry C3H alleles to near the telomere and line 2R9 carries 
more C3H alleles than 2R7 proximally (their breakpoints differ by about 100 Kb), but line 
2R9 is resistant (2R9 vs B6:  P > 0.24). Similarly, the resistance of line 2R11 (2R11 vs. B6:   
P > 0.09), which, like line 2R9, was derived from sensitive line 2R3, together with the 
susceptibility of lines 2R2, 2R10, 2R15, 2R7, and 2R5, suggests there are additional modifiers 
both proximal to and distal of the 175.4 to 178.64 Mb minimal region. Alternatively, some 
lines may have undergone rearrangement in the susceptibility region.  
Recombination between B6 and C3H was suppressed in the minimal susceptibility region, 
between 175.4 and 178.4 Mb. No recombinants were observed among approximately 1350 
segregating progeny, although 24 would be expected. This difference is highly significant  
(P < 10-6). Recombination is frequently suppressed by chromosomal rearrangements such as 
inversions (Kirkpatrick, 2010). 
3.2 B6 alleles on distal Chr 1 are sufficient to suppress hepatocarcinogenesis on a 
C3H background 
To determine whether B6 Chromosome 1 alleles can confer resistance to a sensitive C3H 
background (as C3H alleles confer sensitivity to a resistant B6 background), we generated 
C3H.B6-Ch1 congenics using ten generations of backcrossing B6 to C3H, selecting B6 alleles 
on distal Chromosome 1 at each generation. Heterozygous and homozygous congenic males 
and control inbred C3H males were injected with DEN at 12 days of age and their tumors 
were counted at 32 weeks (Figure 3). While heterozygosity for B6 alleles had no effect on 
tumorigenesis (P>0.84), homozygosity caused a 3.8-fold reduction in tumor multiplicity 
(P<10-3). 
3.3 C57BR/cdJ alleles between 175.35 and 178.64 Mb do not confer susceptibility 
We have shown previously that distal Chromosome 1 carries a modifier that causes 5- to  
6-fold increased susceptibility in male C57BR/cdJ (BR) mice relative to B6 mice (Poole and 
Drinkwater, 1996; Bilger et al., 2004). To determine whether this Hcif2 (formerly Hcf2) 
modifier might involve the same locus that confers susceptibility to C3H, we used 
B6.BR-Ch1 congenic mice to derive mice carrying smaller congenic regions and counted 
their tumors at 32 weeks (Figure 3). The line carrying the largest BR region, B6.BR.R4, 
developed fewer tumors than B6 (though not significantly; P > 0.37). Similarly, lines 
B6.BR.R5A and B6.BR.R5B, which carry part of the minimal region and extend distally 
beyond 191 Mb (R5A) or proximally beyond 165 Mb (R5B), also developed the same number 
of tumors as B6 or fewer (P > 0.86 and P > 0.68, respectively). All three recombinant lines 
developed significantly fewer tumors than the parental B6.BR-Ch1 line (not shown; P < 0.03 
for all). These results indicate that Hcif2 is unlikely to lie in the 175.35 to 178.64 Hcs7 region. 
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lines may have undergone rearrangement in the susceptibility region.  
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segregating progeny, although 24 would be expected. This difference is highly significant  
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inversions (Kirkpatrick, 2010). 
3.2 B6 alleles on distal Chr 1 are sufficient to suppress hepatocarcinogenesis on a 
C3H background 
To determine whether B6 Chromosome 1 alleles can confer resistance to a sensitive C3H 
background (as C3H alleles confer sensitivity to a resistant B6 background), we generated 
C3H.B6-Ch1 congenics using ten generations of backcrossing B6 to C3H, selecting B6 alleles 
on distal Chromosome 1 at each generation. Heterozygous and homozygous congenic males 
and control inbred C3H males were injected with DEN at 12 days of age and their tumors 
were counted at 32 weeks (Figure 3). While heterozygosity for B6 alleles had no effect on 
tumorigenesis (P>0.84), homozygosity caused a 3.8-fold reduction in tumor multiplicity 
(P<10-3). 
3.3 C57BR/cdJ alleles between 175.35 and 178.64 Mb do not confer susceptibility 
We have shown previously that distal Chromosome 1 carries a modifier that causes 5- to  
6-fold increased susceptibility in male C57BR/cdJ (BR) mice relative to B6 mice (Poole and 
Drinkwater, 1996; Bilger et al., 2004). To determine whether this Hcif2 (formerly Hcf2) 
modifier might involve the same locus that confers susceptibility to C3H, we used 
B6.BR-Ch1 congenic mice to derive mice carrying smaller congenic regions and counted 
their tumors at 32 weeks (Figure 3). The line carrying the largest BR region, B6.BR.R4, 
developed fewer tumors than B6 (though not significantly; P > 0.37). Similarly, lines 
B6.BR.R5A and B6.BR.R5B, which carry part of the minimal region and extend distally 
beyond 191 Mb (R5A) or proximally beyond 165 Mb (R5B), also developed the same number 
of tumors as B6 or fewer (P > 0.86 and P > 0.68, respectively). All three recombinant lines 
developed significantly fewer tumors than the parental B6.BR-Ch1 line (not shown; P < 0.03 
for all). These results indicate that Hcif2 is unlikely to lie in the 175.35 to 178.64 Hcs7 region. 
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3.4 Haplotype analysis of sensitive and resistant strains 
The CBA/J strain is a cousin to C3H. Like its relative, CBA/J is highly susceptible to liver 
tumorigenesis, and the dominant modifier mapped in crosses between CBA/J and B6 maps 
to distal Chromosome 1 (Bilger et al., 2004). Because these strains are likely to share a 
susceptibility allele, we generated a haplotype map of the minimal Hcs7 region in CBA 
using SNPs obtained through the Imputed SNP Database (Szatkiewicz et al., 2008). Only 
SNPs that could be determined with greater than 80% confidence were included (Figure 4). 
This map suggests that CBA is highly related to the C3H strain through most of the Hcs7 










Fig. 4. Haplotype maps for the Hcs7 interval. 
Haplotypes were determined for each gene and intergenic region. B6 haplotypes are shown 
as tics above the bar. C3H haplotypes are shown as tics below the bar.  Haplotypes unique 
to CBA are shown as grey tics centered on the bar, while haplotypes unique to BR are 
shown as outlined tics centered on the bar. The starting position of each gene is shown as a 
tic above the position axis. 
3.5 C3H Chromosome 1 alleles increase spontaneous hepatocarcinogenesis 
To determine whether Hcs7 influences spontaneous as well as DEN-induced hepato-
carcinogenesis, homozygous male mice were aged to 15 months and tumors were counted 
(Table 1). B6.C3H-Ch1 males developed significantly more liver tumors than B6 males (one-
sided P < 0.01). The 4-fold higher multiplicity and the 2.5-fold higher incidence in this line 
closely resemble the higher multiplicity and incidence seen in inbred C3H males (P > 0.85). 
Similarly, line 1R33 males developed twice as many tumors and had 50% higher incidence 
than B6. The difference in tumor multiplicity was significant (one-sided P < 0.04). Males of 
the proximally congenic line 1R11, which developed approximately 3-fold more tumors 
than B6 when treated with DEN, had approximately 25% higher incidence and developed 
approximately 25% more spontaneous tumors than B6, but this difference was not 
significant (one-sided P > 0.18). This analysis of spontaneous tumor incidence indicates that 
the majority of the difference between C3H and B6 can be ascribed to alleles on 
Chromosome 1, including alleles in the Hcs7 region.  
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Line N Incidence Multiplicity 
B6 46 0.21 0.28 ± 0.58 
C3H 38 0.53 0.84 ± 1.10 
B6.C3H-Ch1 17 0.47 1.35 ±2.21 
1R33 31 0.35 0.65 ± 1.05 
1R11  44 0.25 0.34 ± 0.71 
Table 1. B6.C3H-Ch1 and 1R33 males are more susceptible to spontaneous liver tumors  
than B6. 
Inbred and recombinant male mice were left untreated to 15 months of age and liver tumors 
were enumerated. N, the number of mice per group. 
Many line 1R33 males developed severe skin disease. Twenty-eight males died or were 
euthanized prior to the 15-month time point (as compared to three B6, eight C3H, ten 
B6.C3H-Ch1, and eight line 1R11 males). These line 1R33 males developed skin problems 
with a frequency that differed from both B6 and the B6.C3H-Ch1 line, suggesting that 
multiple cooperating genes along Chromosome 1 must be derived from the same strain to 
prevent skin lesions. Ifi202b and neighboring genes have been implicated in autoimmune 
skin disease in distal Chromosome 1 congenic lines derived from B6 and the NZB (New 
Zealand Black) strain (Choubey et al., 2010; Panchanathan et al., 2011). 
3.6 Hcs7 affects early lesion growth 
To determine when Hcs7 influences tumorigenesis, we measured preneoplastic lesion size 
in B6, C3H, and congenic lines that had been treated with DEN at 12 days of age. Livers 
were collected at 16 and 24 weeks and frozen immediately on dry ice, followed by 
glucose-6-phosphatase staining to identify preneoplastic lesions. In the first experiment, 
lesions were measured in B6, line 1R11, and line 1R33 livers. By sixteen weeks, lesions in 
the moderately susceptible line 1R11 and the highly susceptible line 1R33 occupied  
3.5 and 3.4 times, respectively, the volume occupied by B6 lesions (P < 10-3 for both lines; 
Table 2). At 24 weeks, 1R11 lesions occupied 1.5-fold more volume than B6 lesions  
(P > 0.15), while 1R33 lesions occupied 2.0-fold more volume than B6 lesions (P < 0.05). 
This result indicates that the growth advantage of lesions in the congenic lines begins 
prior to 16 weeks.  
A second experiment yielded results for line 2R8 that were very similar to those obtained for 
the larger 1R33 congenic. Line 2R8 lesions occupied 3.4-fold more volume than B6 lesions at 
16 weeks; the ratio was 3.3-fold at 24 weeks. This result confirms that Hcs7 modifies 
preneoplastic lesion growth. This second experiment included C3H males, which developed 
lesions that occupied significantly more volume than the congenic at both time points  
(16 wks:  P < 0.01; 24 wks:  P < 10-4). C3H lesions occupied 17-fold more volume than B6 at 
16 weeks, which increased to 33-fold more than B6 at 24 weeks. The magnitude of the 
growth effects in inbred C3H males suggests that Hcs7 C3H alleles are not sufficient to 
recapitulate entirely the early lesion development seen in C3H inbred mice. 
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Experiment/age N Focus Volume  Fraction (VF) ± SD  VF ratio 
Experiment 1    
16 weeks    
B6 14 0.00098 ± 0.0011 - 
1R33 19 0.0033 ± 0.0020 3.4 
1R11 10 0.0034 ± 0.0022 3.5 
24 weeks    
B6 18 0.022 ± 0.029 - 
1R33 12 0.043 ± 0.040 2.0 
1R11 9 0.033 ± 0.040 1.5 
Experiment 2    
16 weeks    
B6 13 0.00071 ± 0.00062 - 
2R8 12 0.0024 ± 0.0016 3.4 
C3H 12 0.012 ± 0.011 17 
24 weeks    
B6 12 0.0042 ± 0.0042 - 
2R8 12 0.014 ± 0.012 3.3 
C3H 11 0.14 ± 0.093 33 
Table 2. Distal Chromosome 1 alleles influence net lesion growth before 16 weeks. 
Male mice were treated at 12 days of age with DEN and sacrificed at 16 or 24 weeks of age. 
Frozen liver sections were evaluated for the presence and size distribution of glucose-6-
phosphatase-deficient foci. N, number of animals per group; VF ratio, volume fraction ratio 
relative to B6. 
3.7 Hcs7 does not modify apoptosis or mitosis in the acute response to DEN injection 
Other modifiers of DEN-induced hepatocarcinogenesis, such as IL-6 and IKKgamma, 
have been shown to affect apoptosis and/or mitosis within 72 hours of DEN 
administration (Maeda et al., 2005; Naugler et al., 2007). To determine whether the tumor 
susceptibility conferred by the Hcs7 region affects mitosis or apoptosis rates during this 
acute response to DEN injection, we collected livers from line 2R8 males one, two, or three 
days after DEN injection at 12 days of age. Livers were fixed in formalin and stained with 
H&E. Mitoses and apoptoses were scored based on staining and morphology, under  
600× magnification. Two microscopic fields centered on a portal vein and two fields 
centered on a central vein were scored. Hepatocytes were counted for 10-25 fields per 
strain and condition (e.g., B6/DEN). Each field represented an equivalent number of 
hepatocytes per field (~330) in resistant and susceptible mice, independent of DEN 
treatment (P > 0.07 for all comparisons). 
Rates of mitosis and apoptosis never differed significantly between B6 and line 2R8, whether 
or not mice were treated with DEN (P > 0.10 for all comparisons; Table 3). These results 
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indicate that the tumorigenic effect of Hcs7 does not involve acute changes in the rates of 
apoptosis or mitosis in response to DEN injection. 
 
  Num. mice  Mitoses / field  Apoptoses / field 
Age Treatment B6 2R8  B6 2R8  B6 2R8 
13 days No DEN 7 11  1.50 1.25  0.50 0.50 
14 days No DEN 9 9  2.00 1.5  0.25 0.50 
15 days No DEN 7 8  1.40 1.00  0.30 0.25 
13 days DEN 7 7  0.5 0.5  0.30 0.25 
14 days DEN 9 11  2.25 2.50  0.25 0.50 
15 days DEN 7 12  2.00 1.85  0.50 0.55 
Table 3. Mitosis and apoptosis do not differ significantly between line 2R8 and B6 during 
tumor initiation. 
3.8 The Hcs7-interval genes most differentially expressed between C3H and B6 are 
immune genes 
To identify potential candidate genes and pathways regulated by the Hcs7 region, we 
collected livers from DEN-treated B6 and 2R8 mice at 13 days, 28 hours after DEN injection. 
RNA from these livers was reverse-transcribed and hybridized to Agilent whole-genome 
arrays, in competition with a B6 mixed-sex control, to identify differentially expressed 
genes. These arrays carry 43,379 probes representing most genes in the genome. Of the 44 
genes in the 175.35 to 178.64 Mb region, 35 are represented by probes. The remaining nine 
include genes for three spliceosomal RNAs, two olfactory receptors, one protein of 
unknown function, and three pyrin-domain-containing genes. Genome-wide, Ifi202b is the 
only significantly differentially expressed transcript based on FDR correction (q < 10-2). The 
expression of Ifi202b is 57-fold higher in line 2R8 than in B6.  
To identify potential candidates that may not be expressed at 13 days, RNA from three B6 
and three 2R8 tumors was reverse transcribed and hybridized individually in competition 
with the mixed-sex control DNA. Genome-wide, Ifi202b was again the only significantly 
differentially expressed transcript, with levels 48-fold higher in 2R8 tumors than in B6 
tumors (genome-wide FDR q < 0.05). When limiting analysis of the expression array data set 
to only the 35 candidate genes in the 175.35 to 178.64 Mb minimal region, both Ifi202b and 
the closely related Aim2 (Absent in melanoma 2) were expressed at significantly different 
levels (q < 10-4 and q < 10-2, respectively). 
Recent resequencing of the C3H genome has revealed many SNPs in the Hcs7 region. Data 
compiled by the Mouse Genome Database (MGD) at the Mouse Genome Informatics 
website (Blake et al., 2011; URL: http://www.informatics.jax.org; 8/2011) show that the 
C3H alleles of eight genes in the Hcs7 region encode amino acids that differ from B6. Ifi202b 
carries a Thr/Ser polymorphism. The most dramatic changes lie in Mndal, which carries 
Arg/Gly and Asp/Tyr polymorphisms. Other genes in the interval with non-synonomous 
SNPs include Olfr433, Olfr419, Olfr220, Fmn2, Chml, and Exo1. 
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4. Discussion 
The Chromosome 1 liver cancer modifier Hcs7 has been localized to a 3.3 Mb region on 
distal Chromosome 1. In DEN-treated mice, the C3H allele of Hcs7 bred onto a resistant B6 
background confers 3- to 7-fold greater tumor multiplicity, dominantly. Consistent with 
these results, the B6 allele of Hcs7 bred onto a susceptible C3H background confers 4-fold 
resistance, recessively. Importantly, C3H alleles on Chromosome 1 including Hcs7 confer 
susceptibility to spontaneous tumorigenesis that is comparable to the susceptibility of 
inbred C3H mice. The Chr 1 hepatocarcinogenesis susceptibility allele in C57BR/cdJ mice, 
Hcif2, does not appear to correspond to Hcs7. B6.BR mice congenic for BR alleles distal of 
170 Mb are not more susceptible to liver tumorigenesis than B6 mice. 
The initiation of tumors after DEN injection is thought to involve the proliferation of DEN-
mutated hepatocytes in response to DEN-induced cell death, within 72 hours of injection 
(Maeda et al., 2005). We found that Hcs7 affects neither apoptosis nor mitosis in this time 
period. We have previously shown that preneoplastic lesions in inbred C3H males grow 
faster than B6 lesions, and that this differential growth can be seen from prior to 16 weeks 
until at least 28 weeks of age (Hanigan et al., 1988). Here, we show that Hcs7 accounts for 
part of this early growth advantage:  the volume of preneoplastic lesions in the B6.C3H 
congenic lines 1R33 and 2R8 is greater than for B6 lesions by 16 weeks and remains so at 24 
weeks. Our results indicate that Hcs7 begins to affect cell proliferation after the acute 
reaction to DEN injection and likely tumor initiation, but before 16 weeks, to promote lesion 
growth. 
The 175.35 to 178.64 Mb minimal interval carries 44 genes, of which 12 are related pyrin-
and/or p200-domain-containing interferon-gamma response genes such as Ifi202b, Aim2, 
and Mnda. Two additional genes encode proteins that are known or likely to mediate 
immune responses (Exo1 and the Crp-like gene 1810030J14Rik). This region also contains the 
cytoskeletal/cell polarity gene Fmn2 that is overexpressed in B-cell leukemias, a renal cell 
cancer tumor suppressor (Fh1), four known or likely signaling protein genes, and 14 
olfactory receptor genes.  
Ifi202b is a strong candidate for the HCC modifier gene in the Hcs7 locus. It was the only 
gene significantly differentially expressed on a genome-wide basis between B6.C3HHcs7 
congenics and B6 mice at 13 days of age (in the presence and absence of DEN) and in tumors 
from 32-week-old males. Importantly, CGH analysis indicates that the 5' end of Ifi202b is 
altered in the resistant B6.C3H congenic line 1R5, though the effect of this alteration on the 
protein or its expression still needs to be established. Finally, Ifi202b lies in the minimal 
susceptibility region determined by congenic lines, between 175.35 and 178.64 Mb. An 
important test of its candidacy will be to determine whether the CBA inbred strain, closely 
related to C3H and similarly susceptible to liver tumors, also expresses high levels of Ifi202b. 
When only genes in the minimal susceptibility region were evaluated for differential 
expression in tumors, Aim2 was the only other significantly differentially expressed gene. 
Aim2 is an interferon-regulated pro-apoptotic protein that is closely related to, can hetero-
dimerize with, and affects the expression of Ifi202b (Panchanathan et al., 2010; Choubey et 
al., 2010). Aim2 is a component of inflammasomes that sense cytoplasmic double-stranded 
DNA and activate caspase 1, which in turn activates IL1-β and induces inflammation 
(Fernandes-Alnemri et al., 2009; Bürckstümmer et al., 2009). 
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In transfected macrophage cell lines, Ifi202b overexpression reduces Aim2 expression, and 
Aim2 knock-down increases Ifi202b expression (Panchanathan et al., 2010). Similarly, Aim2 
null mice overexpress Ifi202b in spleen tissue. Absence of Aim2 expression correlates with 
cell growth in vitro and with cell immortalization in vitro, and Aim2 is inactivated in 
approximately half of colon cancers with microsatellite instability (Woerner et al., 2007; 
Choubey et al., 2010). Therefore, high levels of Ifi202b may prevent Aim2 expression and 
induce growth. Both Aim2 and Ifi202b were overexpressed in line 2R8 tumors relative to B6 
tumors. This result may reflect a tumor-specific response, as 13-day-old line 2R8 mice did 
not express more Aim2 than B6 mice. 
The high expression of Ifi202b in line 2R8 mice relative to B6 might reflect promoter and/or 
enhancer polymorphisms in both Aim2 and Ifi202b. The NZB allele of Ifi202b has been shown 
to be more active than the B6 allele, most likely due to a TATA-box-creating polymorphism 
in the NZB Ifi202b promoter (Choubey et al., 2010). Analysis of congenic lines suggests that 
B6-specific polymorphisms, conversely, enhance the expression of Aim2. Autoimmune-
sensitive congenics carrying NZB alleles from 154.7 to ~194 Mb express high levels of Ifi202b 
mRNA and protein relative to B6. However, mice from a line that carries a smaller NZB 
congenic region between approximately 174.5 to 194 Mb – including the entire Aim2 gene at 
175.2 Mb and the entire Ifi202b gene at 175.9 Mb – are not predisposed to autoimmunity. 
These resistant congenic mice express more Aim2 mRNA and protein and less Ifi202b mRNA 
and protein than the larger congenic. Indeed, levels of Ifi202b protein are similar to those of 
B6 mice (Panchanathan et al., 2010). The breakpoint between B6 and NZB alleles in this 
smaller congenic lies less than one megabase proximal of Aim2. The effect of B6 
polymorphisms near the 5' end of the Aim2 gene on Aim2 expression and, indirectly, Ifi202b 
expression may also explain the resistance to hepatocarcinogenesis of line 2R9. Assessing 
Aim2 and Ifi202b mRNA and protein levels in lines 2R8, 2R16, 2R9, and 2R7 would address 
this hypothesis.  
Interferon-inducible p200 family members have been shown to interact functionally with 
p53, MyoD, and Rb and appear to regulate proliferation, differentiation, apoptosis, and 
senescence (Gariglio et al., 2011). Overexpression of Ifi202b in particular has been shown to 
promote cell survival, while lower levels of expression increase cell death (Roberts et al., 
2009; Choubey et al., 2010). The expression of Ifi202b is upregulated by IL-6, which has been 
shown to be virtually required for hepatocarcinogenesis in DEN-treated mice, and Ifi202b 
can stimulate or inhibit the transcription of NFκB target genes depending on cell type 
(Naugler et al., 2007; Choubey et al., 2010). Given these many cell regulatory functions and 
its effect on Aim2 expression, Ifi202b could promote lesion growth in multiple ways. 
Determining whether preneoplastic cells in lines carrying C3H alleles undergo less cell 
death, an increase in mitosis, or both, will be an important first step in assessing the 
oncogenicity of Hcs7. 
Based on genome-wide analysis, no genes other than Ifi202b were significantly differentially 
expressed. However, nine genes were not represented on the expression array. These 
include several unlikely candidates (olfactory receptors and splicing RNAs that are found 
throughout the genome), as well as the pyrin/p200 proteins BC094916, Pydc3, and Mndal. 
The expression of these genes and the effect of amino acid changes in genes in the region 
will need to be evaluated. Finally, the test of Ifi202b as a candidate will require its over-
expression (e.g., from a transgene) in B6, or its disruption in C3H. 
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p53, MyoD, and Rb and appear to regulate proliferation, differentiation, apoptosis, and 
senescence (Gariglio et al., 2011). Overexpression of Ifi202b in particular has been shown to 
promote cell survival, while lower levels of expression increase cell death (Roberts et al., 
2009; Choubey et al., 2010). The expression of Ifi202b is upregulated by IL-6, which has been 
shown to be virtually required for hepatocarcinogenesis in DEN-treated mice, and Ifi202b 
can stimulate or inhibit the transcription of NFκB target genes depending on cell type 
(Naugler et al., 2007; Choubey et al., 2010). Given these many cell regulatory functions and 
its effect on Aim2 expression, Ifi202b could promote lesion growth in multiple ways. 
Determining whether preneoplastic cells in lines carrying C3H alleles undergo less cell 
death, an increase in mitosis, or both, will be an important first step in assessing the 
oncogenicity of Hcs7. 
Based on genome-wide analysis, no genes other than Ifi202b were significantly differentially 
expressed. However, nine genes were not represented on the expression array. These 
include several unlikely candidates (olfactory receptors and splicing RNAs that are found 
throughout the genome), as well as the pyrin/p200 proteins BC094916, Pydc3, and Mndal. 
The expression of these genes and the effect of amino acid changes in genes in the region 
will need to be evaluated. Finally, the test of Ifi202b as a candidate will require its over-
expression (e.g., from a transgene) in B6, or its disruption in C3H. 
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If Ifi202b is the molecule responsible for promoting hepatocarcinogenesis in mice carrying 
C3H Hcs7 alleles, it would make a tempting target for pharmacological intervention. The 
Hcs7 region corresponds to parts of human chromosome 1q22-23.1 and 1q43. Chromosome 
1q, including these regions, is amplified in 58% to 86% of human hepatocellular carcinomas, 
independent of stage (Thorgeirsson and Grisham, 2002; Lau and Guan, 2005; Chochi et al., 
2009; Zhang et al., 2010). When only parts of 1q are amplified, 1q22-23 is frequently affected. 
These observations imply that chromosome 1q alterations are an early event in 
hepatocarcinogenesis. Chromosome 1q is also frequently amplified in other liver cancers 
such as hepatoblastoma, cholangiocarcinoma, and fibrolamellar carcinoma, as well as 
cancers of other tissues such as the pancreas and the breast (Buendia, 2002; Climent et al., 
2002; Birnbaum et al., 2011; Ward and Waxman, 2011). Humans have four homologs of 
Ifi202b in the 1q22-23.1 region, including an ortholog of Aim2, an ortholog of Mnda, Ifi16 and 
IfiX/Pyhin1 (www.ensembl.org; 9/2011; Gariglio et al., 2011). All of these genes have been 
implicated in growth suppression in cell lines and ectopic tumor models; however, Ifi16 in 
particular is also associated in vivo with rapidly dividing epithelium and with undiffer-
entiated tissue including fetal hepatocytes and hepatocytes following liver transplantation 
(Gariglio et al., 2011). In an analysis of gene expression in a human tumor carrying a 1q 
amplification, four chromosome 1 genes were overexpressed. Only two of these correspond 
to mouse Chromosome 1: Mnda and "interferon-gamma inducible gene" at 1q22 (Ifi16 or IfiX; 
Niketeghad et al., 2001). All four Ifi p200 human genes express transcripts that encode both 
the pyrin cell death and p200 protein interaction domains (www.ensembl.org; 9/2011). Each 
also expresses transcripts that carry only one of the domains, and Ifi16 in particular 
expresses transcripts that carry only the pyrin domain, only the p200 domain, or both. These 
many alternative transcripts suggest the possibility that one of them is orthologous to 
Ifi202b, which expresses only the p200 domain. An analysis of human tumors should reveal 
which p200 family transcripts they express. Transgenesis could then be used to test the 
oncogenicity of these selected transcripts.  
C3H alleles from several regions of mouse Chromosome 1 conferred some significant 
susceptibility to B6 mice. Similarly, several regions on human chromosome 1 are amplified, 
sometimes simultaneously but separately, in human tumors (Lau and Guan, 2005; Chochi et 
al., 2009). It seems likely that multiple genes on Chromosome 1 in both mice and humans 
affect hepatocarcinogenesis.  
5. Conclusion 
We have mapped the mouse Hcs7 liver cancer modifier to a 3.3 Mb region on distal Chromo-
some 1 that carries 44 genes, of which many are involved in responding to immune stimuli.  
This region corresponds to human chromosome 1q22-23.1, which is amplified in most 
hepatocellular carcinomas. Ifi202b is a strong candidate gene for the Hcs7 modifier. Further 
study of the effect of its overexpression or disruption in vivo on short-term proliferation or 
apoptosis and long-term hepatocarcinogenesis will help establish whether its possible 
functional equivalent on human chromosome 1q is a worthy target for pharmacological 
intervention.  
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Hepatocellular carcinoma (HCC) is the sixth most common type of cancer in the world, with 
approximately 630,000 new cases each year (Alves et al., 2011). It is also the third most 
common cause of cancer related mortality (Parkin et al., 2005). Moreover, the incidence of 
HCC has risen in many countries over the past decade. The greatest risk factor associated 
with the development of HCC is hepatitis B and C virus infection. Hepatitis infection is 
believed to increase the risk of developing HCC by 20 fold and is the major etiological factor 
in more than 80% of HCC cases (Anzola, 2004). Other main risk factors include excessive 
alcohol consumption, non alcoholic steatohepatitis, exposure to environmental toxins such 
as aflatoxin B, hemochromatosis, cirrhosis, diabetes and obesity (El-Serag et al., 2006; 
Hassan et al., 2010; Whittaker et al., 2010). 
The standard treatments for early stage HCC, such as surgical resection and liver 
transplantation, can cure certain population of patients. However, due to the asymptomatic 
nature of early HCC and lack of effective screening strategies, 80% of patients present with 
advanced HCC at the time of diagnosis (Thomas and Abbruzzese, 2005). These patients 
have rather limited treatment options which are mainly palliative. If the patient has 
developed HCC that is surgical unresectable, systemic treatments are commonly used. 
However, conventional chemotherapy with cytotoxic agents is not very effective in 
changing the progress of the tumor growth. Consequently, the mortality rate for advanced 
stage HCC is quite high, and 5 year survival rate for patients with HCC is only 7% (Bosch et 
al., 2004; Whittaker et al., 2010). There is clearly an urgent medical need to develop new 
effective and well-tolerated HCC treatment options.  
In recent decades, tremendous progress has been made toward better understanding the 
molecular mechanisms of oncogenic processes. Many cell signaling pathways involved in 
tumor pathogenesis have been identified, leading to the identification of new molecular 
targets for therapeutic development. Unlike conventional chemotherapy which utilizes 
broad spectrum cytotoxic agents, targeted therapy acts directly and specifically on the 
components that regulate tumorigenesis. This strategy has shown clinical benefits in various 
tumor types, such as breast, colorectal and lung cancers (Ansari et al., 2009; Slamon et al., 
2001; Takahashi and Nishioka, 2011). Several major cellular signaling pathways have been 
implicated in HCC, and below we will review those pathways and discuss the potential to 
target the molecular components within those signaling pathways. 
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Fig. 1. Major cellular signaling pathways involved in hepatocellular carcinoma 
tumorigenesis  
2.1 Wnt/-catenin pathway  
Wnt signaling pathway involves three main components which include the cell surface, the 
cytoplasm, and the nucleus (Giles et al., 2003). At the cell membrane, Wnt ligands form 
complexes with Frizzled receptors and LRP5 or LRP6 co-receptors (Dale, 1998; Wehrli et al., 
2000). There are at least 19 known human Wnt family genes and 10 Frizzled family genes, 
and most Wnt proteins can bind to multiple Frizzled receptors and vice versa (Wang et al., 
1996). This ligand receptor interaction can be additionally regulated by other secreted 
factors and cell surface proteins. For example, soluble forms of Frizzled proteins compete 
with cell membrane Frizzled receptor for Wnt ligands (Finch et al., 1997). And DKK proteins 
block Wnt signaling by binding to LRP6 co-receptor (Fedi et al., 1999).  
In the cytoplasm, -catenin associates with a multiprotein complex which includes tumor 
suppressor proteins APC, axin, and Ser/Thr kinase GSK3. Axin and APC form a structural 
scaffold that allows GSK3 to phosphorylate -catenin. Phosphorylation of -catenin targets 
it for ubiquitination and protein degradation (Clevers, 2006; Gordon and Nusse, 2006). 
Therefore, under basal conditions, in the absence of Wnt ligands, -catenin is continuously 
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degraded in the cytosol. Upon Wnt binding, axin is recruited to the membrane to LPR5 and 
the -catenin destruction complex is then inactivated. This allows the unphosphorylated -
catenin to accumulate and to translocate into the nucleus (Clevers, 2006; Gordon and Nusse, 
2006). The nuclear -catenin then forms a complex with TCF/LEF family of DNA binding 
transcription factors to activate TCF/LEF target genes. Many of the target genes are 
involved in cell proliferation, such as cyclin D1 (Shtutman et al., 1999). 
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Although there is little doubt about the strong correlation between aberrant Wnt signaling 
and HCC, the precise role of activated Wnt pathway in the pathogenesis of liver tumor is 
less well understood. It has been shown that pharmacologic inhibition of -catenin 
decreases survival of hepatoma cells (Behari et al., 2007). Inactivation of -catenin 
suppressor APC led to spontaneous development of HCC in a mice model, suggesting the 
direct contribution from activated Wnt signaling to hepatocarcinogenesis (Colnot et al., 
2004). However mice overexpressing a gain-of-function -catenin mutant (exon 3 deletion) 
only showed increased susceptibility to developing HCC after exposure to carcinogen 
diethylnitrosamine (DEN), instead of developing spontaneous liver tumor (Harada et al., 
2002). These results suggest that the role of the Wnt pathway in the development of liver 
cancer is highly context-dependent and involves cross-talk with other pathways. 
Nonetheless, components of the Wnt pathway may represent potential therapeutic 
intervention points for treating HCC. 
Several approaches could be envisioned to target Wnt pathways. Extracellularly, it is 
possible to design molecules to disrupt Wnt ligand-receptor complexes, preventing 
initiation of the signaling events. For this approach, Wnt ligands, extracellular Wnt 
regulators such as DKKs, SFRPs proteins, and members of the receptor complexes can all be 
targeted. These proteins themselves or variants could be directly considered as candidates 
for drug developments. Alternatively, antibodies or other modalities that could block ligand 
receptor interactions may also be explored for therapeutic development. Intracellular 
components could also be targeted. Small molecule ligands toward kinases of the signaling 
pathway could also be screened that may regulate Wnt signaling. In addition, small 
molecule antagonists have been identified to interfere with the binding between -catenin 
and TCF/LEF proteins or its coactivator CEBP, blocking downstream gene activation 
(Dahmani et al., 2011). However, due to the inherent complexity of Wnt signaling in the 
liver, further research is needed to fully understand the implications of therapeutic 
inhibition of the pathway in HCC. 
2.2 VEGF pathway 
Angiogenesis is critical for cancer development. Tumor cells require oxygen and nutrients 
for survival and proliferation and  they need to be located within 100 to 200 m from blood 
vessels to obtain an adequate supply of oxygen (Carmeliet and Jain, 2000). Solid tumors 
smaller than 1 to 2 cubic millimeters are not vascularized (Hawkins, 1995). However, 
beyond the critical volume of 2 cubic millimeters, new blood vessels need to be recruited to 
supply oxygen and nutrients and to remove metabolic wastes (Hawkins, 1995). 
Neovascularization also facilitates the dissemination of cancer cells throughout the entire 
body eventually leading to metastasis formation. 
HCC is a hypervascular tumor and many pro-angiogenic factors are over-expressed in HCC 
cells and in the surrounding microenvironment (Shen et al., 2010). Among them, VEGF 
receptor signaling is one of the most well studied. The major VEGF that mediates tumor 
angiogenesis is VEGF-A, and it has several splicing variants that can be produced 
simultaneously. The most predominant forms are VEGF-A121 and VEGF-A165. Other 
members in the VEGF family include Placenta growth factor (PlGF), VEGF-B, VEGF-C, and 
VEGF-D (Kaseb et al., 2009; Roskoski, 2007). VEGF signals through VEGF receptor (tyrosine 
kinase receptor) on the cell surface. There are three main subtypes of VEGF receptors, 
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numbered 1, 2 and 3 (Kaseb et al., 2009; Roskoski, 2007). They all have an extracellular 
region consisting of 7 immunoglobulin-like domains, a single transmembrane domain, and 
an intracellular portion containing a split tyrosine-kinase domain. VEGF ligand binding 
induces dimerization and autophosphorylation of VEGF receptors. Phosphorylated tyrosine 
residues in the receptor serve as a docking site for various signal transduction proteins that 
can eventually activate cellular processes involved in angiogenesis. For example, VEGFR-2 
phosphorylation activates PLC- which in turn leads to protein kinase C activation (PKC). 
PKC can activate MAP kinase signaling and promote cell proliferation as well as increase 
vascular permeability through activation of endothelial nitric oxide synthase (Kaseb et al., 
2009; Roskoski, 2007). VEGF also induce activation of Rho GTPase, which plays a crucial 
role during angiogenesis processes such as vascular permeability, extra cellular matrix 
degradation, cellular migration and invasion (van der Meel et al., 2011). 
Among the three VEGF receptors, VEGFR-2 appears to mediate almost all of the known 
cellular responses to VEGFs. The activation of VEGFR-2 in endothelial cells results in their 
proliferation, migration, and increased survival and promotes vascular permeability (Kaseb 
et al., 2009; Roskoski, 2007). The function of VEGFR-1 is less known. Although it has higher 
affinity for VEGF than VEFGR-2, it has weak tyrosine kinase phosphorylation activity 
following ligand stimulation. Activation of VEGFR-1 has no direct proliferative or 
cytoskeletal effects. It is possibly involved in modulating VEGFR-2 activity. VEGF-C and 
VEGF-D, but not VEGF-A, are ligands for a third receptor (VEGFR-3), which is important 
for lymphangiogenesis (Kaseb et al., 2009; Roskoski, 2007). 
The VEGF pathway is clearly important for HCC pathogenesis. Expression of VEGF mRNA 
in liver tumors was found in a majority of HCC patients. And the expression of VEGF 
steadily increases with the progression of the hepatocarcinogenic process from a normal 
liver, to a dysplastic nodule, to HCC (Yamaguchi et al., 1998). The levels of VEGF mRNA 
expression in tumors with tumorous emboli and in poor-encapsulated tumors were higher 
than those without tumorous emboli and in well-encapsulated tumors. The principle route 
of HCC dissemination and metastasis is through the portal vein in the liver and VEGF 
mRNA level correlated well with portal vein tumor thrombus (PVTT) formation of HCC, 
suggesting VEGF may play an important role in HCC invasion and metastasis (Zhou et al., 
2000). Immunohistochemical staining also detected very high VEGF expression in well-
differentiated HCC as well as areas surrounding the HCC tissues, where inflammatory cell 
filtration was apparent. High serum VEGF levels have been shown to correlate with poor 
response to chemotherapy and poor survival among HCC patients. Increased preoperative 
serum VEGF may also predict high incidence of tumor recurrence after surgical resection 
(Whittaker et al., 2010). Furthermore, increased VEGF expression has also been detected in 
cirrhotic and dysplastic livers, which often lead to liver cancer (El-Assal et al., 1998). 
The most direct evidence supporting the role of the VEGF signaling pathway in HCC came 
from recent progress in molecular targeted therapy inhibiting this pathway. Bevacizumab, 
an anti–VEGF monoclonal antibody was tested in patients with unresectable HCC and 
resulted in significant disease-stabilizing effect (Siegel et al., 2008). Clinical effects were 
assessed by tumor regression and progression-free survival (PFS). Of the 46 patients in the 
study, 13% had objective response and 65% were progression free at 6 months. The mean 
PFS time was 6.9 months and median overall survival time is 12.4 months. Overall survival 
rates were 53% at 1 year, 28% at 2 years and 23% at 3 years. Treatment was associated with 
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significant reductions in tumor arterial enhancement and circulating VEGF-A level. Besides 
VEGF antibody, small molecule VEGF inhibitors have also been developed and tested in 
clinic. Sorafenib, an inhibitor targeting the VEGF pathway has been shown to prolong 
overall survival in patient with advanced HCC (Llovet et al., 2008). In a randomized, 
placebo-controlled phase III trial, sorafenib prolonged median survival time of advanced 
HCC patients by 2.8 months, from 7.9 months in the placebo group to 10.7 months in the 
sorafenib treatment group. Time to radiologic progression was delayed by 2.7 months, from 
2.8 months to 5.5 months. This result is quite significant since no effective systemic therapy 
ever existed for patients with advanced hepatocellular carcinoma before the sorafenib trial. 
There are several other VEGF small molecule inhibitors that are currently being tested in the 
clinic for HCC treatment including, sunitinib, vatalanib, cediranib, brivanib, and linifanib 
(Shen et al., 2010; Whittaker et al., 2010). Studies have also been carried out to assess the 
benefit of the combined therapy using those compounds. 
2.3 FGF pathway 
Supported by various mouse genetic models as well as human genetic studies, aberrant 
FGF/FGFR signaling is clearly associated with tumorigenesis (Beenken and Mohammadi, 
2009; Knights and Cook, 2010; Krejci et al., 2009; Turner and Grose, 2010). Signaling is 
activated upon FGF ligands binding to the FGF receptors on the cell surface. There are more 
than 20 different FGFs in the FGF family, making it the largest family of growth factors. 
Fibroblast growth factor receptors consist of an extracellular ligand binding domain, a single 
transmembrane domain, and an intracellular domain with tyrosine kinase activity. The 
extracellular domain of the FGF receptor is composed of three immunoglobin-like domains. 
Alternative splicing of four FGF receptors genes (FGFR1-4) results in over 48 different 
isoforms of FGFRs, and they have different affinity towards different FGF ligands and have 
distinct expression patterns (Ornitz and Itoh, 2001; Ornitz et al., 1996). FGFRs are tyrosine 
kinase receptors that upon ligand binding induce dimerization and kinase activation in the 
presence of the co-factor, heparan sulfate (Plotnikov et al., 1999). Phosphorylation of the 
tyrosine residues on the receptor provides docking sites for downstream adaptor proteins, 
which can couple to the activation of different intracellular signaling pathways. One of the 
key adaptor proteins of FGF receptors is FGF substrate 2 (FRS2) which can be 
phosphorylated by FGFR receptors and recruit more adaptor proteins such as son of 
sevenless (SOS) and growth factor receptor-bound 2 (GRB2) to activate RAS GTPase 
(Eswarakumar et al., 2005). RAS GTPase promotes several downstream signaling, such as 
Wnt, MAPK, and PI3K/Akt pathways (Knights and Cook, 2010). These FGF downstream 
signaling pathways have all been implicated in several aspects of tumorigenesis, such as 
proliferation, survival, cell migration and invasion, as well as angiogenesis (Balmanno and 
Cook, 2009; Dailey et al., 2005; Presta et al., 2005; Xian et al., 2005). In HCC, it has been 
shown that plasma FGF2 level was significantly increased (Hsu et al., 1997) and 
overexpression of FGFR1 in hepatocytes accelerated the growth of HCC chemically induced 
by DEN in a mouse model (Huang et al., 2006). 
Recently, attention has focused on a unique FGF family member, FGF19, and its 
involvement in the development of HCC (Nicholes et al., 2002; Wu and Li, 2009). FGF19 
belongs to a unique FGF subfamily that has weakened affinity towards heparan sulfate. The 
reduced affinity liberates FGF19 from tissues where it is expressed, allowing it to act as an 
endocrine hormone. Furthermore, FGF19 requires Klotho as a co-receptor in activating FGF 
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receptors. In the presence of Klotho, FGF19 is able to activate similar downstream signaling 
through FGF receptors (Kurosu et al., 2007; Wu et al., 2007). 
First evidence connecting FGF19 with HCC came from a transgenic FGF19 mice model, 
where human FGF19 driven by myosin promoters was overexpressed from skeleton muscle, 
resulting in elevated serum FGF19 protein levels (Nicholes et al., 2002). HCC development 
was observed in these FGF19 transgenic mice at 8-10 months, while no tumors were 
observed in wild type control mice. Tumors occurred in different liver lobes and were either 
solitary or multifocal. Histological staining showed neoplastic cells invasion and 
replacement of normal hepatocytes (Nicholes et al., 2002). Hepatocytes are normally 
mitotically quiescent in the liver. However, in case of HCC, hepatocellular proliferation is a 
prerequisite for transformation. In vivo 5-bromo-2'-deoxyuridine (BrdU) labeling was 
performed to assess the proliferation in FGF19 transgenic mice. BrdU-labeling index of 
hepatocytes was eight fold higher in the transgenic mice than age-matched wild type mice 
at 2 to 4 months of age (Nicholes et al., 2002). Furthermore, recombinant FGF19 protein also 
induced a significant higher BrdU-labeling index after being injected into normal mice 
(Nicholes et al., 2002; Wu et al., 2010a; Wu et al., 2010b). These results strongly support the 
notion that FGF19 can induce hepatocellular proliferation which eventually leads to 
development of HCC. 
FGF19 is able to activate the Wnt pathway in hepatocytes, and 44% of neoplastic 
hepatocytes in FGF19 transgenic mice have nuclear staining for -catenin (Nicholes et al., 
2002; Pai et al., 2008). Since aberrant Wnt signaling correlates strongly with HCC 
tumorigenesis, this may be one mechanism whereby FGF19 induces liver tumor formation. 
To test the hypothesis of whether FGF19 could be a valid target in HCC treatment, a 
monoclonal anti-FGF19 antibody was generated and tested in tumor inhibition. Anti-FGF19 
antibody or control antibody were used to treat DEN accelerated HCC formation in FGF19 
transgenic mice (Desnoyers et al., 2008). After six months of antibody treatment, all the 
animals treated with control antibody developed multifocal, large HCCs throughout the 
liver lobes while almost none of the mice treated with FGF19 antibody had liver tumors. The 
same anti-FGF19 antibody was also tested in xenograft mice models (Desnoyers et al., 2008). 
Mice xenografted with colon cancer cell lines HCT116 and Colo201 were injected with anti-
FGF19 antibody twice weekly. At day 35, FGF19 antibody suppressed tumor growth by 57% 
compared to the control in HCT116 group and 64% growth inhibition was achieved in 
Colo201 animals treated with the antibody. These data suggest that targeting FGF19 could 
be a valid strategy for HCC treatment. 
The main candidate FGF receptor mediating FGF19 induced tumorigensis in liver is 
believed to be FGFR4, which is the predominant FGF receptor expressed in the liver. Strong 
FGFR4 mRNA was detected in hepatocytes adjacent to central vein by in situ hybridization, 
and the hepatic dysplasia foci and BrdU labeling from FGF19 transgenic livers are also 
located around central vein. In addition, activation of FGFR4 alone was sufficient to induce 
hepatocyte proliferation (Wu et al., 2010a; Wu et al., 2010b) and FGF19 induced hepatocytes 
proliferation was not observed in FGFR4 knockout mice, confirming the role played by 
FGFR4 in hepatocarcinogenesis (Wu et al., 2011). 
FGFR4 has been implicated in HCC in many literature reports (Yang et al., 2011). FGFR4 is 
frequently overexpressed in patients with hepatocellular carcinoma (Yang et al., 2011). 
siRNA against FGFR4 in liver cancer lines HuH7 is able to suppress -fetoprotein 
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production (Yang et al., 2011). However, there have also been reports showing genetic 
deletion of FGFR4 in mice results in faster progression of DEN-accelerated hepatocellular 
carcinoma, suggesting that FGFR4 suppresses hepatoma proliferation (Huang et al., 2009). 
The contribution of FGFR4 in HCC progression requires further clarification. 
2.4 MAPK pathway 
Mitogen-activated protein kinase (MAPK) is serine-threonine kinase that is involved in a 
variety of cellular activities. There are three members in the mammalian MAPK family, 
extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38 (Kim 
and Choi, 2010; Min et al., 2011). Among them, ERK signaling pathway is the most studied 
for its involvement in promoting cell proliferation, migration, survival, and its association 
with tumorigenesis and tumor progression (Gollob et al., 2006). Recent data also implicate 
JNK and p38 as playing important roles during HCC development (Min et al., 2011).  
The ERK pathway is ubiquitous and can be activated by various receptors, particularly 
receptor tyrosine kinases (RTKs). Upon ligand binding, the RTKs dimerize which leads to 
activation of the intracellular tyrosine kinase domain. Activated kinase results in receptor 
phosphorylation on tyrosine residues, that then serves as docking sites for adaptor proteins 
such as GRB2 and SOS (Schulze et al., 2005; Zarich et al., 2006). Upon docking to the 
receptors, the GRB2 and SOS activate the small GTPase RAS (HRAS, NRAS and KRAS) 
which in turn will activate the serine/threonine kinase RAF. RAF is a MAPK kinase kinase 
(MAP3K), and it has three isoforms, ARAF, BRAF and CRAF. Activated RAF will 
phosphorylate and activate MEK, a MAPK kinase (MAP2K) and MEK is the kinase for ERK 
(ERK1 and ERK2) (Avruch et al., 2001; Malumbres and Barbacid, 2003). 
There are more than 100 substrates downstream of ERK, and many of them are transcription 
factors. The altered levels and activities of the transcription factors by ERK activation can 
lead to altered expression levels of genes that are important for cell cycle progression (Davis, 
1995). For example, ERK can phosphorylate and activate C-myc, a transcription factor that 
regulates the expression of many target genes involved in cell growth and proliferation. C-
Myc is a strong proto-oncogene and can be found unregulated in many types of cancers 
(Penn et al., 1990). ERK also directly phosphorylates kinase substrates such as myosin light 
chain kinase, calpain, and focal adhesion kinase, which promotes cell migration (Huang et 
al., 2004). Furthermore, the ERK pathway can regulate proteins involved in apoptotic 
pathway such as BIM and MCL1, promoting survival of cancer cells (Balmanno and Cook, 
2009). 
Given the contribution of ERK signaling towards cell proliferation, migration and survival, 
it is not surprising to see constitutive activation of the ERK pathway in many tumors. In fact, 
genes along the ERK pathway, such as HRAS, KRAS, and CRAF, are often upregulated in 
HCC. One study has shown that CRAF is overexpresed among all 30 HCC tissue samples 
tested (Hwang et al., 2004). Immunostaining also showed around 7 fold increase of MEK 
phosphorylation in HCC tissues compared to surrounding benign liver tissues (Huynh et 
al., 2003). Other studies also found that phosphorylated ERK level is higher in HCC tissues 
and ERK activation is associated with aggressive tumor behavior (Schmitz et al., 2008). In 
addition, negative regulator proteins of MAPK/ERK pathway such as Sprouty and DUSP1 
are down-regulated in HCC tumors (Calvisi et al., 2008) (Yoshida et al., 2006). Sustained 
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activation of ERK signaling can also occur due to point mutations in the RAS gene, which 
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genes such as caspase-3 and 7 and down-regulation of cell cycle regulators such as cyclin 
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(55%) from Chinese HCC patients (Chang et al., 2009). The activation in JNK1 is associated 
with increased tumor size and a lack of encapsulation of the tumors. In addition, JNK1 
activation also associates with increased histone H3 lysines 4 and 9 tri-methylation, which 
leads to up-regulation of genes promoting cell growth (Chang et al., 2009). 
Direct evidence demonstrating the role of JNK pathway in HCC development comes from 
studies in mouse models. JNK1 knockout mice had a significant reduction in liver 
tumorigenesis chemically induced by DEN and hepatocyte proliferation also decreased in 
those animals (Hui et al., 2008). It was proposed that mice lacking JNK1 have increased 
expression of p21, a cell cycle inhibitor. Blocking JNK activity using pharmacological 
inhibitor D-JNKI1 reduced growth of both xenografted human HCC cells and DEN-induced 
mouse liver cancers, further supporting the role played by JNK pathway in HCC 
development (Hui et al., 2008). 
The activation of p38 is induced by MKK3, 4, and 6, as well as autophosphorylation. Its 
substrates include transcription factors such as p53 and protein kinases such as MK2 and 
MK5 (Min et al., 2011). Interestingly, unlike ERK and JNK pathways, p38 seems to play a 
suppressive role in HCC (Min et al., 2011). It was shown that human embryonic fibroblasts 
displayed enhanced proliferation upon treatment with a p38 inhibitor (SB203580) (Wang et 
al., 2002). p38 negatively regulates proliferation partly through suppression of the JNK 
pathway, which is known to promote cell proliferation. Depending upon the cellular 
context, p38 can enhance the protein level of JNK phosphatase and repress the activities of 
JNK kinases (Wagner and Nebreda, 2009). In p38 deficient fetal liver cells and liver tumor 
cells, the JNK pathway activity was found to be increased. Direct evidence supporting the 
suppressive role of p38 in HCC came from a study using mice with liver-specific deletion of 
p38, where enhanced hepatocyte proliferation and tumor development were observed 
during liver carcinogenesis (Hui et al., 2007). After DEN treatment, p38 deficient mice 
clearly developed more tumors in the liver and had larger average tumor size compared 
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with control mice. Moreover, inactivation of JNK pathway with -JNKI1 suppressed the 
hyperproliferation in p38-deficient animals (Hui et al., 2007). 
In summary, numerous data have clearly demonstrated the deep involvement of MAPK 
signaling pathways during liver carcinogenesis. Identifying pharmacological intervention 
points along these pathways could be considered as a very promising strategy for 
combating HCC. 
2.5 PI3k/AKT/mTOR pathway 
Phosphoinositide 3 kinase (PI3K) is an intracellular signal transducer enzyme that can 
phosphorylate the hydroxyl group of phosphatidylinositol (Vanhaesebroeck and Waterfield, 
1999). It belongs to a large family of PI3K-related kinases (Kuruvilla and Schreiber, 1999). PI3K 
is comprised of a catalytic subunit and a regulatory subunit. The regulatory subunit p85 can 
interact with phosphotyrosines on activated RTKs that recruit the enzyme to the plasma 
membrane and activate the enzymatic activities (Paez and Sellers, 2003). PI3K produces the 
lipid second messenger phosphatidylinosoltriphosphate, which is absent in resting cells but 
can be acutely produced in response to activated PI3K (Vanhaesebroeck and Waterfield, 1999).  
Akt is a serine-threonine kinase downstream of PI3K. It contains a pleckstrin homology (PH) 
domain in the N-terminus, a central catalytic kinase domain and a C-terminus regulatory 
domain (Paez and Sellers, 2003). The PH domain will bind to phosphatidylinosoltriphosphate 
with high affinity. Upon PI3K activation and phosphatidylinosoltriphosphate production, Akt 
is recruited to the plasma membrane through its PH domain together with another PH domain 
containing protein, phosphoinositide dependent kinase 1 (PDK1). PDK1 then phosphorylate 
key residues in the kinase domain activation loop of Akt to activate Akt kinase activity (Paez 
and Sellers, 2003). 
Activated Akt phosphorylates multiple protein substrates and regulates a variety of critical 
cellular activities (Paez and Sellers, 2003; Whittaker et al., 2010). Mammalian target of 
rapamycin (mTOR) is one of the most important downstream effectors of Akt. Akt 
phosphorylates the tuberous sclerosis complex (TSC1/TSC2) which activates the small G 
protein, Ras homolog enriched in brain (Rheb). Rheb, in its GTP-bound state, can activate 
mTOR. mTOR is a serine-threonine protein kinase that also belongs to PI3K-related kinase 
family. It is a large protein consists of tandem HEAT repeats, FAT (FRAP-ATM-TRRAP) and 
FATC (FAT C-terminus) domains, FKBP12-rapamycin binding domain (FRB), and  C-
terminus catalytic kinase domain that resembles the catalytic domain of PI3K (Wullschleger 
et al., 2006). For mTOR to activate its signaling cascade, it must form the ternary complex 
mTORC1 (mTOR Complex-1) or mTORC2 (mTOR Complex-2), but mTOR is the catalytic 
subunit of both of these two complexes. mTORC1 complex contains mTOR, RAPTOR 
(Regulatory Associated Protein of mTOR), mammalian LST8/G-protein β-subunit  
like protein (mLST8/GβL), PRAS40 and DEPTOR. mTORC2 complex consists of  
mTOR, rapamycin-insensitive companion of mTOR (Rictor), GβL, and mammalian stress-
activated protein kinase interacting protein 1 (mSIN1) (Wullschleger et al., 2006; Paez and 
Sellers, 2003).  
Another very important component of PI3K/Akt/mTOR pathway is PTEN (phosphatase and 
tensin homolog). It consists of a phosphatase domain which carries out the enzymatic function 
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and a C2 domain which binds the phospholipid membrane. PTEN dephosphorylates 
phosphatidylinosoltriphosphate and serves as a negative regulator of PI3K/AKT/mTOR 
pathway (Paez and Sellers, 2003). 
mTOR controls several important cellular processes including regulation of protein 
translation. Abberent protein translation often leads to abnormal cell growth and 
tumorigenesis (Petroulakis et al., 2006; Wullschleger et al., 2006). mTOR enhances 
translation initiation via two major targets, the eIF4E binding proteins (4E-BPs) and the 
ribosomal protein S6 kinases (S6K1 and S6K2). Eukaryotic mRNAs contain a ‘cap’ structure, 
m7GpppN at the 5’ end and can be specifically recognized by the initiation factor eIF4E, 
which associates with eIF4G and eIF4A to form eIF4F complex and initiate cap-dependent 
translation. 4E-BP binds to eIF4E and inhibits eIF4F complex formation. Upon 
phosphorylation of 4E-BP by mTOR, eIF4E is released to stimulate translation initiation. S6 
kinase is activated by mTOR and phosphorylates 40S ribosomal protein S6, which leads to 
increased translation of a subset of mRNAs containing 5’ tract of oligopyrimidine (TOP). 5’ 
TOP mRNAs encode ribosomal proteins, elongation factors, the poly-A binding protein and 
other components of the translational machinery. Therefore, stimulation of the 5’ TOP 
mRNA translation by S6 results in up-regulation of the overall cellular translation capacity 
(Petroulakis et al., 2006). 
The PI3K/Akt/mTOR signaling pathway is known to be up-regulated in various carcinoma 
cell lines, as well as in human ovarian and breast carcinomas (Altomare et al., 2004) 
(McAuliffe et al., 2010). For HCC, one study has shown overexpression of phospho-mTOR 
in 15% of liver tumors. Phospho-mTOR also positivity correlated with increased expression 
of total S6 kinase, which was found in 45% of the cases (Sahin et al., 2004). Elevated Akt 
phosphorylation was also found in 23% of HCC and implicated early HCC recurrence and 
poor prognosis (Boyault et al., 2007). There is also a high frequency (35.6%) of somatic PI3K 
mutations in HCC specimens (Lee et al., 2005). PTEN, the negative component of the 
PI3K/Akt/mTOR, is mutated in 5% of HCC and its expression is reduced in half of all HCC 
tumors, leading to the over activation of the pathway (Whittaker et al., 2010). In HCC 
patients, reduced PTEN expression has been associated with advanced tumor stage, high 
recurrences rate and poor survival outcome, suggesting inactivation of PTEN is involved in 
the pathogenesis of HCC (Hu et al., 2003). A study using hepatocyte-specific PTEN deficient 
mice further supported such a connection, by demonstrating that at 80 weeks of age, 66% of 
PTEN-deficient mice developed HCC (Horie et al., 2004). 
Given the strong association between aberrant PI3K/Akt/mTOR signaling and HCC, 
pharmacological inhibition of this pathway could be a viable HCC treatment strategy. The 
mTOR inhibitor everolimus has been shown to decrease the growth of HCC cell line 
(Villanueva et al., 2008). Everolimus also induced a significant delay of tumor growth in a 
HCC xenograft mice model (Villanueva et al., 2008). In a separate study, the mTOR inhibitor 
sirolimus was tested in a rat HCC model and the treatment resulted in significantly longer 
survival time, smaller tumor size, and fewer extrahepatic metastases in those animals 
(Semela et al., 2007). Sirolimus has also been tested in human HCC patients, and it induced a 
partial response in 5% of the patients and tumor stabilization for at least 3 months in 24% of 
the patients. Another study has shown that 33% of patients partially response to sirolimus 
treatment (Rizell et al., 2008; Semela et al., 2007). Several new clinical trials are currently 
testing mTOR inhibitors and its combination with other therapies among HCC patients. 
Liver Tumors 48
2.6 Other miscellaneous pathways 
The EGFR (epidermal growth factor receptor) is a receptor tyrosine kinase which is 
activated by ligands including epidermal growth factor (EGF) and transforming growth 
factor α (TGF-α) (Herbst, 2004). Upon activation, EGFR forms a dimer and 
autophosphorylates the tyrosine residues in its intracellular cytoplasmic domain, which in 
turn leads to initiation of many downstream signal transduction cascades (Herbst, 2004). 
The EGFR signaling pathway is one of the most important pathways that regulate growth, 
survival, proliferation, and differentiation in mammalian cells. Numerous studies have 
shown that aberrant EGFR signaling plays a vital role in tumor angiogenesis and 
proliferation and agents that specifically block this pathway showed efficacy in several 
types of solid tumors (Zhang et al., 2007). For HCC, EGFR overexpression was detected 
among 40–70% of the tumors and TGF-α level was also elevated in pre-neoplastic HCC 
(Feitelson et al., 2004). Thus, targeting EGFR may also show beneficial effect for HCC 
patients. EGFR blocking agents include both small molecule tyrosine kinase inhibitors and 
monoclonal antibodies targeting the receptor. Erlotinib is a low molecular weight inhibitor 
of EGFR kinase (Thomas et al., 2007). It is able to suppress the growth of HCC cell lines  
in vitro. Furthermore, during a Phase 2 clinical trial, 17 out of 40 patients with unresectable 
HCC achieved stable disease at 16 weeks of erlotinib treatment. Progression-free survival at 
16 weeks was 43% and median overall survival was 43 weeks, longer than the historical 
controls. Monoclonal antibody cetuximab which targets the extracelluar domain of EGFR 
has also been tested in HCC (Zhu et al., 2007). Although cetuximab was able to inhibit cell 
growth and induce apoptosis in some HCC cell lines, the results from clinical trials testing 
its efficacy among HCC patients have been inconsistent. Currently, several more anti-EGFR 
pathway compounds are being tested in clinic, in some cases in combination with other 
therapeutic methods. The results from those trials might further clarify the benefit of the 
EGFR blocking agents for HCC. 
Deregulation of the insulin-like growth factor (IGF) pathway has also been implicated in the 
development of HCC (Scharf et al., 2001). IGF-1 and 2 bind to IGF receptor IGF-1R and 
activate downstream signaling (Alexia et al., 2004). IGF signaling pathway regulates cell 
proliferation, motility and apoptosis. Pronounced alterations in the expression of 
components of the IGF pathway have been reported during hepatocarcinogenesis 
(Whittaker et al., 2010). IGF-2 is overexpressed in 16-40% of HCC and around 30% of HCCs 
overexpress IFG-1R (Cariani et al., 1988). Neutralizing IGF-2 has been shown to reduce cell 
proliferation and increase apoptosis in HCC cell lines (Lund et al., 2004). Furthermore, a 
monoclonal antibody that selectively inhibits IGF-1R was not only able to decrease viability 
and proliferation of liver cancer cells in vitro but also delay tumor growth and prolong 
survival in HCC xenograft mice model (Tovar et al., 2010). Several small molecules and 
monoclonal antibodies targeting IGF-1R are now under early clinical development. 
In HCC, the transforming growth factor-beta (TGF-β) pathway regulates several steps in 
tumor progression, including angiogenesis, production of the extracellular matrix and 
immune suppression (Giannelli et al., 2011). It is also involved in initiating signaling cascade 
which promotes liver fibrosis, cirrhosis and subsequent progression to HCC (Giannelli et al., 
2011). Increased levels of TGF-β in HCC patients' sera and urine are associated with disease 
progression (Yasmin Anum et al., 2009; Tsai et al., 1997). Specific small molecule inhibitors 
targeting TGF-β type I receptor (TGF-βRI) kinase LY2109761 reduce migration of HCC cells 
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and blocks invasion of HCC cells into the tissue microenvironment and blood vessels. 
LY2109761 also is effective in blocking tumor growth in a HCC xenograft chick embryo 
model and this antitumor activity was associated with anti-angiogenic effect (Mazzocca et 
al., 2009).  
Hepatocyte growth factor (HGF) is a cytokine secreted by mesenchymal cells. It can 
stimulate mitogenesis, cell motility and has been implicated in tumor invasion. HGF is 
secreted as a single inactive polypeptide and is cleaved by serine proteases into a 69-kDa 
alpha-chain and 34-kDa beta-chain (Matsumoto and Nakamura, 1996). Active HGF is a 
herterodimer between alpha-chain and beta-chain linked by disulfide bond. HGF is 
homologous to the plasminogen subfamily of S1 peptidases but has no detectable protease 
activity. The proto oncogene c-Met is a  receptor for HGF that is a heterodimer composed of 
a 50-kDa alpha-chain and a membrane spanning 145-kDa beta-chain with tyrosine kinase 
activity (Matsumoto and Nakamura, 1996). Activation of c-Met by HGF has been shown to 
activate MAPK, PI3K and Wnt signaling (Whittaker et al., 2010; Apte et al., 2006). 
Overexpression of c-Met was noted in 20-48% HCC tissues compared to surrounding non-
cancerous liver tissues, and the overexpression levels correlated with worsening behavior of 
HCC and decreased 5-year survival in HCC patients (Whittaker et al., 2010; Ueki et al., 
1997). A preclinical study reported that inhibition of c-Met by small molecule inhibitor 
SU11274 decreased HCC cell growth (Inagaki et al., 2011). 
3. Conclusion 
Many critical signaling pathways have been indicated in HCC development and a 
considerable amount of crosstalk and redundancy among those pathways have been 
observed. Various strategies targeting these pathways have been explored and have shown 
varying degrees of success in the clinic. Additional novel strategies are being investigated 
and raise the hope that more effective therapies may be on the horizon. However, HCC is a 
complex disease and aberrations in signaling pathways can vary from patient to patient. In 
addition, defects in multiple pathways may also in combination contribute to the 
pathogenesis. Uncovering the specific signaling pathways defects in the individual patient 
and the potential use of combination therapies may be critical for generating effective 
treatment outcomes in the future.  
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1. Introduction 
Cholangiocarcinoma is a type of liver cancer arising from the neoplastic transformation of 
the epithelial cells that line the intra- and extrahepatic bile ducts. Symptoms are usually 
evident only after blockage of the bile duct by the tumor. This is an extremely aggressive 
tumor, which has very poor prognosis and limited treatment options. Cholangiocarcinoma 
is relatively resistant to chemotherapy and radiation therapy leaving conventional treatment 
like surgery as the only option. Therefore, further understanding into the factors that are 
involved in tumor initiation, promotion and progression is required for designing alternate 
therapies to combat this devastating disease.  
The tumor microenvironment is one of the most important factors regulating tumor 
angiogenesis, tumor invasion and metastasis. The microenvironment is a well-recognized 
system that plays a key role in tumor progression. However, the mechanism through which 
tumor microenvironment regulates tumor progression and invasion is largely unknown. In 
this review, we discuss the current knowledge about the role of the tumor 
microenvironment in the pathogenesis of cholangiocarcinoma, the role of the tumor 
microenvironment in the classification of cholangiocarcinoma and efforts to develop 
treatments targeting the tumor microenvironment.  
2. Background 
Cholangiocarcinoma arises from the neoplastic transformation of cholangiocytes and can 
exist as either intrahepatic, perihilar or distal extrahepatic tumors (Alpini et al. 2001). 
Typically, cholangiocarcinomas are adenocarcinomas and have a poor prognosis and 
limited treatment options. This is due, at least in part, to the late presentation of symptoms 
and the relative resistance to current treatment options (Sirica 2005).  
The incidence of both intra- and extra-hepatic cholangiocarcinoma is typically more 
prevalent in Asian countries (Patel 2002). The mortality rates for intrahepatic 
cholangiocarcinoma have increased since the 1970s, whereas deaths from extrahepatic 
cholangiocarcinoma have declined in most countries (Patel 2002). There is a slight 
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preponderance for cholangiocarcinoma in males (Tominaga and Kuroishi 1994) and the 
incidence in both sexes increases with age (Patel 2002). 
2.1 Risk factors 
Cholangiocarcinoma occurs with varying frequency in different regions of the world. This 
can be explained in part by the distribution of risk factors in geographic regions and ethnic 
groups (Ben-Menachem 2007). The common link between these regional risk factors seems 
to involve chronic inflammation and biliary irritation (Gores 2003). 
The prevalence of cholangiocarcinoma in Asian countries shares a relationship with 
infections such as liver flukes, Hepatitis B and Hepatitis C (Ben-Menachem 2007). In 
contrast, approximately 90% of patients diagnosed with cholangiocarcinoma in Western 
countries do not have any recognized risk factors (Ben-Menachem 2007). However, the 
remaining 10% of cases are associated with certain risk factors. Apart from factors related to 
chronic inflammation, both intra- and extrahepatic cholangiocarcinomas are well-known 
complications of primary sclerosing cholangitis (de Groen et al. 1999). Other known risk 
factors include obesity, hepatolithiasis, bacterial infection and/or bile stasis-related chronic 
cholangitis (Chen 1999; de Groen et al. 1999; Catalano et al. 2009). 
3. Tumor microenvironment 
Neoplastic epithelial cells coexist with a biologically complex stroma composed of various 
types of stromal cells as well as the extracellular matrix, both of which create the complexity 
of the tumor microenvironment (Orimo and Weinberg 2006). Mouse models of 
tumorigenesis have revealed that stromal cells, in particular inflammatory cells, vascular 
endothelial cells and fibroblasts actively support tumor growth (Olumi et al. 1999; Tlsty 
2001; Cunha et al. 2003; Bhowmick et al. 2004). In addition, the microenvironment is now 
well recognized as playing a role in neoplastic transformation, malignant progression and 
metastasis and invasion of cancer cells (Tlsty 2001; Bhowmick et al. 2004). Furthermore, the 
interaction between the cancer cells and the tumor microenvironment is a major factor 
influencing cancer treatment resistance to radiotherapy and chemotherapy (de Visser and 
Jonkers 2009; Shinohara and Maity 2009). Research indicates that the interplay between the 
cancer cells and the stromal cells of the microenvironment is bi-directional and dynamic. For 
example, neoplastic cells often secrete factors that work in a paracrine manner to recruit and 
activate a number of types of stromal cells into the tumor microenvironment as required 
(Rasanen and Vaheri 2010; Rojas et al. 2010; Onimaru and Yonemitsu 2011). Conversely, 
stromal cells, once recruited and activated, release factors into the extracellular milieu that 
can either stimulate or inhibit growth of the tumor (Rasanen and Vaheri 2010; Rojas et al. 
2010; Onimaru and Yonemitsu 2011). The effects of the components of the tumor 
microenvironment on tumor growth are summarized in Figure 1. In particular, the 
proliferation and recruitment of vascular endothelial cells and subsequent formation of new 
blood vessels brings a nutrient supply thereby allowing growth and metastasis of the tumor. 
Cancer associated fibroblasts, on the other hand, can stimulate angiogenesis as well promote 
tumor growth and invasion. The presence of immune cells, in particular tumor-associated 
macrophages, in the microenvironment, confers resistance to toxic insults and also promotes 
growth. Lastly, proliferation of lymph endothelial cells and subsequent increase in 
lymphatic vessel density promotes tumor metastasis. 
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Fig. 1. Schematic representation of the effects of stromal support cells on tumor growth and 
metastasis. Abbreviations: B, B cell; BV, Blood vessel; EMT, Epithelial-mesenchymal 
transition; LV, lymph vessel; M, monocyte; T, T cell; TAM, Tumor associated macrophage. 
3.1 Angiogenesis 
The physiological process of the formation of new blood vessels from pre-existing blood 
vessels is termed angiogenesis. Tumors require the formation of new blood vessels to 
supply oxygen and other essential nutrients, without which their growth would be severely 
restricted (McDougall et al. 2006). Generally, the process of angiogenesis involves a 
sequence of co-ordinated events that is initiated with the expression and release of various 
angiogenic factors from the tumor cells, such as vascular endothelial growth factor (VEGF), 
epidermal growth factor (EGF) and fibroblast growth factor (FGF). Once these angiogenic 
factors bind to their corresponding receptors on the cell surface of the endothelial cells, there 
is an increase in vascular permeability, leading to extravasation of plasma proteins and 
dissociation of pericyte coverage (Roberts and Palade 1997; Dvorak 2005). This is followed 
by proliferation and migration of the endothelial cells to initiate new vessel formation 
(Ausprunk and Folkman 1977). For new vessel formation to occur, there also needs to be 
localized degradation of the extracellular matrix, which is performed by the matrix 
metalloproteinases, cathepsin B and other degradation enzymes, as well as the expression of 
matrix proteins such as fibronectin and laminin (Mikkelsen et al. 1995; Gladson 1999; 
Ljubimova et al. 2006). The expression of these essential extracellular matrix proteins largely 
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occurs in the tumor cells or cancer associated fibroblasts (Rasanen and Vaheri 2010), which 
then secrete them into the extracellular milieu. 
3.1.1 Angiogenesis in cholangiocarcinoma 
A recent immunohistochemical study of microvessel density and lymphatic microvessel 
density revealed that intrahepatic cholangiocarcinoma tumors demonstrated tumor-
associated angiogenesis (Thelen et al. 2009). Tumors with increased microvessel density 
were correlated with a higher recurrence rate, lower 5-year survival rates and increased 
nodal spread which in turn influences patient survival (Thelen et al. 2009). Recent studies 
have also shown that the overexpression of the angiogenic factors nerve growth factor- 
(NGF-) and vascular endothelial growth factor-C (VEGF-C) occurred in approximately 
57.1% and 46.4% of cholangiocarcinoma samples, respectively (Xu et al. 2010). A number of 
human cholangiocarcinoma cell lines and samples have also been shown to overexpress 
VEGF-A and VEGF receptors (VEGFRs), the angiogenic factors angiopoietin-1, -2, and 
thrombospondin-1, as well as EGF, EGF receptors (EGFR) and basic fibroblast growth factor 
(Ogasawara et al. 2001; Alvaro et al. 2006; Tang et al. 2006; Yoshikawa et al. 2008; Harder et 
al. 2009). Secretion of these factors may individually or co-ordinately bring about increased 
angiogenesis as demonstrated by increased microvessel density. For example, VEGF-A has 
been shown to play a role in the neovascularization of extrahepatic cholangiocarcinoma 
(Mobius et al. 2007).  
The factors that drive angiogenesis have also been shown to have distinct effects on 
cholangiocyte and cholangiocarcinoma growth in an autocrine manner (Gaudio et al. 2006; 
Tang et al. 2006; Mobius et al. 2007; Yabuuchi et al. 2009; Yoshikawa et al. 2009; Glaser et al. 
2010). Indeed, the proliferative effects of estrogen on cholangiocarcinoma cell lines have 
been attributed to a mechanism involving the upregulation of VEGF expression, as blocking 
VEGF ameliorates the estrogenic effects on proliferation (Mancino et al. 2009).  
Taken together, these data suggest that agents that block angiogenesis (by blocking VEGF 
expression, for example) may also have a direct effect on cholangiocarcinoma cell 
proliferation in addition to their anti-angiogenic effects. In support of this notion, inhibition 
of VEGFR and EGFR signaling with vandetanib (ZD6474, a tyrosine kinase inhibitor) can be 
an important approach for the management of the subset of cholangiocarcinoma that lack 
KRAS mutations and/or have EGFR amplification (Yoshikawa et al. 2009). Furthermore, 
ZD1839 (IRESSA), an orally active, selective inhibitor of EGFR tyrosine kinase has clinical 
activity against cholangiocarcinoma by stabilizing the cell cycle inhibitor, p27Kip1 and 
enhancing radiosensitivity in cholangiocarcinoma cell lines (Yabuuchi et al. 2009). 
Curcumin, a natural phenol found in tumeric has recently been shown to suppress the 
expression of VEGF and decrease the microvessel density in a hamster model of 
cholangiocarcinoma (Prakobwong et al. 2011a). In parallel, curcumin also exerts 
antiproliferative and proapoptotic effects on cholangiocarcinoma cells independent of the 
effects on angiogenesis (Prakobwong et al. 2011a; Prakobwong et al. 2011b). Similar effects 
have been shown with inhibitors of histamine synthesis (Francis et al. 2011), H3 histamine 
receptor agonists (Francis et al. 2009), and Endothelin-1 (Fava et al. 2009) just to name a few. 
The interaction between angiogenesis, angiogenic factors and cholangiocarcinoma growth 
and progression is summarized in Figure 2. 
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The interaction between angiogenesis, angiogenic factors and cholangiocarcinoma growth 
and progression is summarized in Figure 2. 
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Fig. 2. Schematic representation of the interactions between cholangiocarcinoma and 
angiogenic factors regulating cell proliferation and angiogenesis 
3.2 Cancer associated fibroblasts 
Under normal physiological conditions, fibroblasts have a low proliferative index and only 
secrete factors needed to maintain normal tissue homeostasis (Tuxhorn et al. 2001; Beacham 
and Cukierman 2005). Indeed, normal fibroblasts provide biochemical cues that constrain 
epithelial tumor cells within their basement membrane (Tuxhorn et al. 2001; Beacham and 
Cukierman 2005). In contrast, when homeostasis is disrupted during tissue injury, stromal 
cells rapidly and reversibly alter their phenotype and proliferation rate (Tuxhorn et al. 2001). 
However, during tumorigenesis, the fibroblastic wound healing machinery lacks the 
regulatory mechanisms to revert to normal homeostasis (Tuxhorn et al. 2001). The inability 
to down-regulate the wound healing response affects stromal dynamics. Tumor-dependent 
changes in signaling and plasticity of the stroma trigger a continuum of alterations yielding 
a ‘primed’ stroma that can support and incite tumor initiation or progression (Tuxhorn et al. 
2001).  
3.2.1 Cancer-associated fibroblasts in cholangiocarcinoma 
Cancer-associated fibroblasts are the predominant cell type in the stroma of 
cholangiocarcinoma tumors (Sirica et al. 2009). Increased -smooth muscle actin-positive 
fibroblasts were correlated with shorter survival times and larger tumor sizes in resected 
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cholangiocarcinoma tissue (Chuaysri et al. 2009; Okabe et al. 2009). The origin of these 
cancer-associated fibroblasts is unknown, although a number of possibilities have been 
suggested, including hepatic stellate cells (Okabe et al. 2009), portal fibroblasts (Dranoff and 
Wells 2010) or circulating bone marrow-derived precursor cells (Shimoda et al. 2010). Given 
the apparent heterogeneous population of cancer-associated fibroblasts observed in 
cholangiocarcinoma tumors, it is highly likely that these fibroblasts are derived from more 
than one source. Recently, researchers have performed genetic screening to determine the 
differences in gene expression between cholangiocarcinoma-derived cancer-associated 
fibroblasts and non-malignant liver fibroblasts and showed a number of genes associated 
with angiogenesis, cell proliferation and motility (Utispan et al. 2010). In particular, 
periostin, a cell adhesion molecule, was shown to be significantly upregulated correlating 
with shorter survival time in patients and increased cell proliferation and invasive 
properties in vitro (Utispan et al. 2010). Another gene specifically expressed by 
cholangiocarcinoma-derived cancer-associated fibroblasts is the extracellular matrix protein 
tenascin-C (Aishima et al. 2003; Iguchi et al. 2009). This gene was expressed predominantly 
in the stroma near the invasion front of the tumor (Aishima et al. 2003) and was associated 
with poor prognosis in intrahepatic cholangiocarcinoma (Aishima et al. 2003; Iguchi et al. 
2009). Furthermore, the expression of thrombospondin-1 by cancer-associated fibroblasts 
correlated with increased metastatsis (Kawahara et al. 1998; Tang et al. 2006).  
 
Fig. 3. Summary of the signalling molecules released by cholangiocarcinoma-derived cancer-
associated fibroblasts and their known effects on cholangiocarcinoma progression. CAFs; 
cancer-associated fibroblasts, HGF; hepatocyte growth factor, SDF-1; stromal derived factor-1. 
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One last cancer-associated fibroblast gene of note is the expression of the chemokine, 
stromal-derived factor 1, which is released from stromal fibroblasts and stimulates the 
invasion and migration of cholangiocarcinoma cells via interaction with the chemokine 
receptor, CXCR4 (Ohira et al. 2006). A summary of these and other cholangiocarcinoma-
derived cancer-associated fibroblasts can be found in Figure 3. 
The preponderance of data demonstrating a role for cancer-associated fibroblasts in the 
growth and invasion of cholangiocarcinoma suggest that targeting molecular signals released 
from cancer-associated fibroblasts may be a viable option, in addition to strategies for 
suppressing cholangiocarcinoma cell proliferation, for the treatment of cholangiocarcinoma. 
3.3 Tumor-associated macrophages 
Inflammation and the immune system share a long-standing relationship with tumor initiation 
and progression. Indeed, the primary risk factor for the development of a number of different 
tumor types is chronic inflammation of the target organ (Sica 2010). Once a tumor is initiated, 
tumor-associated macrophages (TAMs) are the major immune cell found within tumors. 
Macrophages generally have the potential to express and secrete pro- and anti-inflammatory 
molecules, and as such, may have pro- and anti-tumor activities depending upon the 
activation stimulus (Sica 2010). For example, macrophages activated with tumor necrosis factor 
, (considered M1 activation), have anti-tumor activity and signal tissue destruction (Mantovani 
et al. 2002). Alternatively, in response to interleukin-4, macrophages undergo M2 activation  
and are involved in tissue repair, remodelling and tumor promotion (Mantovani et al. 2002).  
 
Fig. 4. Schematic representation of the pro- (M1) and anti-(M2) inflammatory activation of 
macrophages and their effect on tumor growth.  
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Logically, most TAMs have an M2-like phenotype (Mantovani and Sica 2010) thought to be 
brought about by various signals expressed within the tumor microenvironment, including 
interleukin-10, transforming growth factor- and colony stimulating factor-1 (Sica 2010). These 
signals responsible for the M2-activation of macrophages have been reported to come from 
myeloid-derived suppressor cells, IL-10+ B lymphocytes, Th2 subtype of T helper cells and the 
tumor cells themselves (Sica 2010). Once alternatively activated, TAMs exhibit reduced anti-
tumor activities, while increasing the production of mediators of angiogenesis such as VEGF 
and IL-10 (Mantovani and Sica 2010), as well as M2-specific genes that are known to be 
involved in promoting cell proliferation (Mantovani and Sica 2010). These events are 
summarized in Figure 4.  
It has been proposed that strategies to inhibit the M2- and activation of the M1-inducing 
signals may lead to the restoration of the anti-tumor functions of TAM and help to remove 
the protective signals originating from the M2 TAM (Sica and Bronte 2007), which may 
trigger an innate immune response, thereby reducing tumor size (Sica 2010).  
3.3.1 Tumor-associated macrophages in cholangiocarcinoma 
As mentioned previously, cholangiocarcinoma shares a long-standing relationship with 
chronic inflammation (Gores 2003). Indeed, cholangiocarcinoma cells are known to over-
produce many inflammatory cytokines, with IL-6 being the most studied (Isomoto et al. 
2007). The role of TAMs in the development and progression of cholangiocarcinoma is 
poorly understood. However, recent studies have demonstrated that the density of 
infiltrating macrophages (as demonstrated using the MAC387 antibody to specifically stain 
macrophages) was high in over half of the tumor samples studied and that a high density of 
MAC387-positive cells correlated to a poor survival rate although conclusive proof that 
these cells were of the M2-phenotype is lacking (Subimerb et al. 2010a). Similarly, a subset of 
monocytes (CD14+CD16+) thought to be the precursors of tissue-resident macrophages are 
increased in the blood from cholangiocarcinoma patients, the levels of which were 
correlated with the density of MAC387-positive infiltrating macrophages (Subimerb et al. 
2010b). The circulating CD14+CD16+ monocytes also expressed higher levels of angiogenic 
factors such as VEGF and the chemokine CXCL3 (Subimerb et al. 2010b). Lastly, Hasita et al. 
demonstrated that the macrophages infiltrating intrahepatic cholangiocarcinoma are mainly 
of the M2 phenotype (using CD163 as a marker of M2-type macrophages); their number 
correlates closely with neovascularization and infiltration of FOXP3+ regulatory T cells 
(Hasita et al. 2010). Furthermore, treatment of macrophages in culture with the supernatant 
from a number of CCA cells induced macrophage polarization toward the M2 phenotype 
and induced the macrophage-derived expression and secretion of VEGF-A, IL-10 and TGF 
(Hasita et al. 2010). Taken together, these data suggest that TAMs may play a role in 
cholangiocarcinoma progression. However, the molecules regulating the crosstalk between 
M2-type TAMs and cholangiocarcinoma cells needs to be further clarified. 
3.4 Lymphangiogenesis in cancer 
Tumor metastasis is the most lethal aspect of cancer. The spread of tumor cells is often via 
the lymphatic vasculature and the presence of tumor foci in lymph nodes is considered an 
adverse prognostic factor in most carcinomas (Achen and Stacker 2008). Metastatic spread of 
tumor cells via the lymphatic system was previously thought to be via a passive process by 
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which detached tumor cells enter pre-existing lymphatic vessels in the vicinity of the tumor 
(Achen and Stacker 2008). However, recent studies suggest that the formation of new 
lymphatic vessels in the tumor microenvironment correlates with lymphatic metastasis 
(Achen et al. 2005).  
To date, the growth factors recognized to be associated with the control of 
lymphangiogenesis are similar to those that control angiogenesis. That is, the most 
characterized factors are VEGF-C and VEGF-D, which are secreted from the tumors, and 
then activate VEGFR-3 expressed on lymphatic endothelium (Lymboussaki et al. 1998). 
Activation of VEGFR-3 induces the proliferation of lymphatic endothelial cells in vitro 
(Makinen et al. 2001) and the formation of new lymphatic vessels in vivo (Veikkola et al. 
2001). Other identified lymphangiogenic factors include VEGF-A (Nagy et al. 2002), 
fibroblast growth factor-2 (Kubo et al. 2002), angiopoietin-2 (Gale et al. 2002) and platelet-
derived growth factor-BB (Cao et al. 2004).  
Because of the overlap in angiogenic and lymphangiogenic activity of the above-mentioned 
factors, agents designed to block angiogenesis may also be effective in blocking 
lymphangiogenesis. For example, inhibitors that block the VEGF-C/VEGF-D/VEGFR3 
signalling mechanism might have the potential to not only block angiogenesis, but to also 
block lymphangiogenesis and hence to block lymphogenous metastatic spread (Baldwin et al. 
2002; Stacker et al. 2002a; Stacker et al. 2002b). Indeed, a neutralizing VEGF-D monoclonal 
antibody designed to block the interaction between VEGF-D and its receptors, inhibited 
angiogenesis, lymphangiogenesis and metastatic spread via the lymphatics in a mouse tumor 
model (Stacker et al. 2001). Further studies into therapeutic strategies designed to block 
lymphangiogenesis are required in an attempt to stop the metastatic spread of tumors.  
3.4.1 Lymphangiogenesis in cholangiocarcinoma 
The role of lymphangiogenesis in cholangiocarcinoma metastasis and progression is largely 
unknown and controversial. However, recent studies suggest that there is a correlation 
between lymphangiogenesis and lymph node metastases and prognosis; patients diagnosed 
with cholangiocarcinoma tumors exhibiting low lymphatic vessel density have a longer 
survival rate than those with higher lymphatic vessel density (Thelen et al. 2008). In 
addition, in intrahepatic cholangiocarcinoma tumors, high lymphatic vessel density 
correlated with increased nodal spread and higher recurrence rate (Thelen et al. 2009). 
Conversely, other researchers demonstrated that in intrahepatic cholangiocarcinoma 
tumors, lymph node metastasis did not correlate with lymphangiogenesis, but did correlate 
with VEGF-C expression and the presence of a subset of myofibroblasts expressing the same 
markers as lymphendothelial cells (Aishima et al. 2008), which may explain the discrepancy 
in conclusions.  
NGF has previously been linked to tumor progression and growth (Sortino et al. 2000; 
Descamps et al. 2001a; Descamps et al. 2001b) as well as VEGF expression (Lazarovici et al. 
2006a; Lazarovici et al. 2006b) in a number of other cell types. Therefore, Xu et al. assessed 
the correlation of NGF- expression with lymphangiogenesis, lymph node metastasis or 
VEGF-C expression in hilar cholangiocarcinoma tissue (Xu et al. 2010). Indeed, high NGF 
expression was correlated with VEGF-C overexpression, lymphatic vessel density, and 
lymph node metastasis suggesting that NGF may also be responsible for stimulating 
lymphangiogenesis in cholangiocarcinoma tumors. 
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4. Conclusions 
The work highlighted in this review clearly demonstrates a role for the tumor 
microenvironment in the growth, progression and metastatic invasion of 
cholangiocarcinoma. There is obviously a strong interplay between the cells found in the 
stroma and cholangiocarcinoma cells with signaling molecules passing back and forth 
between the cell types to co-ordinately support an environment that nurtures tumor growth 
and suppresses innate immunity while conferring resistance to cytotoxic insults (both 
endogenous and chemotherapeutic). The mechanism by which each of the support cells 
found in the stroma of cholangiocarcinoma tumors are recruited and activated is still largely 
unknown. Therapeutic strategies designed to target the microenvironment rather than 
specifically targeting the cholangiocarcinoma cells might prove fruitful in the quest to 
combat this devastating cancer. 
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1. Introduction 
1.1 Definition of ultrasonographic method 
Ultrasound exploration (ultrasonography) is a very common diagnostic method. It is part of 
imaging procedures, without using ionizing radiations but ultrasounds (US) with usual 
frequencies of 2 - 5 - 12 MHz. Ultrasounds cross biological environments and are reflected at 
the demarcation limit between structures of different consistencies. The current procedure 
of ultrasound examination called "scanning" is based on the analysis of every plane from a 
region of interest in the human body. Each plane contains a high number of points with 
different brightness (within the limit of the gray scale used by the equipment) and their sum 
makes a defining "echostructure" for each organ. Ultrasound diagnosis is based on changes 
in tissue density due to pathological changes, resulting in echostructure transformation. 
Ultrasonography is an anatomical, hemodynamic and functional exploration. 
1.2 Brief history 
Since the 1940s there have been pioneers (physicians, biologists, physicists) who intuited 
that acoustic energy, at that time used only in war industry to detect submarines, could have 
applications in medical diagnosis. The first ultrasound images contained information about 
the density of tissues displayed along an axis ("A- mode" ultrasound). Later, "sectional" 
ultrasound was invented, which detailed echoes in a plane ("B-mode" ultrasound with 
applications in obstetrics). In the '60s the procedure had an accelerated development by 
diversifying examination techniques, identifying more clinical applications and increasing 
access to a large number of specialties. In the ‘70s clinical specialties such as obstetrics and 
cardiology "claimed" the method, using as the main argument its clinical character arising 
from the direct relationship between the examining physician and the patient. After the ‘90s, 
emergency physicians requested the presence of miniature, portable ultrasound equipment 
in the emergency room proving that ultrasound, using accordingly well defined algorithms, 
contributed to saving lives. Today, ultrasonography is used by clinicians in more than 50% 
of cases. Although there is still an ongoing "battle" between clinicians and radiologists for 




the method, considered today the most common diagnostic imaging procedure in the world 
(Derchi & Claudon, 2009). In the near future the ultrasound examination will be 
unrestrictedly generalized with the introduction of the procedure as basic training for 
medical students, as part of clinical examination. 
1.3 Advantages and disadvantages of the ultrasound method 
Ultrasound is useful for the practitioner as a first imaging procedure in direct correlation to 
the clinical examination. The method has a very good cost/quality ratio, the image is very 
accurate and precise and the information has a dynamic character ("real time imaging"). It is 
important to note that ultrasound has its limitations which the examining physician must 
take into account. Thus, the ultrasound image contains a number of artifacts and is mainly 
limited by phenomena such as US attenuation related to distance and density. Ultrasound is 
an operator-dependent method, thus its reproducibility is reduced. 
1.4 Ultrasound techniques and procedures 
The principles of ultrasonography are complex. The US picture is generated by ultrasound 
penetration into the human body. US are reflected as echoes and converted by the 
transducer into signals. The ultrasound image is multimodal. There are multiple US 
procedures systematized into "clinical applications" and the information obtained is tissular 
("morphometric" type) and vascular ("hemodynamic "type). Finally, US examination is a 
“real time” procedure which reflects the movements of the organs.  It is mandatory to 
connect the US information to the clinical and functional-biochemical data in order to obtain 
the final diagnosis.  
1.4.1 Tissue investigation 
The conventional US currently used in practice is called “2D, gray scale” sonography. The 
technique is based on US property with frequencies > 20 kHz and constant acoustic power 
to cross tissues with an average speed of 1540 cm/sec. US are returned with different 
acoustic power at a variable timeframe depending on the acoustic density of the crossed 
environment and on the position of the reflecting element. There is a proportional 
relationship between the intensity of the echo and the density of a crossed biological 
environment; therefore, ultrasound is a noninvasive tissue density assessment procedure. 
There are two categories of echoes according to their frequency: basic (similar to the incident 
beam, i.e. 3 MHz) and "harmonic" (multiples of the emission frequency, i.e. 6 MHz). 
Harmonic echoes arise from the non-linear vibration of the tissues. Due to their high 
frequency, the result is a high quality image. Harmonic ultrasound technique ("coded 
harmonics" or "tissue harmonic imaging," THI) combined with the pulse inversion 
procedure ("pulse inversion harmonic imaging") allows to obtain information regardless of 
the depth where the region of interest lies and is available on most commercial equipment 
(Choudhry et al, 2000). 
Image resolution (minimum size at which a reflected structure is distinctly shown on the 
screen) is essential for tumor detection. The number of crystals included into the transducer 
and the nominal frequency of the ultrasound beam (the higher the frequency the better the 
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frequency, the result is a high quality image. Harmonic ultrasound technique ("coded 
harmonics" or "tissue harmonic imaging," THI) combined with the pulse inversion 
procedure ("pulse inversion harmonic imaging") allows to obtain information regardless of 
the depth where the region of interest lies and is available on most commercial equipment 
(Choudhry et al, 2000). 
Image resolution (minimum size at which a reflected structure is distinctly shown on the 
screen) is essential for tumor detection. The number of crystals included into the transducer 
and the nominal frequency of the ultrasound beam (the higher the frequency the better the 
resolution) also contribute to the ultrasound image quality. The gain of echoes ("gain" 
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function) and the time compensation of echoes gain ("time gain compensation" function) 
measured in decibels, image depth and the number of focuses, echoes acquisition and their 
representation rate are other elements that allow information rendering with the same 
quality at an approximate ultrasound penetration of 20 to 25 cm. All these phenomena 
contribute to image the tissue echostructure. The sonography has a very good capacity to 
discriminate lesions depending on their consistency (a parenchymal cyst is detectable at a 2-
3 mm size!; a solid nodule is distinctly shown at sizes of  5 - 6 mm). In addition, the method 
allows accurate assessment of the lesion size and the evaluation of organ motility 
(gastrointestinal tract, heart, main vessels). 
The ultrasound image is planar, two-dimensional (2D ultrasound). In recent years 
equipments have been developed, allowing 3D reconstruction of ultrasound images. The 
resulting images are not planes but volumes that can be static (3D) or dynamic (4D). 3D/4D 
exploration has recognized obstetrical applications but other areas of application of this 
method have been identified in recent years, mainly in oncology. 3D/4D ultrasound 
provides accurate information in connection with the space, shape, size and tumors texture. 
This procedure may be useful to measure the real tumor volume as well as the healthy 
surrounding parenchyma which should to be removed in case of surgery. Combining this 
procedure with intratumoral circulation assessment methods allows more accurate 
diagnosis of the tumor nature (Badea et al, 2007). 
1.4.2 Blood flow and microcirculation investigation 
Blood flow can be explored by ultrasound using various techniques. Some are based  
on Doppler principle (or derivatives) and others on the use of intravenous contrast agents 
(CA). 
1.4.2.1 Doppler ultrasound 
It is an established method for the assessment of blood flow based on the frequency 
variation of a US beam hitting a target (in our case, groups of red blood cells) in motion. The 
difference in frequency and its positive or negative character are elements that allow 
vectorial representation of blood speed and direction of movement against the transducer. 
Doppler ultrasound has several technical options: spectral and color coded, each of them 
with their advantages and disadvantages. Thus: spectral ultrasound describes the flow type 
(arterial or venous) and allows measurements. Color flow mode (CFM) ultrasound encodes 
speed vectors related to red blood cells groups thus detecting blood flows. Evaluation of 
tumor vasculature will be made first using the CFM module and then spectral Doppler 
module by positioning the Doppler sample on reference regions. On CFM investigation 
tumor vessels have tortuous paths, aberrant spatial ramifications, they intercommunicate 
and can abruptly end in "glove finger" (Cherrington et al, 2000). Spatial positioning of 
intratumoral vessels can also be illustrated by 3D/4D reconstruction procedures and 
quantitative assessment can be achieved with techniques using color pixel count per unit 
area. Spectral investigation measurements into the tumor vessels lumen show either low 
values (RI<0.65; S/D <2.5) suggesting the absence of arterial precapillary sphincter and the 
presence of arterio-venous shunts or high values secondary to increased interstitial pressure. 
Accelerated flow speed can be identified in the input vessels from the tumor hilum 




1.4.2.2 Contrast Enhanced Ultrasound (CEUS) 
The introduction of intravenous (i.v.) contrast agents (CAs) is a great step forward for 
ultrasound. The first attempts to contrast ultrasound emerged in the '60s and had 
applications in interventional cardiology. After the 90s, first generation contrast agents were 
introduced into the clinical practice (the most used product is Levovist, Schering AG). These 
are air containing microbubbles, wrapped in a stabilizing membrane with the property to 
enhance the intensity of the echoes received from the blood flow thus making the Doppler 
signal more evident. This type of CAs has the disadvantage of a "blooming” effect of the 
color on CFM examination which masks the information derived from the microcirculation. 
With the development of transducer technology and the introduction of intermittent pulses 
emission with high mechanical index (MI> 0.2) it was possible to detect slow flows by 
identifying signals resulting from "breaking" microbubbles. This technique, called 
"destructive" contrast ultrasound is similar to that of contrast CT or MRI. Its disadvantage is 
that information cannot be obtained in "real time". After the year 2000, second generation 
contrast agents were introduced in clinical practice [SonoVue® in Europe, SonazoidTM in 
Japan, Definity in Canada, OptisonTM). They consist of microbubbles filled with different 
gases other than air, with stability and elasticity in the bloodstream higher than that of the 
first generation CAs. The exposure of these CAs to low mechanical index (MI <0.1 to 0.2) US 
generates harmonics echoes resulting from non linear microbubble oscillation (table 1). 
 
Particularity Importance 
They do not cross vessel walls, being 
strictly confined to the circulatory 
bed.  
They are real angiospecific tracers useful for 
quantification of circulation in a region of 
interest. 
Characterized by repeated 
recirculation from the large to small 
circulation until complete clearance 
High persistence and prolonged investigation 
Elimination of contrast agent is made 
through respiration and breakage Can be used in renal and hepatic failure 
They show a non-linear oscillation 
when exposed to low MI ultrasounds  
Ultrasound information is found in harmonic 
echoes  
Ultrasound exploration is dynamic, “in real 
time” 
Table 1. Characteristics of second generation contrast agents. Particularities and importance. 
As low acoustic power US are used, this procedure does not break the microbubbles, which 
allows "real time" blood flow examination during several minutes (Burns & Wilson, 2006). 
Harmonic contrast US examination, using second generation CAs requires special software 
equipment which suppresses 2D ultrasound image derived from the tissues by inverted 
phase ultrasound emission (the technique is called "pulse inversion"). In this way the 
information on the screen will correlate only to harmonic echoes generated by the 
microbubbles (Burns et al, 2000). 
CEUS examination is a qualitative examination. As it is a continuous exploration, CEUS 
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As low acoustic power US are used, this procedure does not break the microbubbles, which 
allows "real time" blood flow examination during several minutes (Burns & Wilson, 2006). 
Harmonic contrast US examination, using second generation CAs requires special software 
equipment which suppresses 2D ultrasound image derived from the tissues by inverted 
phase ultrasound emission (the technique is called "pulse inversion"). In this way the 
information on the screen will correlate only to harmonic echoes generated by the 
microbubbles (Burns et al, 2000). 
CEUS examination is a qualitative examination. As it is a continuous exploration, CEUS 
allows successive identification of vascular phases: arterial (approximately 10 - 15 sec. from 
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the time of injection in the peripherals up to approx. 30-40 seconds) and venous. Some 
circulation areas (liver, spleen) have a "late" phase due to the "capture" of microbubbles into 
the reticulo-histiocyte system (RHS). In addition, the investigation also allows the 
assessment of vascular morphology which provides information similar to angiography. 
CEUS investigation has a high temporal resolution, superior to CT or MRI explorations. 
CEUS liver investigation has two important elements that make it distinct (Cosgrove, 2007; 
Claudon et al, 2008): 
a. the liver has a complex vascularization: for input (arterial and portal phase, the first  
can be identified in approx. 10 - 30 seconds after injection and the second in approx.  
30 - 90 seconds after i.v. CA injection) and for elimination (sinusoidal phase, 
progressively occurs in approx. 120 seconds after injection and has a total duration of 
approx. 4-5 minutes); 
b. liver tumors have a characteristic vasculature according to their nature, e.g. 
hepatocellular carcinoma is highly arterialized; metastases have a mixed input 
vasculature; benign tumors have a variable circulatory bed (hemangioma is highly 
capillarized). Tumor characterization using CEUS procedure is based on the contrast 
agent crossing the region of interest (dynamic, particularities) and on the vascular bed 
characteristics (presence, spatial distribution, vascular morphology, areas lacking signal 
which means scar or necrosis). This analysis is separately carried out in the arterial, 
portal venous and late phases. Algorithms are currently available that help liver mass 
discrimination (Bolondi et al, 2007). The procedure can be combined with 3D 
reconstruction techniques, which confers additional utility to the method (Luo et al, 
2009). 
A useful procedure to obtain more quantitative details is contrast curves analysis. These 
consist of graphical representation of the CA dynamics while crossing a region of interest. 
The method is useful for assessing chemotherapy efficacy in various malignancies. 
 
Fig. 1. Contrast dynamic analysis curves in the region of interest - TIC. Tracer dynamics in 
the region of reference is marked with blue and with yellow in the region of interest 





Limitations of CEUS examination. Harmonic contrast examination has some limitations 
including: a) the procedure is indicated only correlated with good 2D image; b) it has a 
relatively high cost; c) it is operator dependent examination. 
2. 2D and harmonic ultrasonography in detecting and characterizing liver 
tumors 
2.1 Characteristics of ultrasound diagnosis 
Ultrasound diagnosis of liver tumors involves two stages: detection and characterization.  
Tumor detection is based on the performance of the method as already presented and should 
include morphometric information (three axes dimensions, volume) and topographic 
information (number, location specifying liver segment and lobe/lobes). The specification of 
these data is important for staging liver tumors and prognosis.  
Tumor characterization is a complex process based on a sum of criteria leading towards 
tumor nature definition. Often, other diagnostic procedures, especially interventional ones 
are no longer necessary. Ultrasound examination has the same morphological and 
hemodynamic criteria as those of CT and MRI imaging procedures. However, semiology 
will be adjusted to the specifics of this method. Tumor characterization using the ultrasound 
method will be based on the following elements: consistency (solid, liquid, mixed), 
echogenity, structure appearance (homogeneous or heterogeneous), delineation from 
adjacent liver parenchyma (capsular, imprecise), elasticity, posterior acoustic enhancement 
effect, the relation with neighboring organs or structures (displacement, invasion), 
vasculature (presence, Doppler and CEUS characteristics). The substrate on which the tumor 
condition develops (if the liver is normal or if there is evidence of diffuse liver disease) and 
the developing context (oncology, septic) are also added. Particular attention should be paid 
to the analysis of the circulatory bed. Microcirculation investigation allows for 
discrimination between benign and malignant tumors. Characteristic elements of malignant 
circulation are vascular density, presence of vessels with irregular paths and size, some of 
them intercommunicating, some others blocked in the end with “glove finger” appearance, 
the presence of arterio-arterial and arterio-venous shunts, lack or incompetence of arterial 
precapillary sphincter made up of smooth musculatures (Weidener et al, 1991). 
Diagnosis and characterization of liver tumors require a distinct approach for each group of 
conditions, using the available procedures discussed above for each of them. The correlation 
with the medical history, the patient’s clinical and functional (biochemical and 
hematological) status are important elements that should also be considered. 
2.2 Benign liver tumors 
They generally develop on normal or fatty liver, are single or multiple (generally 
paucilocular), have distinct delineation, with increased echogenity (hemangiomas, benign 
focal nodular hyperplasia) or absent, with posterior acoustic enhancement effect (cysts), 
have distinct delineation (hydatid cyst), lack of vascularization or show a characteristic 
circulatory pattern,  displace normal liver structures and even neighboring organs (in case of 
large sizes), are quite elastic and do not invade liver vessels. The patient has a good general 
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condition develops (if the liver is normal or if there is evidence of diffuse liver disease) and 
the developing context (oncology, septic) are also added. Particular attention should be paid 
to the analysis of the circulatory bed. Microcirculation investigation allows for 
discrimination between benign and malignant tumors. Characteristic elements of malignant 
circulation are vascular density, presence of vessels with irregular paths and size, some of 
them intercommunicating, some others blocked in the end with “glove finger” appearance, 
the presence of arterio-arterial and arterio-venous shunts, lack or incompetence of arterial 
precapillary sphincter made up of smooth musculatures (Weidener et al, 1991). 
Diagnosis and characterization of liver tumors require a distinct approach for each group of 
conditions, using the available procedures discussed above for each of them. The correlation 
with the medical history, the patient’s clinical and functional (biochemical and 
hematological) status are important elements that should also be considered. 
2.2 Benign liver tumors 
They generally develop on normal or fatty liver, are single or multiple (generally 
paucilocular), have distinct delineation, with increased echogenity (hemangiomas, benign 
focal nodular hyperplasia) or absent, with posterior acoustic enhancement effect (cysts), 
have distinct delineation (hydatid cyst), lack of vascularization or show a characteristic 
circulatory pattern,  displace normal liver structures and even neighboring organs (in case of 
large sizes), are quite elastic and do not invade liver vessels. The patient has a good general 
status, as tumors are often asymptomatic, being incidentally discovered. 
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2.2.1 Liver cysts 
They can be single or multiple, with variable size, generally less than 20 mm (congenital). 
Rarely, sizes can reach several centimeters, leading up to the substitution of a whole liver 
lobe (acquired, parasitic). They may be associated with renal cysts; in this case the disease 
has a hereditary, autosomal dominant transmission (von Hippel Lindau disease).  
The ultrasound appearance is a well defined lesion, with very thin, almost unapparent 
walls, without circulatory signal at Doppler or CEUS investigation. The content is 
transonic suggesting fluid composition. The presence of membranes, abundant sediment 
or cysts inside is suggestive for parasitic, hydatid nature. Posterior from the lesion the 
"acoustic enhancement" phenomenon is seen, which strengthens the suspicion of fluid 
mass. They typically displace normal liver vessels but no vascular or biliary invasion 
occurs. 
      
Fig. 2. Liver cyst – left image. Hydatid liver cyst (2D exam) – right image. Diagnostic criteria 
are the presence of membranes and sediment inside. 
2.2.2 Hemangioma 
It is the most common liver tumor with a prevalence of 0.4 - 7.4%. It is generally 
asymptomatic but also can be associated with pain complaints or cytopenia and/or 
anemia when it is very bulky. It is unique or paucilocular. It can be associated with other 
types of benign liver tumors. Characteristic 2D ultrasound appearance is that of a very 
well defined lesion, with sizes of 2-3 cm or less, showing increased echogenity and, when 
located in contact with the diaphragm, a "mirror image" phenomenon can be seen. When 
palpating the liver with the transducer the hemangioma is compressible sending 
reverberations backwards. Doppler exploration reveals no circulatory signal due to very 
slow flow speed. CEUS investigation has real diagnosis value due to the typical behavior 
of progressive CA enhancement of the tumor from the periphery towards the center. The 
enhancement is slow, during several minutes, depending on the size of hemangioma and 
on the presence (or absence) of internal thrombosis. During late (sinusoidal) phase, if 
totally "filled" with CA, hemangioma appears isoechoic to the liver. Deviations from the 
above described behavior can occur in arterialized hemangiomas or those containing 
arterio-venous shunts. In these cases differentiation from a malignant tumor is difficult 
and requires other imaging procedures, follow up and measurements of the tumor at 





Fig. 3. Hepatic hemangioma (2D). The lesion is located in the left hepatic lobe. Note precise 
delineation, their increased echogenity and the heterogeneous internal structure. 
 
Fig. 4. Hepatic hemangioma (CEUS). Progression of CA from the periphery toward the 
center of the lesion is evidenced by examination at various time intervals (a – arterial phase; 
b – late phase). 
2.2.3 Focal nodular hyperplasia 
It is a tumor developed secondary to a circulatory abnormality with abundant arterial 
vessels having a characteristic location in the center of the tumor, within a fibrotic scar. A 
radial vessels network develops from this level with peripheral orientation. The tumor’s 
circulatory bed is rich in microcirculatory and portal venous elements. The incidence is 
higher in younger women and tumor development is accelerated by oral contraceptives 
intake. 2D ultrasound appearance is a fairly well-defined mass, with variable sizes, usually 
single, solid consistency with inhomogeneous structure. Rarely the central scar can be 
distinguished. Spectral Doppler examination detects central arterial vessels and CFM 
exploration reveals their radial position. CEUS examination shows central tumor filling of 
the circulatory bed during arterial phase and completely enhancement during portal venous 
phase. During this phase the center of the lesion becomes hypoechoic, enhancing the tumor 
scar. During the late phase the tumor remains isoechoic to the liver, which strengthens the 





Fig. 3. Hepatic hemangioma (2D). The lesion is located in the left hepatic lobe. Note precise 
delineation, their increased echogenity and the heterogeneous internal structure. 
 
Fig. 4. Hepatic hemangioma (CEUS). Progression of CA from the periphery toward the 
center of the lesion is evidenced by examination at various time intervals (a – arterial phase; 
b – late phase). 
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It is a tumor developed secondary to a circulatory abnormality with abundant arterial 
vessels having a characteristic location in the center of the tumor, within a fibrotic scar. A 
radial vessels network develops from this level with peripheral orientation. The tumor’s 
circulatory bed is rich in microcirculatory and portal venous elements. The incidence is 
higher in younger women and tumor development is accelerated by oral contraceptives 
intake. 2D ultrasound appearance is a fairly well-defined mass, with variable sizes, usually 
single, solid consistency with inhomogeneous structure. Rarely the central scar can be 
distinguished. Spectral Doppler examination detects central arterial vessels and CFM 
exploration reveals their radial position. CEUS examination shows central tumor filling of 
the circulatory bed during arterial phase and completely enhancement during portal venous 
phase. During this phase the center of the lesion becomes hypoechoic, enhancing the tumor 
scar. During the late phase the tumor remains isoechoic to the liver, which strengthens the 
diagnosis of benign lesion.  
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Fig. 5. Benign focal nodular hyperplasia (CEUS). Gray scale examination (left) detects the 
lesion. CEUS examination (right) allows characterization of tumor nature based on central 
contrast enhancement and centrifugal dispersion. 
2.2.4 Adenoma 
It is a benign tumor made up of normal or atypical hepatocytes. It has an incidence of 0.03%. 
Its development is induced by intake of anabolic hormones and oral contraceptives. The 
tumor is asymptomatic, but may be associated with right upper quadrant pain in case of 
internal bleeding. 2D ultrasound shows a well-defined, un-encapsulated, solid mass. It may 
have a heterogeneous structure in case of intratumoral hemorrhage. Doppler examination 
shows no circulatory signal. CEUS exploration is quite ambiguous and cannot always 
establish a differential diagnosis with hepatocellular carcinoma. Thus, during the arterial 
phase there is a centripetal and inhomogeneous enhancement. During the portal venous 
phase there is a moderate wash out. During late phase the appearance is isoechoic or 
hypoechoic, due to lack of Kupffer cells. 
2.3 Malignant liver tumors 
Malignant liver tumors develop on cirrhotic liver (hepatocellular carcinoma, HCC) or 
normal liver (metastases). They are single or multiple (especially metastases), have a 
variable, generally imprecise delineation, may have a very pronounced circulatory signal 
(hepatocellular carcinoma and some types of metastases), have a heterogeneous structure 
(the result of intratumoral circulatory disorders, consequence of hemorrhage or necrosis) 
and are firm to touch, even rigid. The patient's general status correlates with the underlying 
disease (vascular and parenchymal decompensation for liver cirrhosis, weight loss, lack of 
appetite and anemia with cancer). 
2.3.1 Hepatocellular carcinoma (HCC) 
It is the most common liver malignancy (Parkin et al, 2005). It develops secondary to 
cirrhosis (in approx. 80% of cases) (Llovet et al, 2003) therefore, ultrasound examination 
every 6 months combined with alpha fetoprotein (AFP) determination is an effective 
method for early detection and treatment monitoring for this type of tumor (Bruix & 
Sherman 2005; Llovet & Bruix 2008). Clinically, HCC overlaps with advanced liver cirrhosis 




due to variceal leakage) in addition to accelerated weight loss in the recent past and lack of 
appetite. 
HCC appearance on 2D ultrasound is that of a solid tumor, with imprecise delineation, 
with heterogeneous structure, uni- or multilocular (encephaloid form).  An "infiltrative" 
type is also described which is difficult to discriminate from liver nodular reconstruction 
in cirrhosis. Typically HCC invades liver vessels, primarily the portal veins but also the 
hepatic veins (Badea R. & Badea Gh, 1991). Doppler examination detects a high speed 
arterial flow and low impedance index (correlated with described changes in tumor 
angiogenesis). The spatial distribution of the vessels is irregular, disordered. CEUS 
examination shows hyperenhancement of the lesion during the arterial phase. During the 
portal venous phase there is a specific "wash out" of ultrasound contrast agent (UCA) and 
the tumor appears hypoechoic during the late phase. Poorly differentiated tumors may 
have a stronger wash out leading to an isoechoic appearance to the liver parenchyma 
during portal venous phase. This appearance was found in approx. 30% of cases (Nicolau 
et al, 2004). The described changes have diagnostic value in liver nodules larger than  
2 cm.  
 
    
 
Fig. 6. Encephaloid hepatocellular carcinoma (CEUS). Contrast tumor enhancement is 
observed on the left during arterial phase. The “wash-out” phenomenon can be seen on the 
right, during portal venous phase. 
Ultrasound is useful in HCC detection, stadialization and assessing therapeutic efficacy. 
In terms of staging related to therapy effectiveness, the Barcelona classification is used 
(Llovet et al, 1999) which identifies five HCC stages. Curative therapy is indicated in early 
stages, which include very early stage (single nodule <2 cm), curable by surgical resection 
(survival 50-70% five years after surgical resection) (Llovet et al, 2003) and early stage 
(single nodule of 2-5 cm, or up to 3 nodules <3 cm) which can be treated by 
radiofrequency ablation (RFA) and liver transplantation. Intermediate stage (polinodular, 
without portal invasion) and advanced stage (N1, M1, with portal invasion) undergo 
palliative therapies (TACE and sorafenib systemic therapy) and in the end stage only 
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Ultrasound is useful in HCC detection, stadialization and assessing therapeutic efficacy. 
In terms of staging related to therapy effectiveness, the Barcelona classification is used 
(Llovet et al, 1999) which identifies five HCC stages. Curative therapy is indicated in early 
stages, which include very early stage (single nodule <2 cm), curable by surgical resection 
(survival 50-70% five years after surgical resection) (Llovet et al, 2003) and early stage 
(single nodule of 2-5 cm, or up to 3 nodules <3 cm) which can be treated by 
radiofrequency ablation (RFA) and liver transplantation. Intermediate stage (polinodular, 
without portal invasion) and advanced stage (N1, M1, with portal invasion) undergo 
palliative therapies (TACE and sorafenib systemic therapy) and in the end stage only 
symptomatic therapy applies. 




It develops on non cirrhotic liver. 2D ultrasound appearance is uncharacteristic - solid mass 
with heterogeneous structure, poorly delineated, often with peripheral location and weak 
Doppler circulation signal. CEUS examination reveals a moderate enhancement of the 
tumor periphery during arterial phase followed by wash-out during portal venous phase 
and hypoechoic appearance during late phase. 
2.3.3 Liver metastases 
US examination is required to detect liver metastases in patients with oncologic history. In 
addition, the method can incidentally detect metastases in asymptomatic patients. Early 
identification (small sizes, small number) is important to establish an optimal course of 
treatment which can be complex (chemotherapy, radiofrequency ablation, surgical 
resection) but welcomed. In addition, discrimination of synchronous lesions that have a 
different nature is also important knowing that up to 25-50% of liver lesions less than 2 cm 
detected in cancer patients may be benign (Kreft et al, 2001). US sensitivity for metastases 
detection varies depending on the examiner’s experience and the equipment used and 
ranges between 40-80% (Wernecke et al, 1991). Sensitivity is conditioned by the size and 
acoustic impedance of the nodules. For a lesion diameter below 10 mm US accuracy is 
greatly reduced, reaching approx. 20%. Other elements contributing to lower US 
performance are: excessive obesity, fatty liver disease, hypomobility of the diaphragm, and 
certain patterns of hyperechoic or isoechoic metastases that can be overlooked or can mimic 
benign conditions. Conventional US appearance of metastases is uncharacteristic, consisting 
of circumscribed lesions, with clear, imprecise or "halo" delineation, with homogeneous or 
heterogeneous echo pattern. They can be single (often liver metastases from colonic 
neoplasm) or multiple. Echogenity is variable. When increased, they can compress the bile 
ducts (which may be dilated) and the liver vessels. Liver involvement can be segmental, 
lobar or generalized. In this situation a pronounced hepatomegaly occurs. Generally, 
metastases have non-characteristic Doppler vascular pattern, with few exceptions (carcinoid 
metastases). Cyst-adenocarcinoma metastases due to semifluid content may have a 
transonic appearance. When increasing, they can result in central necrosis. CEUS 
examination is a real breakthrough for detection and characterization of liver metastases. 
Increased performance is based on identifying specific vascular patterns during the arterial 
phase and seeing metastases in contrast to normal liver parenchyma during the sinusoidal 
phase. CEUS increased accuracy is due to the different behavior of normal liver parenchyma 
(captures CA in Kuppfer cells) against tumor parenchyma (does not contain Kuppfer cells, 
therefore CEUS appearance is hypoechoic). To this adds the particularities of intratumoral 
circulation represented by a reduced arterial bed compared to that of the surrounding 
normal liver and the absence of the portal vessels (Cosgrove & Blomley 2004). In terms of 
vascularity, metastases can be hypovascular (in gastric, colonic, pancreatic or ovarian 
adenocarcinomas) with hypoechoic pattern during arterial phase, and similar during portal 
venous and late phases, respectively hypervascular (neuroendocrine tumors, malignant 
melanoma, sarcomas, renal, breast or thyroid tumors) with hyperechoic appearance during 
arterial phase, with washout during the portal venous phase and hypoechoic pattern  





Fig. 7. Liver metastases (CEUS). Peripheral vascular pattern of the lesion is observed on the 
left in colon cancer metastasis. Lesion hyperenhancement in ovarian cancer liver metastasis 
is seen on the right during the arterial phase. 
Using CEUS examination to detect metastases a sensitivity of 80-95% is obtained, similar to 
that of contrast CT and MRI (Quaia et al, 2006 ; Piscaglia et al, 2007). Intraoperative use of 
the procedure increases its performance even if it does not have a decisive contribution to 
change the therapeutic behavior (Konopke et al, 2005). Limitations of the method are those 
related to US penetration (pronounced fatty liver disease, deep lesion, excessive obesity) and 
to the experience of the examiner. To this the risk of confusion between hypervascular 
metastases, hepatocellular carcinoma and hemangioma and the confusion between 
hypovascular metastases and small liver cysts is added. Routine use of CEUS examination to 
detect liver metastases is recommended when conventional US examination is not 
conclusive, when precise information on some injuries (number, location) is necessary in 
conjunction with contrast CT/MRI and to assess the effectiveness of treatment when using a 
antiangiogenic therapy for hypervascular metastases (Claudon et al, 2008). The method 
cannot replace CT/MRI examinations which have well established indications in oncology 
(Larsen, 2010). 
2.4 Pseudotumors and inflammatory masses of the liver 
Besides the entities listed above inflammatory masses or even pseudo-masses can occur. 
Their diagnosis is quite difficult and the criteria used for differentiation are often 
insufficient, requiring morphologic diagnostic procedures, use of other diagnostic imaging 
methods or patient reevaluation from time to time. This includes lesions developed on liver 
parenchyma reconstruction, as occurs in cirrhosis, steatosis accumulation or in case of acute 
or chronic inflammatory diseases. 
2.4.1 Focal steatosis 
It consists of localized accumulation of fat-rich liver cells. In some cases this accumulation can 
mimic a liver tumor. Sometimes the opposite phenomenon can be seen, that is an "island" of 
normal parenchyma in a “shining” liver.  In both cases ultrasound examination identifies a 
well defined, un-encapsulated area, with echostructure and vasculature similar to those of 
normal liver parenchyma. The lesion can have different forms, most cases being oval and 
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Using CEUS examination to detect metastases a sensitivity of 80-95% is obtained, similar to 
that of contrast CT and MRI (Quaia et al, 2006 ; Piscaglia et al, 2007). Intraoperative use of 
the procedure increases its performance even if it does not have a decisive contribution to 
change the therapeutic behavior (Konopke et al, 2005). Limitations of the method are those 
related to US penetration (pronounced fatty liver disease, deep lesion, excessive obesity) and 
to the experience of the examiner. To this the risk of confusion between hypervascular 
metastases, hepatocellular carcinoma and hemangioma and the confusion between 
hypovascular metastases and small liver cysts is added. Routine use of CEUS examination to 
detect liver metastases is recommended when conventional US examination is not 
conclusive, when precise information on some injuries (number, location) is necessary in 
conjunction with contrast CT/MRI and to assess the effectiveness of treatment when using a 
antiangiogenic therapy for hypervascular metastases (Claudon et al, 2008). The method 
cannot replace CT/MRI examinations which have well established indications in oncology 
(Larsen, 2010). 
2.4 Pseudotumors and inflammatory masses of the liver 
Besides the entities listed above inflammatory masses or even pseudo-masses can occur. 
Their diagnosis is quite difficult and the criteria used for differentiation are often 
insufficient, requiring morphologic diagnostic procedures, use of other diagnostic imaging 
methods or patient reevaluation from time to time. This includes lesions developed on liver 
parenchyma reconstruction, as occurs in cirrhosis, steatosis accumulation or in case of acute 
or chronic inflammatory diseases. 
2.4.1 Focal steatosis 
It consists of localized accumulation of fat-rich liver cells. In some cases this accumulation can 
mimic a liver tumor. Sometimes the opposite phenomenon can be seen, that is an "island" of 
normal parenchyma in a “shining” liver.  In both cases ultrasound examination identifies a 
well defined, un-encapsulated area, with echostructure and vasculature similar to those of 
normal liver parenchyma. The lesion can have different forms, most cases being oval and 
located in the IVth segment, anterior from the hepatic hilum. It occurs in dyslipidemic or 
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alcohol intake patients with normal physical and biological status. Benign diagnosis 
confirmation is made using CEUS examination which proves a normal circulatory bed similar 
to adjacent liver parenchyma in all three phases of investigation (Molins et al, 2010). 
2.4.2 Liver abscess 
Liver abscess have heteromorphic ultrasound appearance, the most typical being that of a 
mass with irregular shapes, fringed, with fluid or semifluid content, with or without air inside. 
Doppler examination shows the lack of vessels within the lesion. CEUS exploration shows 
hyperenhancement during arterial phase close to the lesion, this being suggestive of a liver 
parenchymal hyperemia. During venous and sinusoidal phase the pattern is hypoechoic, and 
the central fluid is contrast enhanced. CEUS examination is useful because it confirms the 
clinical suspicion of abscess. In addition, it allows for an accurate measurement of the 
collection size and an indication regarding its topography inside the liver (lobe, segment). 
 
Fig. 8. Liver abscess (2D and CEUS). 2D Examination reveals the fluid nature of the mass 
and imprecise delineation. CEUS examination shows congestion in the surrounding liver 
parenchyma and excludes a vascular tumor. 
3. Preneoplastic status. Cirrhotic liver monitoring 
Cirrhotic liver is characterized by the occurrence of nodules with different sizes and 
evolution degrees, so that regenerative nodules, dysplastic nodules and even early 
hepatocellular carcinoma can coexist at some moment during disease progression. There are 
studies showing that between 59-94% of newly diagnosed liver nodules in cirrhotic patients 
have malignant histology and up to 50% of hyperechoic lesions, with ultrasound appearance 
of hemangioma, ultimately prove to be hepatocellular carcinoma. Therefore, current practice 
in many centers considers that any new lesion revealed in a cirrhotic patient should be 
regarded as malignant until otherwise proven (Andreana et al, 2009). There are three 
categories of cirrhotic liver nodules: regenerative, dysplastic (considered as premalignant 
conditions) and tumoral (HCC) (Int WP, 1995). 
3.1 Regenerative nodules (RN) 
These lesions are well defined, with isoechoic or hypoechoic appearance and sizes less than 




liver segments. They can crowd resulting in large pseudo tumors. At Doppler examination, 
these nodules have no circulatory signal. CEUS exploration is indicated when a nodule is 
different against the general pattern of restructured liver either by different echogenity or by 
a different size than the majority of nodules. During the arterial phase, the signal is weak or 
absent. During the portal venous and late phase, the appearance is persistently isoechoic. 
Generally, RN is not distinct from the surrounding parenchyma. CEUS examination is 
useful to exclude an active lesion at the moment of exploration but does not have absolute 
prognostic value; therefore the patient should be periodically examined at short intervals 
(Kojiro, 2004; Bolondi et al, 2005). Correlation with clinical status and AFP measurements is 
required. 
 
Fig. 9. Regenerative nodule (CEUS). One can see the hypovascular pattern of the solid 
nodule, with a size <10 mm. 
3.2 Dysplastic nodules (DN) 
These lesions have various patterns (hypo or hyperechoic) with at least 1 cm diameter. They 
are hepatocytes with dysplastic changes, but without clear histological criteria for 
malignancy. They are divided into low-grade dysplastic nodules, where cellular atypia are 
mild and high-grade dysplastic nodules with moderate or severe cellular atypia, but 
without any established signs of malignancy. Occasionally, well-differentiated HCC foci can 
be identified in high-grade dysplastic nodules (appearance called "nodule in nodule") 
(Minami & Kudo, 2010). Most authors accept the carcinogenesis process as a progressive 
transformation of DN from low-grade to high-grade and into HCC. The nodule’s 
vasculature changes progressively, correlated with the degree of malignancy, and it is 
characterized by decrease until absence of portal venous input and by increase of arterial 
intratumoral input. Neoformation vessels occur with increasing degree of dysplasia. Arterial 
neovascularization is enhanced in a chaotic and explosive way, while normal, arterial and 
portal vasculature continues to decline. High-grade dysplastic nodules are hypo-
vascularized both arterial and portal phases, while early HCC nodules may have similar 
arterial pattern with the surrounding parenchyma or exacerbated, and portal hypo-
vascularization. In moderate or poorly differentiated HCC (classic HCC) tumor nutrition is 
performed only by neoformation vessels (abundant), the normal arterial and portal 
vasculature completely disappearing (Matsui 2004). This behavior of intratumoral 
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nodule, with a size <10 mm. 
3.2 Dysplastic nodules (DN) 
These lesions have various patterns (hypo or hyperechoic) with at least 1 cm diameter. They 
are hepatocytes with dysplastic changes, but without clear histological criteria for 
malignancy. They are divided into low-grade dysplastic nodules, where cellular atypia are 
mild and high-grade dysplastic nodules with moderate or severe cellular atypia, but 
without any established signs of malignancy. Occasionally, well-differentiated HCC foci can 
be identified in high-grade dysplastic nodules (appearance called "nodule in nodule") 
(Minami & Kudo, 2010). Most authors accept the carcinogenesis process as a progressive 
transformation of DN from low-grade to high-grade and into HCC. The nodule’s 
vasculature changes progressively, correlated with the degree of malignancy, and it is 
characterized by decrease until absence of portal venous input and by increase of arterial 
intratumoral input. Neoformation vessels occur with increasing degree of dysplasia. Arterial 
neovascularization is enhanced in a chaotic and explosive way, while normal, arterial and 
portal vasculature continues to decline. High-grade dysplastic nodules are hypo-
vascularized both arterial and portal phases, while early HCC nodules may have similar 
arterial pattern with the surrounding parenchyma or exacerbated, and portal hypo-
vascularization. In moderate or poorly differentiated HCC (classic HCC) tumor nutrition is 
performed only by neoformation vessels (abundant), the normal arterial and portal 
vasculature completely disappearing (Matsui 2004). This behavior of intratumoral 
vascularization is typical for HCC and is the key to imaging diagnosis (Lencioni et al 2008).  
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B-mode ultrasonography is unable to distinguish between regenerative nodules and 
"borderline" lesions such as dysplastic nodules and even early HCC. Doppler examination 
also has a low sensitivity in differentiating dysplastic nodules from early HCC. Doppler 
signal may be absent in both regenerative and dysplastic nodules. Some authors indicate the 
presence of venous type Doppler flow which reflects the portal venous nutrition of the 
nodule as a characteristic feature of dysplastic nodules and early HCC (Minami & Kudo, 
2010). Other authors noticed the presence of an arterial flow with small frequency variations 
and a normal resistivity index (RI) (Lencioni et al 2008). 
On CEUS examination both RN and DN may have quite a variable enhancement pattern. 
Generally, both nodules enhances identically with the surrounding liver parenchyma after 
UCAs injection.  Dysplastic nodules are hypovascular in the arterial phase. In case of high-
grade dysplastic nodule sometimes a hypervascularization can be detected, but without 
associating "wash out" during portal and late CEUS phases. In these cases, biopsy may 
clarify the diagnosis. 
 
Fig. 10. Dysplastic nodule (2D, CFM, CEUS). The nodule is well-defined with a size between 
10- 20 mm, lacks vessels in CFM and CEUS exploration. 
3.3 Early hepatocellular carcinoma (Early HCC) 
The suggestive appearance of early HCC on 2D ultrasound examination is that of hypo-
echoic nodule, with distinct pattern, developed on cirrhotic liver. Hypoechoic appearance is 
characteristic of moderate/poorly differentiated HCC, with low or absent fatty changes. 
Rarely, HCC may appear isoechoic, consist of a tumor type with a higher degree of 
differentiation and therefore with slower development. Another common aspect is "bright 
loop" or "nodule-in-nodule" appearance, hypoechoic nodules in a hyperechoic tumor. 




Spectral Doppler characteristics of early HCC overlap those of the dysplastic nodule, as they 
are represented by the presence of portal venous signal type or arterial type with normal RI 
(well differentiated HCC) or increased RI (moderately or poorly differentiated HCC). The 
CFM exploration identifies a chaotic vessels pattern. 
On CEUS examination, early HCC has an iso- or hypervascular appearance during the 
arterial phase followed by wash out during portal venous and late phase. There are studies 
showing that the wash out process is directly correlated with the size and features of 
neoplastic circulatory bed. Thus, highly differentiated HCC illustrates the phenomenon of 
late or even very late "wash out" while poorly differentiated HCC has an accelerated wash 
out at the end of arterial phase (Strobel et al, 2005; von Herbay et al, 2009; Jang et al, 2009). It 
is therefore mandatory to analyze all these three phases of CEUS examination for a proper 
characterization of liver nodules. Tumor wash out at the end of the arterial phase allows the 
HCC diagnosis with a predictability of 89.5%. Some authors consider that early pronounced 
contrast enhancement of a nodule within 1-2 cm developed on a cirrhotic liver is sufficient 
for HCC diagnosis (Jang et al, 2009). These results prove that for a correct characterization of 
the lesions it is necessary to extend the examination time to 5 minutes or even longer (von 
Herbay et al, 2009). 
 
Fig. 11. Early hepatocellular carcinoma (2D, CFM). The 2D examination reveals a solid, 
hypoechoic nodule in IVth liver segment, without encapsulation. CFM shows a central vessel 
with ramifications to the periphery. The underlying liver is cirrhotic. 
 
Fig. 12. Early hepatocellular carcinoma (2D, CFM). “Nodule in nodule” image: small 
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Fig. 12. Early hepatocellular carcinoma (2D, CFM). “Nodule in nodule” image: small 
hypoechoic early HCC inside monitored dysplastic nodule. 
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3.4 The ultrasound value in HCC "screening" 
Baseline 2D ultrasound has an important role in surveillance programs for patients at risk to 
develop HCC (Bruix & Sherman, 2011). The examination has an acceptable sensitivity which 
increases with the tumor size. Sensitivity varies between 42% for lesions <1 cm and 95% for 
tumors larger than 1 cm, and specificity can reach 90% (Andreana et al, 2009). Optimal time 
interval for ultrasound screening of “at risk” population is 6 months as it results from 
clinical trials that investigated the tumor size doubling time (Bruix, 2005; Maruyama et al, 
2008). For a recently developed nodule the dimensional criteria will be taken into account. 
Thus, for a nodule with a size of less than 10 mm the patient will be reevaluated by 
ultrasound every 3 months, as the growth trend is an indication for completion of 
investigations with other diagnostic procedures; at a size between 10 - 20 mm two 
concordant imaging procedures are necessary, supplemented if necessary by an ultrasound 
guided biopsy; at a size over 20 mm one single dynamic imaging technique with 
characteristic appearance is enough for positive diagnostic. In uncertain cases 
complementary dynamic imaging techniques or biopsy should be performed. When 
Doppler exploration is not enough, CEUS examination will be performed (Gaiani et al, 
2001). One should always keep in mind the risk of false positive results for HCC in case of 
cholangiocarcinomas so complementary diagnostic procedures should be considered (Bruix 
& Sherman, 2011). 
The effectiveness of screening programs is proved by an increase in detection rate of HCC 
<2 cm (from <5% in the 90s in Europe to > 30% today in Japan) with curative therapy 
options (Llovet & Bruix 2008). The main problem of ultrasound screening is that, in order to 
be cost-effective, it should be applied to the general population and not in tertiary hospitals. 
This raises the importance of the operator and equipment dependent part of the ultrasound 
examination (Bruix et al, 2001). The efficiency of such a program is linked to the functional 
liver parenchyma of the cirrhotic patient. Therefore, some authors argue that screening 
should be excluded in patients with etiologies that prevent curative treatment or in patients 
with advanced liver disease (Child-Pugh class C) (Zapata et al, 2010). 
After curative therapies (surgical resection, local ablative therapies) continuing ultrasound 
screening is recommended first at 1 month then at 3 months intervals after the therapy to 
assess the effectiveness of therapy and to detect other nodules. 
4. Antitumor therapies 
Ultrasound exploration can be an effective procedure for the assessment of liver tumors 
response to treatment. Over the years, different criteria for assessing the effectiveness of 
curative or palliative therapies have been considered. Now it has been proved that the 
degree of tumor necrosis is not correlated with tumor diameter, therefore simple 
measurement of the tumor diameter (RECIST criteria) is not enough for therapy assessment. 
Currently, local response to treatment is focused on tumor necrosis diagnosed by contrast 
dynamic imaging techniques and recognized by the presence of intratumoral non-enhanced 
areas. Local response to treatment is defined as:  
a. complete response, defined as complete disappearance of all known lesions (absence of 
tumor enhanced areas, reflecting total tumor necrosis) and absence of other new lesions 




b. partial response, defined as more than 50% reduction in total tumor enhancement in all 
measurable lesions, determined by two observations not less than 4 weeks apart 
c. stable disease (is not described by a, b, or d)  
d. progressive disease, defined as 25% increase in size of one or more measurable lesions 
or the appearance of new lesions (Bruix et al, 2001). 
4.1 Techniques for evaluating the efficiency of therapy  
The efficiency of 2D ultrasound is low in assessing the effects of HCC or metastasis therapy, 
as it is unable to differentiate viable tumor tissue from post-therapy tumor necrosis. 
However, it is able to detect the appearance of new lesions and to assess the occurrence of 
any complications of disease progression (ascites or portal vein thrombosis). Color Doppler 
ultrasound can be useful sometimes being able to show the presence of intratumoral 
vasculature as a sign of incomplete therapy or intratumoral recurrence. The absence of 
Doppler signal does not exclude the presence of viable tumor tissue. CEUS exploration, by 
its ability to enhance intra-lesion microcirculation, has proved its utility in monitoring 
therapeutic efficacy. Its indications are defined for HCC ablative treatments (pre, intra and 
post-therapy), while monitoring of systemic therapies of HCC and metastases are not 
validated indications at this time, but with proved efficacy in extensive clinical trials 
(Claudon et al, 2008). CEUS examination cannot completely replace the other imaging 
diagnostic methods currently in use because of the known limitations of the ultrasound 
method (operator/ equipment dependent, ultrasound examination limitations). In addition 
to bloating, in cancer patients post-therapy steatosis occurs, which prevent deep visibility. 
Spiral CT scan remains the method of choice in monitoring cancer therapies because it 
provides an overview of tumor extension and it is not limited by bloating or steatosis 
(Bartolozzi et al, 1999). 
Gadolinium MRI examination is a procedure used more and more often, and its advantages 
are the absence of irradiation and its high sensitivity in tumor vasculature detection, 
especially in smaller tumors (Dromain et al, 2002). However it remains an expensive and not 
a very accessible procedure, although it has a high specificity. Currently, CEUS and MRI are 
considered complementary methods to CT scan. 
4.2 Ultrasound monitoring ablative therapies (alcoholization - PEI, radiofrequency 
ablation - RFA) 
Ablative therapies are considered curative treatments for HCC together with surgical 
resection and liver transplantation and they are indicated for early tumor stages in patients 
with good liver function (Bruix & Sherman, 2005; Bruix & Sherman, 2011). Also they are 
successfully applied in the treatment of liver metastases, where surgical resection is 
contraindicated. They are chemical (intratumoral ethanol injection) or thermal 
(radiofrequency, laser or microwave ablation). They are applied in order to obtain a full 
therapeutic response, without affecting liver function. Complete response is locally proved 
by complete tumor necrosis with a safety margin around the tumor. 
2D ultrasound, Doppler ultrasound and especially CEUS can play an important role in pre-
therapeutic staging, particularly when sectional imaging investigations (CT, MRI) provide 
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Ablative therapies are considered curative treatments for HCC together with surgical 
resection and liver transplantation and they are indicated for early tumor stages in patients 
with good liver function (Bruix & Sherman, 2005; Bruix & Sherman, 2011). Also they are 
successfully applied in the treatment of liver metastases, where surgical resection is 
contraindicated. They are chemical (intratumoral ethanol injection) or thermal 
(radiofrequency, laser or microwave ablation). They are applied in order to obtain a full 
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allows guidance of the needle into the tumor. CEUS allows guidance in areas of viable tissue 
and avoids intratumoral necrotic areas. CEUS also allows assessment of therapeutic effect 
immediately post-procedure (with the possibility of reintervention in case of partial response) 
(Claudon et al, 2008). To accurately assess the effectiveness of treatment it is mandatory to 
compare the tumor diameter before therapy with the ablation area. The volume of damaged 
tissue must be higher than the initial tumor volume. CEUS appearance is that of central non-
enhanced area showing a peripheral homogeneous hyperenhanced rim due to post-procedure 
inflammation. 24 hours after the procedure the inflammatory peripheral rim is thinning and 
the necrotic area appears larger than at the previous examination. Thus, a possible residual 
tumor may appear more evident. Residual tumor has poorly defined edges, irregular shape, 
and the tumor diameter is unchanged. Residual tumor tissue is evidenced at the periphery of 
the tumor as an eccentric area behaving as the original tumor at CEUS examination, with 
arterial hyperenhancement and portal and late wash-out. Ultrasound examination 24 hours 
after the procedure, including CEUS, can show apart from the character of the lesion any 
potential post-intervention complications (e.g. active bleeding). 
In the first days after RFA both CEUS and spiral CT have low sensitivity in assessing 
therapeutic efficacy. CT sensitivity 24 hours post-therapy is reported to be even lower than 
CEUS (Vilana et al, 2006). Difficulties in CEUS examination result from post-lesion 
hyperemia, presence of intratumoral air, ultrasound limitations (too deep lesion or the 
presence of fatty liver) or lack of patient’s cooperation (immediately after therapy). For this 
reasons contrast imaging (CT or CEUS) control should be performed one month after 
ablation to confirm the result of the therapy (Spârchez et al, 2009). 
Local recurrence is defined as recurrence of a hyperenhanced area at tumor periphery in the 
arterial phase, with portal and late wash-out. Sometimes, especially for HCC treated by 
alcoholization (PEI) hyperenhanced septa or vessels can be shown inside the lesion 
(Spârchez et al, 2009). 
In case of successful treatment, US monitoring using CEUS is performed every three 
months. Although CE-CT and/or MRI are considered the method of choice in post-therapy 
monitoring, CEUS can be used in follow-up protocols (Claudon et al, 2008), its diagnostic 
accuracy being equivalent to that of CE-CT or MRI (Frieser et al, 2011). 
    
Fig. 13. Assessment of therapeutic efficacy on ultrasound (2D, CFM, CEUS). US exam shows 





4.3 Ultrasound monitoring of TACE therapy (transarterial chemoembolization)  
Transarterial chemoembolization (TACE) is part of palliative therapies for HCC used in 
intermediate stages of the disease. It consists of selective angiographic catheterization of the 
hepatic artery and injection of chemotherapeutic agents (usually adriamycin, but other 
molecules are currently the subject of clinical trials), followed by embolization of hepatic 
artery with gelfoam, alcohol or metal rings (Bruix & Sherman, 2005). A similar procedure is 
transarterial embolization but without chemotherapeutic agents injection, used in the 
treatment of hypervascular liver metastases. These therapies are based on the 
predominantly arterial vasculature of HCC and hypervascular metastases, while the 
remaining liver parenchyma has a dual vascular intake, predominantly portal. Their efficacy 
is high only for lesions who are hyperenhanced during arterial phase. The role of US is 
limited in the first few days after the procedure, and refers only to its complications, due to 
Lipiodol retention mainly intratumoral, but also diffusely intrahepatic. On ultrasound, 
Lipiodol appears intensely hyperechoic inside the tumor, with significant posterior 
attenuation which make US examination more difficult. On the other hand, CE-CT is also 
limited by the presence of Lipiodol (iodine oil), therefore the evaluation of therapeutic 
efficiency is currently made by indirect assessing Lipiodol binding to the tumor using non-
enhanced CT (Maruyama et al, 2008). CE-MRI is not influenced by the presence of Lipiodol, 
but it is an expensive method and still difficult to reach. Several studies have proved similar 
efficacy, even superior, of CEUS compared to CE-CT and CE-MRI for the evaluation of post-
TACE treatment results, while other studies have shown the limitations of CEUS especially 
for deep or small lesions. Given the CEUS limitations, currently some authors consider CT 
as standard method for the evaluation of TACE and local ablative therapies and CEUS and 
CE-MRI as complementary methods (Lim et al, 2006, Maruyama et al, 2008). Monitoring 
TACE therapeutic results by contrast imaging techniques is performed as for ablative 
therapies initially after one month then after every 3 months post-TACE. 
Given that TACE is indicated only for hyperenhanced lesions during arterial phase, CEUS 
plays a very important role in monitoring the dysplastic nodules to identify the moment 
when changes occur in arterial vasculature, being able to have an early therapeutic 
intervention in order to limit tumor progression, to increase patient survival, and thus to 
create a bridge to liver transplantation. 
  
Fig. 14. Small HCC is seen on the left (nodule in nodule). Efficient chemoembolization of the 
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Fig. 14. Small HCC is seen on the left (nodule in nodule). Efficient chemoembolization of the 
nodule (right). CEUS examination shows no circulatory signal within the nodule.  
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4.4 Ultrasound monitoring of systemic therapies 
Systemic therapies are procedures based on the affinity of certain molecules to inhibit either 
tumor cell replication or multiplication of neoplastic vasculature (antiangiogenic therapies). 
They are intravenously administered and are indicated in advanced stages of liver tumor 
diseases, when there are no other effective therapeutic solutions. Among ultrasound 
techniques, CEUS is the one that brought a significant benefit not only by increasing the 
sensitivity and specificity of ultrasound in detecting liver metastases, but also by assessing 
the efficacy of systemic therapy for HCC and metastases. The method has been adopted by 
oncologists since 2003, because it involves no irradiation and has no hepatic or renal toxicity, 
and it is now currently used in tumor therapeutic evaluation (Lassau et al, 2011). It is 
currently used in large clinical trials aimed at determining the efficacy of different types of 
anti-angiogenic molecules by quantifying intratumoral perfusion based on the statistical 
analysis performed using specific software during post-processing in order to assess 
therapeutic efficacy as early as possible. 
4.5 Ultrasound monitoring of post-surgical resection status 
Surgical resection is the treatment of choice for non-cirrhotic or cirrhotic patients with 
well preserved liver function with single liver lesion. After resection, recurrence rate 
exceeds 70% at 5 years and is mainly due to primary tumor dissemination. The strongest 
predictors of tumor recurrence are the development of other tumors near the primary 
tumor scar and vascular microinvasion (Bruix & Sherman, 2005). 2D ultrasound is used 
within screening programs. CEUS efficacy has not been proven so far in monitoring post-
resection patients. 
5. Other applications of ultrasound in liver tumor pathology. Technical 
progress 
Ultrasound has known a great development arising from the need to increase patient access 
to advanced investigations while avoiding procedures using radiation (CT), contrast agents 
with allergic potential (iodine substances) and hepatic or renal toxic agents. 
Interventional and intraoperative ultrasound. Ultrasound exploration by maneuverability of the 
equipment and dynamic character of the image allows guided interventional procedures or 
intraoperative examination. Combining ultrasound with such procedures is necessary due 
to the lack of specificity of the method in case of tumors. Even if tumor markers for defining 
the nature of some masses are available, their accuracy is not good enough; therefore 
biological samples from the nodules detected by imaging is often required. Accuracy of 
ultrasound guided puncture in the diagnosis of liver tumors is dependent on the operator’s 
experience and can reach up to 87.5 - 99% (Horigome et al, 1999). The extracted material can 
be either a histology fragment or cytology aspiration; in both cases the credibility of the 
method is sufficient to ensure optimal cancer therapies (Badea R & Badea Gh 1991). 
Intraoperative ultrasound is also a complementary investigation that allows detection of 
very small nodules. In addition it allows the characterization of tumor using Doppler and 





Targeted therapy using contrast agents. The introduction of second generation contrast agents 
has been a great progress. Diagnostic performance is already proven. A step forward is 
tumor targeted therapy under ultrasound guidance. The principle is that of transporting 
chemotherapeutic agents to the target using microbubbles as vectors. Experiments have 
been made for binding different substances and/or genes to the lesion, with local release by 
"breaking" and intracellular penetration using the phenomenon of cellular membrane 
permeability called "sonoporation" (Lindner, 2004, Newman & Bettinger, 2007). 
Image fusion. Techniques for image fusion obtained by different imaging procedures allow 
the correlation of real-time ultrasound examination with CT or MRI images, enabling 
positioning of the needle in relation to the exact position of the tumor. The technique allows 
a better guidance both for biopsies and percutaneous ablative procedures, replacing CT 
guidance and thus avoiding irradiation. Combination with CEUS allows a better 
characterization of lesions as well as successful monitoring of percutaneous procedures or 
TACE effects (Sandulescu et al, 2011; Ewertsen et al, 2011). 
Elastography. It was initially introduced in practice to assess the degree of fibrosis in chronic 
liver disease. In liver tumors it allows detection of liver nodules due to the difference of 
elasticity between the hepatic nodule and the parenchyma. There are few studies that try to 
assess the benign or malignant character of the lesion based only on elasticity. By 
combination with CEUS the method could be beneficial for early detection and 
characterization of HCC. 
High Intensity Focused Ultrasound (HIFU). It is a new technique capable of destroying tumor 
tissue by hyperthermia, allowing percutaneous ablation without requiring tumor puncture. 
There are studies showing the efficacy of this technique in combination with TACE, with 
anti-tumor effect and better survival than using TACE alone (Wu, 2005). The method is 
expected to be an alternative to PEI and RFA because it avoids the puncture of the cirrhotic 
liver, but more studies are needed to prove its efficacy as a single therapy in the curative 
treatment of HCC (Maruyama et al, 2008). 
Techniques for visualizing blood circulation independently from the angle of insonation 
based on transversal oscillation of red blood cells groups. This technique is now 
implemented on conventional transducers and can real time evidence different features of 
the blood flow visualized so far only on MRI angiography (Hansen et al, 2011). 
6. Conclusions 
Ultrasound exploration using current technologies has excellent possibilities for practical 
use. Several elements related to the lack of standardization and reproducibility of 
ultrasound procedures as well as operator-dependent nature of the method require 
structured approach to its use in liver tumors pathology (Bolondi et al, 2007). Structuring 
these applications and description of their actual performance are included in successive 
recommendations made by expert groups, known as "EFSUMB guidelines" (Albrecht et al, 
2004; Claudon et al, 2008). In the current stage the following applications in liver pathology, 
especially in tumors are accepted as valid and represent indications for CEUS: 
a. characterization of nodular lesions found on non-cirrhotic liver. Ultrasound examination is 
often the first imaging procedure performed in patients with abdominal pathology. 
Quite often lesions are detected and their nature has to be further on defined. 
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especially in tumors are accepted as valid and represent indications for CEUS: 
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often the first imaging procedure performed in patients with abdominal pathology. 
Quite often lesions are detected and their nature has to be further on defined. 
Ultrasound procedures that allow achieving this purpose are multiple and 
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complementary: 2D/3D ultrasound and elastography for morphometric informations; 
Doppler ultrasound (with its variants) and CEUS allow hemodynamic information. 
CEUS examination is the most specific of them as it is based on different behavior of 
contrast agent transiting liver masses depending on their nature. CEUS accuracy for 
characterization of focal lesions detected on noncirrhotic liver is similar to that of 
CT/MRI, being of 94.5% for metastases, 97% for hemangiomas, and of 90% for focal 
nodular hyperplasia. The method has a performance superior to 2D ultrasound and a 
high rate of diagnosis confidence regardless of the operator in what concerns tumor 
characterization and nodules count (Quaia et al, 2004). 
b. characterization of nodular lesions found on the cirrhotic liver. Ultrasound examination is a 
"screening" procedure used to detect early HCC (Bolondi et al, 2001). The cirrhotic liver 
during the restructuring process develops nodules that often raise questions regarding 
their nature. The criteria used to determine the nature of these nodules involve size, 
circulation pattern (Doppler evaluated) and vascular bed behavior (CEUS evaluated). In 
over 90% of cases, HCC has a characteristic behavior. CEUS exploration has a 
sensitivity of 92-94% and a specificity of 87-96% in characterizing HCC (Tanaka et al, 
2001, Nicolau et al, 2004). 
In a linear study, covering 36 months, (January 2006 – December 2008), made on a cohort of 
379 patients with liver tumors, (fig. 15), we had similar results concerning the performances of 
CEUS compared to other imaging procedures such as CT/MRI and histopathology as other 
groups (personal experience; unpublished results from the project Angiotumor nr. 138/2006 
financed by the Ministry of Education and Research from Romania) (fig. 16) (Badea et al, 2008). 
 
Fig. 15. Types of liver focal lesions diagnosed by CEUS in our study (HCC=hepatocellular 
carcinoma, META=liver metastasis, CCC=cholangiocarcinoma, A-V FIST=arterio-venous 
fistula, FATTY-FREE=fatyy-free area, DISPL NOD=cirrhotic displastic nodule, FNH=focal 
nodular hyperplasia, HEMANG=liver hemangioma) 
c. Detection and characterization of liver metastases. Ultrasound is a method widely used in 
the early detection of liver metastases in patients with cancer pathology. Beyond the 
known limitations of the method, the examination is used because it is accessible, non-
irradiant and it can detect metastases of quite small sizes and allows their 
characterization using vascular criteria. CEUS examination increases the performance of 
conventional ultrasound to values comparable with CT/MRI, becoming an alternative 





Fig. 16. The performance of CEUS in our study for the main malignant and benign lesions 
(HCC=hepatocellular carcinoma, META=liver metastasis, HEMANG=liver hemangioma, 
FNH=focal nodular hyperplasia, Se=sensitivity, Sp=specificity, PPV=positive predictive 
value, NPV=negative predictive value) 
d. Assessing therapeutic efficacy. Using the vascular criteria allows the assessment of 
therapeutic efficacy under chemotherapy (Bolondi et al, 2007). Performing an 
interventional procedure (with diagnostic or therapeutic purpose) simultaneously with 
the administration of i.v. CAs increases the procedure’s efficiency by a better 
visualization of the tumor and by correct guidance of the ablation needle in the active 
(vascularized) area of the tumor (Skjoldbye et al, 2002, Lencioni et al, 2004). After 
ablative procedures, or even better in one month after the procedure, the absence of the 
circulation bed in the tumor in arterial phase suggests an effective treatment (Solbiati et 
al, 2004; Vilana et al, 2006, Bartolotta et al, 2008). This principle is also true for 
chemotherapy with antiangiogenic agents. Even under these conditions combination of 
CEUS with i.v. contrast CT examination is required to detect small metastases between 
procedures (Bartolotta et al, 2008). 
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1. Introduction 
Liver cancer is considered one of the major causes of death in humans [1]. Early detection of 
tumors is essential for increasing the survival chances of patients. Recent advancements in 
medical imaging modalities have enabled the acquisition of high-resolution CT datasets, 
and thus, allowing physicians to identify both small and large tumors by manual visual 
inspection. Owing to the large number of images in medical datasets, it is difficult to 
manually analyze all images, and useful diagnostic information may be overlooked. 
Moreover, the diagnoses are mainly based on the physician’s subjective evaluation and are 
dependent on the physician’s experience. Therefore, computer assisted diagnosis (CAD) and 
computer assisted surgery have become one of the major research subjects.  
Until now, many methods have been proposed for tumor detection and segmentation in 
liver CT images. These methods can be classified as semi-automatic [2][3] and automatic 
[4][5]. Smeets et al. have proposed a semi-automatic level set method, which combines a 
spiral scanning technique with supervised fuzzy pixel classification [2]. Mala et al. employed 
wavelet-based texture features in order to train a neural network for use in tumor detection 
[4]. In the method proposed by Park et al. [5], the voxels representing the liver vessels are 
removed from liver images and a bimodal histogram is assumed for the intensity 
distribution of the liver and tumors. The optimal threshold to segment tumors is determined 
by a “mixture probability density” algorithm. In our previous study [6], we proposed tumor 
detection [7], which is a technique combining the expectation maximization algorithm and a 
three-dimensional region of interest (ROI) detection method. However, if the image contrast 
is low, it is difficult to accurately remove vessels from the image. All the above-mentioned 
methods can locate tumors that are sufficiently large and have distinct boundaries. Semi-
automatic approaches for handling a large number of tumors would need extensive user 
interactions, and therefore are error prone and tedious. 
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Liver Tumors 104 
We propose a new method for detecting tumors in CT images. Our method is based on 
adaptive contrast enhancement and the expectation maximization / maximization of the 
posterior marginal (EM/MPM) algorithm. User interaction is not required and both large 
and small tumors can be accurately found. Compared with our previously reported method 
[6], the newly proposed method is also suitable for images with poor contrasts. We describe 
the method in Sections 2–6 and present the experimental results in Section 7, followed by 
our conclusions. 
2. Overview of the proposed method 
Our method is composed of seven steps: (1) read the CT images; (2) extract the liver region 
using a well-established liver region segmentation program [8]; (3) smooth out the noise 
from the CT images; (4) enhance the CT image contrast by using probability density 
functions (PDFs) estimated from the training data; (5) remove vessels by applying 
Maximum likelihood method; (6) detect tumor candidates by employing the EM/MPM 
algorithm; and (7) detect and segment the tumor regions by using a shape filter. 
 
Fig. 1. The flowchart of our proposed method for tumor detections 
3. Contrast enhancement 
As tumor detection is mainly based on the intensity of CT images, the contrast of the images 
is very important. Two typical histograms of CT images having high and low contrasts are 
shown in Figs. 2(a) and 2(b), respectively. As shown in Fig.2(a), if the contrast of CT images 
is high, the tumor is in a different intensity range (left small peak) with the liver (right large 
peak) and the tumor can be easily detected by the intensity threshold, while if the contrast of 
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We propose a new method for detecting tumors in CT images. Our method is based on 
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CT images is low,  the tumor is in the same narrow intensity range as the liver as shown in 
Fig.2(b) and it is difficult to detect the tumor from the liver volume. Density value of all 
objects is in a narrow range as shown in Fig.2(b). So we have to enhance the contrast of CT 
images as a preprocessing. 
 
(a)     (b) 
Fig. 2. Histograms with (a) high (b) low contrasts 
A piecewise linear histogram transformation is usually employed to enhance the intensity 
contrast. However, it is difficult to determine a fixed set of lower and upper limits of the 
transformation slope for all images because they are data dependent. In this study, we 
automatically and adaptively determine the parameters from each image. In liver CT 
images, there are three classes of tissues: tumor, healthy liver, and vessels. First, sample 
voxels of the three classes are manually selected from the training data. The intensity PDFs 
of each class is estimated. 




vessel ), their standard derivations ( tumor ,
liver , vessel ), and 
AM .  AM  is the intensity value which has the highest probability in the 
liver class. The mean values have the property of A A Atumor liver vessel     . In Fig. 3(a), the three 
curves, from left to right, represent the PDFs of the tumor, the (healthy) liver, and the vessel 
classes. The mean and standard deviation values may differ among images, but the mean 
value of the (healthy) liver is always larger than that of the tumor and smaller than that of 
the vessels. This can be used for the classification of the three classes. The pattern of these 
three curves is called Curve Pattern A.  
Given a new image and its segmented liver volume, we first compute the intensity 
histogram of all voxels in the liver volume. We find the intensity value BM , which has the 
most component in the liver class, and assume that BM  corresponds to the probability 
density peak of the class of healthy liver tissues in the new liver volume. Such an 
assumption is viable because the healthy tissues normally dominate the volume.  
As a result, the mean values of the tumor and vessels are estimated as 
    B A Atumor tumorM M  and     
B A A
vessel vesselM M , respectively. Now, we set the lower limit 
as min 3   tumor tumorT and the upper limit as max 3   vessel vesselT . The intensity transform 
formula for the range 0–255 is given in Eq. (1). Using the formula, the intensity histograms 
of the liver images are re-estimated [Fig. 3(c)] for later use. 
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Fig. 3. (a) Estimated intensity PDFs for tumor (curve on the left), liver (curve in the center), 
and vessel (curve on the right); (b) Overlap the Curve Pattern A to the new image’s liver 
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4. Removement of vessels by applying Maximum likelihood method 
Before tumor detection step, we first remove vessels from CT images. In the conventional 
method [5], as the intensity of vessels is higher than those of health liver tissues and tumor 
tissues, intensity threshold method is used to remove vessels. We classify the CT volume 
into 3 classes by using Maximum likelihood method. And then, voxels of the class with the 
highest mean are removed as vessels. After this process, CT images only include tumor and 
healthy liver tissues. The tumor detection problem can be simplified as a 2-class 
classification problem. This process will also significantly reduce the detection time. 
5. Tumor candidate detection by using EM/MPM algorithm 
To extract tumor candidate, we used the EM/MPM algorithm [9]. It is based on a Bayesian 
framework that assumes a Gaussian mixture to model intensity distribution and 
concurrently estimates both the labels of the voxels and the model parameters. In MPM, the 
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method [5], as the intensity of vessels is higher than those of health liver tissues and tumor 
tissues, intensity threshold method is used to remove vessels. We classify the CT volume 
into 3 classes by using Maximum likelihood method. And then, voxels of the class with the 
highest mean are removed as vessels. After this process, CT images only include tumor and 
healthy liver tissues. The tumor detection problem can be simplified as a 2-class 
classification problem. This process will also significantly reduce the detection time. 
5. Tumor candidate detection by using EM/MPM algorithm 
To extract tumor candidate, we used the EM/MPM algorithm [9]. It is based on a Bayesian 
framework that assumes a Gaussian mixture to model intensity distribution and 
concurrently estimates both the labels of the voxels and the model parameters. In MPM, the 
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cost function is defined to minimize the total number of misclassified voxels. It can be 
proved that minimization of the cost function is equivalent to maximization of the posterior 
marginal probability of the label fields (Eq. 2) [10]. 
 
,
| |ˆ arg max ( | , ) arg max ( | , )MPM s
k s
s X Y s X Yx x X
x P x y P x y 

    (2) 
In Eq. (2), x, y, and θ are the label vector, feature vector, and model parameters, respectively, 
s is a pixel, k is the label of pixel s, and   refers to all possible labels of the image in 
which the label of pixel s equals k. The posterior probability is composed of two factors, 
namely the likelihood function and the prior probability. The likelihood function is a 
multiplication of the Gaussian distribution function and the prior probability is modeled by 
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In Eq. (3), N is the total number of voxels, (xi ,
2
xi ) are model parameters of class xi, yi is the 
intensity of a voxel, T(n) is called temperature, and δ(xr, xs) is a function that contributes to 
the labels of the neighboring voxels (r) when determining the label of s. For all neighboring 
voxels whose labels (xr) same as xs, the output of the weighting function is zero. Otherwise, 
a value of 0.5 or 1 is assigned according to Fig. 3. In our method, we consider six 
neighboring voxels; four in the same slice and two in the upper and the lower slices (Fig. 4.) 
 
Fig. 4. Weight functions for 6-neighbours of a voxel. 
Optimization of Eq. (2) is not simple. We use the simulated annealing method to iteratively 
determine an estimate [9], which is given by 1( ) / log( )T n T n c  . Here, T1 is the initial 
temperature which is a large constant, c is a constant number and n is the iteration number. 
After determining the MPM estimate (the E-step), the model parameters are calculated (the 
M-step). We continue the iteration of the two steps until convergence is achieved. As a 
result, we obtain tumor candidates that may include both true and false positive regions. In 
our experiments, we assign the values of 1.4 to c, 50 to n, and 2.0 to T1 through several 
testing runs. To remove false results, we use the shape information described below. 
6. Candidate selection with shape filter 
The tumor candidates, which were detected in the previous section, include many false 
positives because the detection used only intensity information. Therefore, in this step, we 
perform a selection process using a shape filter. We define the following five evaluation 
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criteria: (1) size, (2) shape of each slice, (3) regional variation among the slices, (4) location in 
the image, and (5) numbers of connectivity among the slices.  
In this study, we assume that the shape of a tumor is approximately spherical. Therefore, for 
the second criteria, we use a shape filter as shown in Fig. 5. For each tumor candidate, we 
first find a center of gravity, and then calculate distances from it to the 12 points which are 
on the edge of tumor candidate as shown in Fig.5. 4 points are cross points with the 
bounding box (line of a rectangle), which are shown in Fig.5 as diamond points. 8 points are 
boundary points sampled at intervals of 45 degree, which are shown in Fig.5 as small circle 
points. The ratio of maximum distance and minimum distance is used as a measure of 
shape. The ratio is a value larger than or equal to 1. If the candidate’s shape is like a circle, 
the ratio will be 1. Since the tumor is considered having a spherical shape, the candidates are 
rejected if their ratio is larger than a pre-defined threshold (in our research, the threshold is 
set as 4). 
 
Fig. 5. Illustration of a shape filter 
Though most false positive candidates can be rejected by the use of above 5 criterions, some 
tumor points will also be rejected. In order to recover the rejected true tumors, we use a new 
criterion, which is shown in Fig. 6 to check the rejected candidates. For each rejected tumor 
candidate, we first generate an edge image, and then superimpose it with two circles Lin and 
Lout having radius rin and rout, respectively, and centers corresponding to the center of the 
tumor candidate’s 2D ROI. Their parameters are defined in Eq. 4. 
 
 
Fig. 6. Illustration of a shape filter for recheck 
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Here, L is the longer side length of 2D ROI. If the shape of a tumor candidate is 
approximately spherical, then a major portion of the tumor region is bounded by the circle 
Lin and the edge of the tumor is between the circles Lin and Lout. 
7. Experimental results 
We applied our proposed method to five sets of CT images. Information on each image is 
shown in Table 1. Data sets 1, 2, and 3 were used in the JAMIT CAD contest in July 2010, 
while Data sets 4 and 5 were used in the MICCA Liver Tumor Segmentation Challenge 2008 
[11]. Table 2 shows the results of tumor detection. In this study, if a part of a tumor is 
detected in the correct region, we consider the result as a true positive. Because only the 
ground truth for Data sets 1, 2, and 3 were known, Table 2 shows comparisons between the 
detected results and the ground truth for Data sets 1–3. The proposed method provides 
accurate detection results for Data sets 1 and 2. For Data set 3, the detection rate is about 




ｘ ｙ ｚ ｘ ｙ ｚ 
1 512 512 156 0.625 0.625 1.00 
2 512 512 191 0.732 0.732 1.00 
3 512 512 200 0.72 0.72 1.00 
4 512 512 173 0.59 0.59 1.50 
5 512 512 172 0.77 0.77 1.50 
Table 1. Information on each dataset 
 
Data set False negative True Positive Actual number 
1 0 2 2 
2 0 5 5 
3 7 6 13 
Table 2. Number of detected tumors 
Fig. 7 shows the results of tumor detection using the EM/MPM algorithm and the method 
based on [6]. It removed high intensities without employing Maximum likelihood method 
and applied the EM algorithm. The results show that our proposed method is superior to 
the previous one. The reason is considered to be the use of histogram transformation with 
PDFs. In the previous method, the EM algorithm took more time to converge compared 
with that in our proposed method; this was because the proposed method employs 
Maximum likelihood method. Moreover, irregular shapes could be removed by using the 
shape filter [Fig. 7(d)]. 
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(a)  (b)  (c)  (d) 
Fig. 7. (a) the original image (Data set 4). The tumor detection result obtained (b) using the 
method based on [6], (c) the proposed method, and (d) by the application of a shape filter to 
the image in (c). (In (b)–(d), the detected regions are white and the arrows indicate the 
locations of the detected tumors.) 
Fig. 8 show the results of the experiments for Data set 3. We used four methods: EM with and 
without preprocessing (contrast enhancement) and EM/MPM with and without 
preprocessing. As we used different pre-processing for EM and EM/MPM, it may affect the 
result a little. However, Figures 8(c)–(f) are the images obtained after morphology operations. 
Figures 8(c), (d) demonstrate the effectiveness of our histogram transformation. Comparing 
Figs. 8(c), (e) with Figs. 8(d), (f), we find that using EM/MPM improves performance.   
(a)   (b)  (c) 
(d)  (e)   (f) 
Fig. 8. Results after morphology (white lines) (a) Smoothed original image (b) answer (c) EM 
without preprocessing (d) EM with preprocessing (e) EM/MPM without preprocessing (f) 
EM/MPM with preprocessing  
Next, we quantitatively evaluate the tumor segmentation performance in terms of the metrics 
proposed in the MICCAI Liver Tumor Segmentation Challenge 2008 [11]. The metrics are the 
volumetric overlap error (Overlap Error), absolute relative volume difference (Vol. dif.), 
average symmetric surface distance (Ave. Dist.), RMS symmetric surface distance (RMS Dist.), 
and maximum surface distance (Max. Dist.). For ideal segmentation, all metrics should be 
zero. Table 3 shows the results obtained for one slice of a segmented region in a tumor by the 
metrics given in [11]. For Data set 1, regions in which tumors are detected are not solely 
represented by dark regions but also by bright voxels around them. Our proposed method can 
detect dark tumor regions; however, it cannot detect the bright tumor regions. Therefore, we 
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Next, we quantitatively evaluate the tumor segmentation performance in terms of the metrics 
proposed in the MICCAI Liver Tumor Segmentation Challenge 2008 [11]. The metrics are the 
volumetric overlap error (Overlap Error), absolute relative volume difference (Vol. dif.), 
average symmetric surface distance (Ave. Dist.), RMS symmetric surface distance (RMS Dist.), 
and maximum surface distance (Max. Dist.). For ideal segmentation, all metrics should be 
zero. Table 3 shows the results obtained for one slice of a segmented region in a tumor by the 
metrics given in [11]. For Data set 1, regions in which tumors are detected are not solely 
represented by dark regions but also by bright voxels around them. Our proposed method can 
detect dark tumor regions; however, it cannot detect the bright tumor regions. Therefore, we 
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excluded the results for Data set 1 and included only the results for the other data sets. We 
compared the current method with the previous method on the basis of the abovementioned 





















previous 74.27 68.09 1.28 1.84 5.00 
proposed 59.54 50.92 0.84 1.45 5.00 
3 
previous 75.63 72.08 2.76 4.20 13.45 
proposed 66.43 61.29 1.84 3.08 11.18 
4 
previous 84.29 84.29 4.84 6.57 16.27 
proposed 16.87 8.45 0.17 0.65 5.00 
5 
previous 6.71 4.53 0.04 0.28 4.24 
proposed 5.82 1.94 0.04 0.24 3.60 
Table 3. Performance comparisons 
8. Conclusions 
We have proposed a new method to detect tumors automatically in CT image. By using 
contrast enhancement with PDFs of different tissue classes in a newly devised histogram 
transformation method, we can enhance the image contrast. Moreover, by using the 
EM/MPM algorithm, we can detect tumors more accurately. We plan to improve our work 
to handle the large morphology variation of tumors. 
9. Acknowledgement 
We thank associate professor Akinobu Shimizu of Tokyo University of Agriculture and 
Technology for providing liver region extract program. We also thank JAMIT and MICCAI 
for providing CT images. This work was supported in part by the Grant-in Aid for Scientific 
Research from the Japanese Ministry for Education, Science, Culture and Sports under the 
Grant No. 21300070 and 22103513, and in part by the Research fund from Ritsumeikan 
Global Innovation Research Organization (R-GIRO). Wei Xiong and Jiayin Zhou 
acknowledge supports from Singapore A*STAR project JCOAG03_FG05_2009. 
10. References 
[1] Center for Cancer Control and Information Services, National Cancer Center, Japan, 
http://ganjoho.jp/public/statistics/pub/statistics01.html 
Liver Tumors 112 
[2] D. Smeets, D. Loeckx, B. Stijnen, B. De Dobbelaer, D. Vandermeulen, P. Suetens, Semi-
automatic level set segmentation of liver tumors combining a spiral scanning 
technique withsupervised fuzzy pixel classification, Medical image analysis, vol. 
14, no. 1, pp. 13-20, February 2010.  
[3] Häme, Y., Alhonnoro, T., Pollari, M.: Image Analysis for Liver Tumor Ablation 
Treatment Planning, Hands-on Image Processing 2009, Robotiker-Tecnalia.  
[4] K. Mala, V. Sadasivam, S. Alagappan, “Neural Network Based Texture Analysis of Liver 
Tumor from Computed Tomography Images, ” International Journal of Biomedical 
Sciences 2, 33–40, 2006.  
[5] Seung-Jin Park, Kyung-Sik Seo, Jong-An Park: "Automatic Hepatic Tumor Segmentation 
Using Statical Optimal Threshold", Computational Science - ICCS 2005, Springer 
Berlin / Heidelberg, Volume 3514, pp 934-940, 2005.  
[6] Y. Masuda, A. H. Foruzan, T. Tateyama, Y. W. Chen, “Automatic liver tumor detection 
using EM/MPM algorithm and shape information ”, IEICE technical report 110(28), 
25-30, 2010-05-13 
[7] Y. Masuda, A. H. Foruzan, T. Tateyama, Y. W. Chen, “Automatic liver tumor detection 
using EM algorithm and 3DROI,” Kamsao-section Joint Convention of Institutes of 
Electrical Engineerin, G310, 2009.  
[8] A. Shimizu,  http://www.tuat.ac.jp/~simizlab 
[9] M.L. Comer and E. J. Delp. The EM/MPM Algorithm for Segmentation of Textured 
Images: Analysis and Further Experimental Results, IEEE Transactions on Image 
Processing. , 9 (10) 1731-1744 October 2000.  
[10] J.L. Marrquin, S. Mitter and T. Poggie. Probabilistic Solution of Ill-Posed Problems in 
Computational Vision, Journal of American Statistical Association, 28 (397) 76-89 
March 1987.  
[11] X. Deng and G. Du:”Editorial: 3D Segmentation in the Clinic: A Grand Challenge II – 
Liver Tumor Segmentation”,  
 http://grand-challenge2008.bigr.nl/proceedings/liver/articles.html 
Liver Tumors 112 
[2] D. Smeets, D. Loeckx, B. Stijnen, B. De Dobbelaer, D. Vandermeulen, P. Suetens, Semi-
automatic level set segmentation of liver tumors combining a spiral scanning 
technique withsupervised fuzzy pixel classification, Medical image analysis, vol. 
14, no. 1, pp. 13-20, February 2010.  
[3] Häme, Y., Alhonnoro, T., Pollari, M.: Image Analysis for Liver Tumor Ablation 
Treatment Planning, Hands-on Image Processing 2009, Robotiker-Tecnalia.  
[4] K. Mala, V. Sadasivam, S. Alagappan, “Neural Network Based Texture Analysis of Liver 
Tumor from Computed Tomography Images, ” International Journal of Biomedical 
Sciences 2, 33–40, 2006.  
[5] Seung-Jin Park, Kyung-Sik Seo, Jong-An Park: "Automatic Hepatic Tumor Segmentation 
Using Statical Optimal Threshold", Computational Science - ICCS 2005, Springer 
Berlin / Heidelberg, Volume 3514, pp 934-940, 2005.  
[6] Y. Masuda, A. H. Foruzan, T. Tateyama, Y. W. Chen, “Automatic liver tumor detection 
using EM/MPM algorithm and shape information ”, IEICE technical report 110(28), 
25-30, 2010-05-13 
[7] Y. Masuda, A. H. Foruzan, T. Tateyama, Y. W. Chen, “Automatic liver tumor detection 
using EM algorithm and 3DROI,” Kamsao-section Joint Convention of Institutes of 
Electrical Engineerin, G310, 2009.  
[8] A. Shimizu,  http://www.tuat.ac.jp/~simizlab 
[9] M.L. Comer and E. J. Delp. The EM/MPM Algorithm for Segmentation of Textured 
Images: Analysis and Further Experimental Results, IEEE Transactions on Image 
Processing. , 9 (10) 1731-1744 October 2000.  
[10] J.L. Marrquin, S. Mitter and T. Poggie. Probabilistic Solution of Ill-Posed Problems in 
Computational Vision, Journal of American Statistical Association, 28 (397) 76-89 
March 1987.  
[11] X. Deng and G. Du:”Editorial: 3D Segmentation in the Clinic: A Grand Challenge II – 
Liver Tumor Segmentation”,  
 http://grand-challenge2008.bigr.nl/proceedings/liver/articles.html 
7
Surgical Strategies for Locally
Advanced Hepatocellular Carcinoma 
Shugo Mizuno and Shuji Isaji 
Department of Hepatobiliary-Pancreatic and Transplant Surgery,  
Mie University School of Medicine, Tsu, Mie,  
Japan 
1. Introduction 
Patients with advanced liver tumors extending into the portal vein or hepatic vein exhibit 
extremely poor prognosis after undergoing several nonsurgical therapeutic modalities, 
including transcatheter arterial chemoembolization (TACE) and radiofrequency ablation 
(RFA). Aggressive surgical treatments have been recommended in selected patients with 
advanced liver tumors accompanied with intravascular tumor thrombus (1). Complete 
surgical resection of the advanced liver tumors with tumor thrombus extending to the 
inferior vena cava (IVC) is beneficial for patients since it prevents the risk of pulmonary 
embolisms and prolongs long-term prognosis. However, IVC involvement increases the 
surgical risk and has been considered as a limiting factor for the curative resection of 
advanced tumors. The difficulty of surgery varies according to the tumor type and the 
region of the IVC involved; especially, the resection of tumors invading the junction of 
hepatic veins and the IVC is challenging. When the tumor thrombi extend above the 
diaphragm, cardiopulmonary bypass (CPB) is often suggested (2). Traditionally, it is 
necessary to perform sternotomy or thoracotomy for intrathoracic IVC isolation and to 
achieve adequate tumor-free margin and prevent emboli formation from the tumor thrombi 
(3). However, the set-up time for CPB exceeds 30 minutes (4) and the procedure of 
sternotomy needs additional 20 minutes or so, including the time required for closing the 
sternum wound. Furthermore, the complications and risks of CPB are similar to those 
observed in certain types of heart surgery (5). Moreover, the postoperative pain and wound 
adhesion caused by sternotomy and coagulopathy, and the central nervous complications 
inherent to the CPB and circulatory arrest have prompted the search for an alternative 
technique (6, 7). 
Therefore, many surgeons continue to perform this aggressive surgery but try to avoid 
median sternotomy and CPB (8-11). This chapter introduces surgical approaches to loop the 
supradiaphragmatic IVC by avoiding sternotomy and thoracotomy (Figure 1).  
Miyazaki et al. (8) first reported an approach to reach intrapericardial IVC through the 
abdominal cavity without sternotomy (Fig 1a). They suggested that after dissecting the 
coronary and triangular ligaments and mobilizing the bilateral hepatic lobes, the bilateral 
diaphragm just below the pericardial cavity can be transversely incised. The bottom of the 
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pericardium is consecutively incised, and the intrapericardial cavity is reached. While the 
left lobe of the liver is retracted caudally, long-curved vascular forceps are inserted into the 
intrapericardial cavity, and the IVC is encircled just below the confluence into the atrium. 
 
 
Fig. 1. Approach to the intra-thoracic IVC. (a) Miyazaki’s technique: The figure was copied 
from the original paper (8), with permission from Thieme. (b) Ciancio’s technique: The 
figure was copied from the original paper (9), with permission from Elsevier. (c) Chen’s 
technique: The figure was copied from the original paper (10), with permission from 
Elsevier. (d) Our technique: The figure was copied from the original paper (11), with 
permission from Springer. 
Ciancio et al. (9) showed the technique to gain access to the supradiaphragmatic IVC by 
circumferentially dissecting the central diaphragm tendon (Fig 1b, 2). The falciform 
ligament is divided using a cautery probe, and the incision is continued around each 
portion of the divided falciform ligament up to the right superior coronary ligament. The 
left triangular ligament and the central diaphragm tendon are dissected until the 
supradiaphragmatic, intrapericardial IVC is identified. The dissection should be 
circumferential so that the intrapericardial IVC can be encircled below or above the 
confluence into the right atrium. 
Chen et al. (10) reported the method of IVC isolation through a transdiaphragmatic 
pericardial window (Fig 1c, 3). They suggested that the left lateral segment of the liver can 
be mobilized, and a plane between the liver and the diaphragm developed carefully to 
create a transdiaphragmatic pericardial window, about 5 × 5 cm. Through this window, the 
intrapericardial IVC is isolated with an umbilical tape by blunt and sharp dissection. 
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Fig. 2. Ciancio’s technique (9). (a) Magnetic resonance imaging of RCC. Arrow indicates 
tumor thrombus in IVC extending above diaphragm into right atrium. (b) Diaphragm 




Fig. 3. Chen’s technique (10). (a) Computed tomography image of an adrenocortical 
carcinoma. The arrow indicates the tumor thrombus extending to the junction of the hepatic 
vein and the inferior vena cava. (b) Transdiaphragmatic pericardial window approach for 
intrapericardial isolation of the inferior vena cava. 
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With regard to the adverse events of cutting the pericardium, there are intraoperative and 
postoperative problems. Intraoperatively, opening the pericardium increases the right 
ventricular end-diastolic and end-systolic volumes, resulting in diminished right ventricular 
ejection fraction (12). Postoperatively, there have been many case reports suggesting that 
pericardial effusion, constrictive and/or purulent pericarditis, and cardiac tamponade 
develop after cardiac or noncardiac surgery (13, 14). 
Our technique is simpler, easier to perform, and less invasive, as compared to these 
approaches because it does not involve opening of the thoracic cavity and cutting of the 
pericardium (Fig 1d). We focused on the line of the fusion of pericardium to diaphragm 
(LFPD) (8), which is connected between the pericardium and diaphragm but can be easily 
disconnected (Fig. 4).  
 
 
Fig. 4. The anatomy of the line of fusion of pericardium to diaphragm (LFPD) 
For advanced hepatocellular carcinoma (HCC) patients (Fig. 5), LFPD was dissected, and the 
pericardium and diaphragm were completely separated without causing injury to the 
pericardium. From just below the xiphoid process to the IVC, the diaphragm was vertically 
dissected using LigaSure○R  without median sternotomy. Then, the intrathoracic IVC was 
exposed easily and was encircled with an umbilical tape to prevent emboli formation from 
the tumor thrombi (Fig. 6). After liver parenchyma transection, total hepatic vascular 
exclusion (THVE) was achieved by clamping the intrathoracic IVC, the infrahepatic IVC, 
right hepatic vein, right hepatic artery, and right portal vein. During the THVE, IVC wall 
Liver Tumors 116 
With regard to the adverse events of cutting the pericardium, there are intraoperative and 
postoperative problems. Intraoperatively, opening the pericardium increases the right 
ventricular end-diastolic and end-systolic volumes, resulting in diminished right ventricular 
ejection fraction (12). Postoperatively, there have been many case reports suggesting that 
pericardial effusion, constrictive and/or purulent pericarditis, and cardiac tamponade 
develop after cardiac or noncardiac surgery (13, 14). 
Our technique is simpler, easier to perform, and less invasive, as compared to these 
approaches because it does not involve opening of the thoracic cavity and cutting of the 
pericardium (Fig 1d). We focused on the line of the fusion of pericardium to diaphragm 
(LFPD) (8), which is connected between the pericardium and diaphragm but can be easily 
disconnected (Fig. 4).  
 
 
Fig. 4. The anatomy of the line of fusion of pericardium to diaphragm (LFPD) 
For advanced hepatocellular carcinoma (HCC) patients (Fig. 5), LFPD was dissected, and the 
pericardium and diaphragm were completely separated without causing injury to the 
pericardium. From just below the xiphoid process to the IVC, the diaphragm was vertically 
dissected using LigaSure○R  without median sternotomy. Then, the intrathoracic IVC was 
exposed easily and was encircled with an umbilical tape to prevent emboli formation from 
the tumor thrombi (Fig. 6). After liver parenchyma transection, total hepatic vascular 
exclusion (THVE) was achieved by clamping the intrathoracic IVC, the infrahepatic IVC, 
right hepatic vein, right hepatic artery, and right portal vein. During the THVE, IVC wall 
Surgical Strategies for Locally Advanced Hepatocellular Carcinoma 117 
was cut at the root of the left hepatic vein, and then the intracaval tumor thrombus and the 
left lobe of the liver were removed en bloc (Figure 7). The IVC defect was closed by a 
continuous suture with 5-0 monofilament. 
 
 
Fig. 5. Computed tomography image of hepatocellular carcinoma. The arrow indicates the 
tumor thrombus extending to the intra-pericardial inferior vena cava. (a)  transverse 
sections, (b) sagittal section. 
 
 
Fig. 6. After detachment of the line of fusion of pericardium to diaphragm (LFPD) and 
transection of the liver parenchyma, the infrahepatic IVC, right hepatic vein, right hepatic 
artery and right portal vein were taped. 
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Fig. 7. During the THVE, the wall of the IVC was cut at the root of the left hepatic vein,  
and tumor thrombus was exposed. 
Before applying THVE, we have to assess the preoperative hepatic functional reserve and 
carefully monitor intraoperative hemodynamic changes (16). Our selection criteria for liver 
resection are the same as Makuuchi criteria (17): the resection volume of the liver is 
determined based on total bilirubin and the Indocyanine green retention rate at 15 minutes. 
However, since THVE runs the risk of ischemic liver damage, these criteria should be 
determined more strictly. 
In conclusion, the technique we have described here appears to be easy and beneficial in the 
surgical treatment of IVC tumors, since it provides a longer tumor-free margin of the IVC; 
short operative time; and abolishes the need for sternotomy, CPB, and cutting the 
pericardium. However, more experience is necessary to validate the benefits of this 
approach. 
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1. Introduction 
Hepatocellular carcinoma is an important malignancy of global significance. It is the seventh 
commonest cancer and the fourth leading cause of cancer deaths worldwide (GLOBOCAN, 
2008). While hepatectomy remains to be the gold standard for treating HCC, long-term 
prognosis after curative resection remains unsatisfactory with high incidence of recurrence. 
The reported cumulative 5-year recurrence rate after curative partial hepatectomy averages 
above 70% in both Eastern and Western centers and the remnant liver is the commonest site 
of recurrence (Chong et al., 2011; Ercolani et al., 2003; Poon et al., 2001; Yeh et al., 2002). 
Intra-hepatic metastasis from the primary resected tumor and multicentric occurrence of a 
new tumor in the liver remnant are the two major patterns of intra-hepatic recurrence of 
HCC. In general, intrahepatic metastasis represented early recurrence (within 1 year after 
hepatectomy) and is associated with the vascular invasion and the subsequent intrahepatic 
venous spread while multicentric occurrence is associated with the underlying liver status 
and represented late recurrence (Jwo et al., 1992; Matsumata et al., 1989; Yamamoto et al., 
1998). Although the exact mechanism has not been clarified, many studies had shown that 
late recurrence was associated with a better survival than early recurrence (Poon et al., 1999; 
Poon et al., 2000; Shimada et al., 1996). 
Appropriate treatment for intrahepatic recurrence is crucial in improving long-term 
outcome after initial hepatectomy. Increased survival rates after aggressive treatment of 
post-resection HCC recurrence have been reported (Itamoto et al., 2007; Matsuda et al., 2001; 
Sugimachi et al., 2001; Tralhao et al., 2007; Wu et al., 2009; Zhou et al., 2010). Currently, 
various therapeutic modalities such as repeat hepatectomy, local ablation therapy and 
transcatheter arterial chemoembolization (TACE) have been used to treat recurrent HCC. 
However, there is no standard strategy for selection among different modalities so far. 
2. Treatment options for recurrent HCC 
2.1 Liver transplantation 
Theoretically, liver transplantation would be the optimal treatment for HCC within Milan 
criteria as it allows radical resection of the tumor together correction of the underlying liver 
cirrhosis. However, due to the shortage in organ supply and long waiting time, 
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recommending liver transplantation as the standard treatment for recurrent HCC deems 
logistically impractical. 
2.2 Re-hepatectomy 
Repeat hepatic resection has been widely recognised as one of the most effective 
treatments for intra-hepatic recurrent HCC compared to other therapeutic modalities 
(Chen et al., 2004; Itamoto et al., 2007; Minagawa et al., 2003; Sugimachi et al., 2001; 
Tralhao et al., 2007; Wu et al., 2009; Zhou et al., 2010). It should be the treatment of choice 
in suitable patients with preserved liver function and functional status. The safety and 
long-term results of repeated resection has been well-established, with operative mortality 
rates ranging from 0% to 8.5% and the reported cumulative 5-year survival rate after a 
second hepatectomy was comparable to the survival after initial hepatectomy for primary 
HCC (Aeii et al., 1998; Farges et al., 1998; Hu et al., 1996; Itamota et al., 2000; Kakazu et al., 
1993; Matsuda Y et al., 1993; Minagawa et al., 2003; Nagano et al., 2009; Nagasue et al., 
1996; Poon et al., 1999; Shimada et al., 1996, 1998; Suenaga M et al., 1994; Sugimachi et al., 
2001; Zhou et al., 2010). 
In a recent systemic review where studies reporting in at least 10 patients are included, 
Zhou et al analysed 29 studies of repeat hepatectomy for recurrent HCC with a curative 
intent (Zhou et al., 2010). A total of 1149 patients underwent repeat hepatectomy for 
recurrent HCC and the rate of repeat hepatectomy ranged from 8.7% to 44%. The median or 
mean operating time ranged from 136 to 365 minutes and the median or mean estimated 
blood loss ranged from 211 to 1980 ml. Majority of patients received minor resection at the 
time of repeat resection. The reported ranges of the 1-, 3- and 5-year survival were 69% to 
100%, 21% to 87% and 25% to 87% respectively. 
These results may support the use of repeat resection for recurrent HCC. Moreover, it is 
noteworthy that the rate of extra-hepatic spread after hepatic resection is low. The reported 
incidence of extra-hepatic metastases after primary liver resection was 5% to 20% while that 
after second resection was almost the same (Belghiti et al., 1991; Bismuth et al., 1995; Kosuge 
et al., 1993; Makuuchi et al., 1998). Nevertheless, repeat resection is technically demanding 
and difficult due to possible adhesions between the raw liver surface and the surrounding 
organs, distortion and anatomical disorientation caused by the rotation of liver remnant as a 
result of regeneration and limited liver reserve after previous resection (Figure. 1). 
So far, no consensus has been reached for the standard selection criteria for re-hepatectomy. 
In general, patients with good performance status and adequate liver functional reserve 
could be selected for re-hepatectomy if oncological clearance can be achieved (Zhou et al., 
2010). The main consideration remains the probability of patients developing post-
hepatectomy liver failure. 
An important finding reported by the Japanese groups is that the overall survival after 
second hepatectomy was significantly poorer in patients who recurred within 1 year after 
first hepatectomy than those who recurred more than 1 year after initial operation 
(Minagawa et al., 2003; Nagano et al., 2009). The authors postulated that many of these 
cases of early recurrence might be a result of intrahepatic metastasis from primary HCC 
and hence, associated with a poorer outcome. As a result, Minagawa et al, after reviewed 
67 patients received repeated hepatectomy for recurrent HCC, concluded that a disease-
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free interval of more than 1 year after primary hepatectomy, single HCC at primary 
resection, and negative portal vein invasion at repeated resection were favourable 
prognostic factors after repeated resection with excellent 3- and 5-year survival rates of 
100% and 86% respectively. They, therefore, recommended these patients should be 
indicated for repeat resection even if they have undergone major hepatic resection as the 
primary hepatectomy as long as the liver function can be preserved (Minagawa et al., 
2003). 
 
Fig. 1. Intra-operative picture of a patient who underwent right posterior sectionectomy for 
a recurrent HCC at segment VIII. Multiple adhesions over liver surface were also showed. 
The good results from repeat hepatectomy should be interpreted with caution as patients 
selected for repeat hepatectomy were usually patients with better prognosis, e.g. better liver 
reserve and smaller tumours. 
Recently, laparoscopic hepatectomy is well accepted as a safe and feasible treatment for 
primary HCC in selected patients with similar result to the open approach (Lee et al., 2007; 
Vignano et al., 2009). It is recommended for peripheral lesion requiring limited hepatectomy 
or left lateral sectionectomy (Lee et al., 2011; Vignano et al., 2009). Feasibility of repeat 
laparoscopic liver resection in recurrent HCC had been reported (Belli et al., 2009; Cheung et 
al., 2010; Hu et al., 2011; Liang et al., 2009). However, all these reports only focused on the 
technical aspects and the short-term outcomes. The importance of careful patient selection 
should be emphasized when considering laparoscopic re-resection and it should only be 
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done by surgeons who are highly experienced in both laparoscopic and open hepatic 
surgeries.  
2.3 Local ablation therapies 
Tumor ablation is defined as the direct application of chemical or thermal therapies to a 
tumor to achieve eradication or substantial tumor destruction. Although repeat 
hepatectomy is the most effective treatment for recurrent HCC, impaired liver function and 
the presence of multicentric tumours often precludes repeat hepatectomy in more than 80% 
of patients with recurrent HCC (Arii, et al. 1998; Kakazu et al., 1993; Lu et al., 2005; 
Minagawa et al., 2003; Poon et al., 1999; Shimada et al., 1996; Suenaga et al., 1993). Local 
ablative therapies have been increasingly used to treat recurrent HCC. They are particularly 
suitable for treatment of recurrent HCC as recurrence can usually be detected at an early 
stage on the surveillance imaging after hepatectomy while the nodules are still small.  
Radiofrequency ablation (RFA), microwave coagulation therapy (MCT) and percutaneous 
ethanol injection (PEI) are the three most commonly used local ablative treatment modalities 
for treatment of small primary HCC. Reports on the use of PEI in treating HCC recurrence 
are scarce. Both RFA and MCT can be applied percutaneously, laparoscopically, or at open 
surgery. From the experience in treating primary HCC, RFA and MCT are able to destroy 
bigger tumor up to 6cm or 7cm in diameter and require fewer treatment sessions than PEI 
and are therefore gaining attention as a valuable treatment options for ablating recurrent 
HCC (Goldberg & Gazelle, 2001; Ikeda et al., 2001; Livraghi et al., 1999; Lu et al., 2001; Seki 
et al., 1999). Currently, most of the currently available results on local ablative therapy for 
recurrent HCC were using RFA. 
2.3.1 Radiofrequency ablation (RFA) 
RFA is a thermo-ablative technique, which works by using a high-frequency alternating 
current applied via electrodes placed within the tissue to induce temperatures changes and 
generate areas of coagulative necrosis and tissue desiccation. RFA has been increasingly 
used to treat small primary or recurrent HCC (<5cm) in patients with poor liver reserve 
(Lau & Lai, 2009). High complete ablation rate (over 90%) and long-term survival 
comparable to those achieved by hepatectomy have been reported by cohort studies on RFA 
to treat recurrent HCC after partial hepatectomy. The reported 3-year survival rate averaged 
above 60% and the 5-year overall survival rate ranged from 18%-51.6% (Camma et al., 2005; 
Chen et al., 2006; Choi et al., 2007; Lu et al., 2005; Poon et al., 2002; Tateishi et al., 2005; Taura 
K et al., 2006; Yang et al., 2006).  
Besides the good results it achieves, RFA also has a few advantages over the repeat 
hepatectomy. First of all, it can be used in patients with poor liver function who might not 
be able to tolerate a repeat hepatectomy. Being a minimally invasive technique, RFA can be 
applied percutaneously in suitable patients and avoid the risk associated with general 
anesthesia and laparotomy (Figure. 2). Furthermore, RFA can be applied repeatedly for 
repeated treatment of recurrence. It is particularly important since in the background of 
liver cirrhosis, HCC tends to recur repeatedly and repeated treatment may be necessary. 
Hence, treatment with minimal damage to the non-tumoral hepatic parenchyma may be 
more preferable.  
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HCC (Goldberg & Gazelle, 2001; Ikeda et al., 2001; Livraghi et al., 1999; Lu et al., 2001; Seki 
et al., 1999). Currently, most of the currently available results on local ablative therapy for 
recurrent HCC were using RFA. 
2.3.1 Radiofrequency ablation (RFA) 
RFA is a thermo-ablative technique, which works by using a high-frequency alternating 
current applied via electrodes placed within the tissue to induce temperatures changes and 
generate areas of coagulative necrosis and tissue desiccation. RFA has been increasingly 
used to treat small primary or recurrent HCC (<5cm) in patients with poor liver reserve 
(Lau & Lai, 2009). High complete ablation rate (over 90%) and long-term survival 
comparable to those achieved by hepatectomy have been reported by cohort studies on RFA 
to treat recurrent HCC after partial hepatectomy. The reported 3-year survival rate averaged 
above 60% and the 5-year overall survival rate ranged from 18%-51.6% (Camma et al., 2005; 
Chen et al., 2006; Choi et al., 2007; Lu et al., 2005; Poon et al., 2002; Tateishi et al., 2005; Taura 
K et al., 2006; Yang et al., 2006).  
Besides the good results it achieves, RFA also has a few advantages over the repeat 
hepatectomy. First of all, it can be used in patients with poor liver function who might not 
be able to tolerate a repeat hepatectomy. Being a minimally invasive technique, RFA can be 
applied percutaneously in suitable patients and avoid the risk associated with general 
anesthesia and laparotomy (Figure. 2). Furthermore, RFA can be applied repeatedly for 
repeated treatment of recurrence. It is particularly important since in the background of 
liver cirrhosis, HCC tends to recur repeatedly and repeated treatment may be necessary. 
Hence, treatment with minimal damage to the non-tumoral hepatic parenchyma may be 
more preferable.  
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Fig. 2. CT image of a CT-guided percutaneous RFA of a segment VIII recurrent HCC which 
was performed under local anaesthesia. 
Liang et al compared the long-term survival outcomes of percutaneous RFA and repeat 
partial hepatectomy for recurrent HCC (Liang et al., 2009). They found that there was no 
significant difference in the overall survival of patients with recurrent HCC treated by 
repeat hepatectomy or RFA while RFA had the advantage over hepatectomy in being less 
invasive and causing fewer treatment-related morbidities. The authors attempted to make 
the baseline demographics in two arms comparable by using the same selection criteria to 
identify patients received repeat hepatectomy and percutaneous RFA in order to minimize 
the selection bias. The criteria included fewer than three recurrent tumours with the largest 
one less than 5cm, no radiological evidence of venous invasion, no extrahepatic metastases, 
no severe liver dysfunction (Child-Pugh class C), no significant coagulopathy, and no 
history of encephalopathy, refractory ascites or variceal bleeding. 
Of note, as in repeat hepatectomy, the benefit of RFA was more promising for patients with 
a longer disease-free interval from hepatectomy (Liang et al., 2009; Yang et al., 2006). Yang et 
al studied 41 patients with 76 recurrent HCC who received percutaneous RFA after 
hepatectomy. Early and late recurrences were defined as recurrence that occurred within 1 
year and after 1 year respectively (Yang et al., 2006). The late-recurrence group had a 
significantly longer overall survival than the early-recurrence group (mean overall survival 
42.9 months versus 16.4 months).  
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Needle tract dissemination is one of the major complications of great concern in percutaneous 
ablations. (Figure. 3) In a phase II study assessing the treatment-related complications and 
response rate of RFA in 32 patients by Llovet et al reported that the incidence of needle tract 





Fig. 3. Patient with metastasis at the needle tract (a) after underwent CT-guided RFA for 
HCC (b).  
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2.3.2 Microwave Coagulation Therapy (MCT) 
Initially developed for intra-operative haemostasis during hepatectomy, MCT has now 
developed as a new ablative therapy for treatment of HCC with high ablation rate, even for 
tumor with wider diameters, rapid ablation time and low morbidity and mortality rates and 
minimal heat sink effect (Itoch et al., 2011; Lloyd et al., 2011) (Figure. 4 & 5). 
MCT works by agitating water molecules in the surrounding tissue and producing friction 
and heat, hence inducing cellular death via coagulative necrosis (Simon et al., 2005) (Figure. 
5). Although reports on the efficacy of MCT in primary HCC are numerous, results of MCT 
on recurrent HCC are limited. Boutros et al reported their experience with MCT in 60 
patients with unresectable HCC (Boutros et al., 2010). Complete ablations were achieved in 
57 of the 60 patients (95%) judged by contrast-enhanced CT carried out 1-2 weeks after 
procedure and 1-2 months after discharge. However, 39 of the 60 patients (65%) had 
recurrence and 7 (11.6%) had local recurrence resulting in a low recurrence-free survival. 
Among these 60 patients, 45 had recurrent HCC. The reported 1- and 3-year recurrence-free 





Fig. 4a. Pre-operative CT image of a recurrent HCC at segment VIII of liver. 
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Fig. 4b. Open MCT for segment VIII recurrence guided by operative USG. 
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Fig. 4c. Segment VIII tumor after open MCT ablation. 
Several studies compared RFA to MCT in treating hepatic tumour (Lu et al., 2005; Ogata et 
al., 2008; Ohmoto & Yamamoto, 2006; Shibata et al., 2002; Xu et al., 2005). Most of them 
failed to detect a superiority of one over another. With the currently available evidence, 
MCT is a safe and effective treatment for HCC. However, further prospective studies with 
long-term results are needed in order to confirm its role in treatment of recurrent HCC and 
its performance compared to RFA or liver resection. 
2.4 Transarterial therapies 
Hepatic flow to the hepatocellular carcinoma and liver parenchyma has a very unique 
pattern. Typical hepatocarcinoma nodules are highly vascularized with arterial afferents 
originating from the hepatic artery, whereas the hepatic parenchymal flow is largely derived 
from the portal vein. This forms the basis of the transarterial therapies. 
2.4.1 Transarterial Chemoembolization (TACE)  
Despite the results from repeat hepatic resection for intra-hepatic recurrence was well 
recognised, the re-resection rate is low because of the impairment of functional reserve in 
the liver remnant and multiplicity of nodules (Eguchi et al., 2006; Kanematsu et al., 1984; 
Poon et al., 2002). Local ablation should be best performed in patients with recurrences 
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featuring three or fewer small nodules (Shimada et al., 2007). In contrast, transarterial 
chemoembolization (TACE) can be applied in any type of HCC, irrespective of tumor size, 
location, or number of lesions provided that patients have reasonable liver function. In 
addition, the benefit of TACE on survival in patients with unresectable HCC had already 
been demonstrated (Llovet & Bruix, 2003; Shim et al., 2009). Therefore, TACE is widely 
applicable and practical in patients with intra-hepatic HCC recurrence (Choi et al., 2009; 
Eguchi et al., 2008; Shim et al., 2010). 
 
Fig. 5. CT image of a patient with a 5cm segment VIII recurrent HCC at 6 months after 
microwave ablation. Three passes were performed for a bigger ablative zone and the needle 
tracts were showed on the follow up scan. 
TACE is the intra-arterial administration of chemotherapy combined with arterial 
embolization and is commonly used as an alternate treatment for recurrent HCC (Figure. 6). 
There is no standardized protocol in the optimal time interval between treatments and also 
the choice, dosage, concentration, rate of injection of the chemotherapeutic and the 
embolizing agents.  
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Fig. 6a. Hepatic angiogram showing a hypervascular tumor supplied by left hepatic artery. 
 
Fig. 6b. The tumor was stained by lipiodol after TACE.  
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Shim et al analysed data from 199 consecutive HCC patients who underwent curative liver 
resection and later received repeat TACE for intra-hepatic HCC recurrence. They found that 
complete tumor necrosis after repeated TACE offered favorable long-term survival 
outcomes to HCC-recurrent patients, with a median survival time after first TACE of 48.9 
months. Despite this, unlike repeat hepatectomy and RFA, TACE cannot be regarded as a 
curative treatment for recurrent HCC yet. 
Although it is not a surgical procedure, the problems of decreased liver reserves and 
anatomic changes due to previous operation still exist. Moreover, neovascularisation or 
collaterals that feed the recurrent tumour, damage to the non-tumorous liver tissue, and 
accumulation of drug toxicity from repeated TACE sessions are the main concern for the use 
of TACE. Post-embolization syndrome, which is a combination of fever, abdominal pain, 
nausea and vomiting, elevated liver enzymes and white cell counts for a few hours to a few 
days, is the most common complication of TACE. Although this syndrome is experienced 
after 80-90% of TACE procedures, it is mostly self-limited and the treatment is mainly 
symptomatic. Occasionally, more severe complications like acute cholecystitis, biliary tract 
necrosis, pancreatitis, gastric erosion or even ulcers can occur as a result of inadvertent 
injection of the chemotherapeutic and embolizing agents into these organs. Liver failure can 
develop after TACE and may result in mortality after TACE especially in patients with 
borderline liver function before treatment. Therefore, patients with portal vein thrombosis 
or poor liver function are contraindication to TACE. 
2.4.2 Selective Internal Radiation Treatment (SIRT) 
Selective internal radiation treatment (SIRT) is the delivery of radiation treatment via 
intrahepatic arterial administration of yttrium 90 (Y-90) microspheres. This technique 
involved the administration of Y-90 microspheres into the hepatic arterial via the trans-
femoral route. The administered Y-90 microspheres are then entrapped within the 
microvasculature and release irradiation. The high tumor concentration of Y-90 
microspheres results in an effective tumoricidal radiation-absorbed level while the radiation 
injury to the normal liver parenchyma is limited.  
Its role as a safe and effective therapeutic option for patients with unresectable 
hepatocellular carcinoma is increasingly recognized. Recently, Lau et al (Lau et al, 2011) 
reviewed the role of SIRT with Y-90 microspheres for hepatocellular carcinoma, including 
recurrent unresectable HCC. SIRT is a recommended option of palliative therapy for large or 
multifocal HCC without major portal vein invasion or extrahepatic spread. It can be used as 
a bridging therapy before liver transplantation or as a tumor downstaging treatment, or as a 
curative treatment for patients who are not fit for surgery. However, the evidence was 
limited to cohort studies and comparative studies with historical control and was mainly 
targeted on primary HCC. Future research may yield more information on its role on 
recurrent HCC and the efficacy when compared to chemoembolization or target therapy. 
In contrary to chemoembolization, optimal perfusion is required to enhance the free radical-
dependent cell death in SIRT. In order to minimize the treatment-related toxicity, hepatic 
scintigraphy with technetium Tc 99m (99mTc) macro-aggregate albumin (MAA) should be 
performed to determine the arterial anatomy and to calculate the shunt fraction delivered to 
the lungs before subjecting the patient to SIRT. Pulmonary shunt fraction greater than 15% 
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on 99mTc-MAA scan predisposes to radiation pneumonitis and is therefore a contraindication 
for SIRT. In addition to radiation pneumonitis, other serious complication associated with 
SIRT include gastric or duodenal ulcers or perforation as a result of reflux of Y-90 
microspheres into the gastrointestinal vascular bed and radiation hepatitis resulting from a 
radiation dose higher than the tolerable level. Nevertheless, most patients only reported 
mild symptoms like abdominal pain, lethargy or nausea, which may require symptomatic 
treatment. (Rossi et al, 2010) In most cases, it is a well-tolerated minimally invasive therapy. 
3. Extrahepatic recurrence 
Extra-hepatic recurrence or extra-hepatic metastasis occurs as a result of tumor extension 
from the liver or direct spreading to adjacent structures such as the diaphragm, the bowel 
and the adrenal gland; haematogenous spread via the systemic circulation to the lung; 
lymphatic spread from the liver to the portal and abdominal lymph nodes; or peritoneal 
dissemination from tumor rupture. Lung and abdominal lymph nodes are the commonest 
sites of metastasis, followed by musculoskeletal system, adrenal gland and peritoneum 
(Katyal et al., 2000; Yang et al., 2007). 
There were very few studies addressing the aggressive management of extra-hepatic 
recurrence after liver resection. This is probably related to the extremely poor prognosis in 
these patients before the introduction of sorafenib. 
3.1 Systemic treatment 
In general, extra-hepatic metastasis is regarded as an advanced systemic disease and 
therefore, only systemic chemotherapy or supportive treatment will be offered only. 
Unfortunately, the response rate of HCC to systemic chemotherapy such as adriamycin is 
very low and the results were mostly disappointing (Simonetti et al., 1997). 
With better understanding of the mechanism of hepatocarcinogenesis, effective molecularly 
targeted agents, such as sorafenib, have been emerged and improved survival benefits have 
been demonstrated in large, placebo-controlled phase III trials in Europe and Asia for 
patients with advanced HCC (Cheng et al., 2009; Llovet et al., 2008). While some may 
criticize that the benefit gained from sorafenib over placebo in patients with extra-hepatic 
metastasis from HCC was marginal only, the extra months gain may well be extremely 
valuable to patients. 
3.2 Surgical resection 
Recently, the role of resection of extra-hepatic metastasis from hepatocellular carcinoma has 
been reviewed (Chua & Morris, 2011). From the results reported in the literatures, 
prolonged survival after surgical resection may be achieved in selected patients with 
solitary extra-hepatic recurrence at the sites of the abdominal lymph node, adrenal gland, 
lung, and peritoneum. Surgical resection might be an effective option in patients with one or 
two isolated extrahepatic metastases if the patient has otherwise good performance status, 
good hepatic functional reserve, and well-controlled intrahepatic HCC recurrence. 
However, it might just reflect a group of patients with a more favourable natural course of 
disease (Chan et al., 2009; Lam et al., 1998; Nakayama et al., 1999; Sakamoto et al., 1999). 
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Fig. 7. Algorithm protocol for treatment of recurrent HCC 
4. Prevention 
Unfortunately, there is still no universally accepted form of adjuvant therapy for preventing 
recurrence after hepatic resection (Lau et al., 2009). Adjuvant regional therapy and anti-viral 
therapy are the two main directions that researches on this field are working on. 
4.1 Role of adjuvant regional therapy 
The preventive effect of TACE on recurrence after operation had been studied by 
prospective (Peng et al., 2009; Zhong et al., 2009) and retrospective series (Ren et al., 2004; Xi 
et al., 2007) mostly in eastern centers. The survival benefit of adjuvant TACE after hepatic 
resection was demonstrated in patients with high risk factors for recurrence while the effect 
in low risk for recurrence remains questionable. However, the quoted high risk factors for 
recurrence varied between studies, namely large tumor, multiple nodules, vascular invasion 
and presence of portal vein tumor thrombus. With the currently available evidence, the 
adjuvant regional chemotherapy with or without embolization or combination of systemic 
chemotherapy does not provide any additional benefit (Chan et al., 2000; Lau et al., 2009; 
Schwartz et al., 2002). Adjuvant transarterial treatments with 131I-lipiodol and adjuvant 
immunotherapy with interferon had demonstrated early promising results, which may have 
a role in preventing early intra-hepatic recurrence (Boucher et al., 2003; Ikeda et al., 2000; 
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Kudo et al., 2002; Lau et al., 2008; Partensky et al., 2000; Sun et al., 2006; Takjayama et al., 
2000). However, its role remains to be confirmed by further studies.  
4.2 Antiviral therapy 
In Asia, chronic hepatitis B virus (HBV) infection is the major cause of HCC. The risk for 
HCC development is closely associated with hepatitis B e antigen (HBeAg) status and the 
serum HBV-DNA level. Recent studies showed that tumour recurrence after curative 
treatment of HCC was increased with the level of HBV-DNA and alanine aminotransferase 
(ALT) (Cheung et al., 2008; Huang et al., 2008). This implies that HBV viral replication may 
play a role in HCC development and tumour recurrence. Scattered results from perspective 
and retrospective studies have shown that continuous treatment with nucleotide analogue 
in patients with chronic hepatitis B or cirrhosis could reduce the risk of HCC development 
(Liaw et al., 2004; Matsumoto et al., 2005). Wong et al reviewed the results of nine cohort 
studies including more than 500 patients in a recent meta-analysis concluded that anti-viral 
therapy could significantly reduce the risk of HCC recurrence after curative treatment of 
HBV-related HCC (Wong et al., 2011). Furthermore, anti-viral therapy might also allow 
salvage therapy in case of HCC recurrence by better-preserved liver function as supported 
by the result of two other studies (Kuzuya et al., 2007; Piao et al., 2005). Hence, anti-viral 
therapy with nucleotide analogues should be considered after curative treatment of HBV-
related HCC for the potential benefit in tumor recurrence and overall survival. 
5. Conclusion 
The principles of therapy for recurrent HCC should be, in fact, the same as those for primary 
HCC. Patients should have proper pre-operative assessment for their general functional 
status and evaluation of the functional liver reserve. Active hepatitis seems to be an 
important factor for patients considered for repeated liver resection, and therefore viral 
status, viral activity and finally liver function have to be evaluated thoroughly before 
resection. Depending on the local availability of various imaging modality, detail workup 
for restaging the disease and to rule out extra-hepatic metastasis is an important part in the 
decision of the best treatment for patient with recurrent HCC. Re-hepatectomy should be 
the treatment of choice if the tumour is resectable in terms of patient’s performance status, 
tumour staging and functional reserve of the liver remnant. For patients with small 
recurrence and borderline liver functional, local ablation therapy is a safe and effective 
treatment option. In case of multiple intra-hepatic recurrences, TACE can be considered in 
patients with good liver function as long as the portal veins remain patent. 
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1. Introduction 
Colorectal cancer (CRC) is the third most frequent in men in developed countries (after lung 
and prostate tumours) and second among women (after breast cancer), with approximately 
one million new cases per year throughout the world (550,000 men and 470,000 women), 
representing 14.6% and 15.2% respectively of all malignant tumours diagnosed. The role of 
colonoscopy in the screening of this pathology is crucial. CRC affecting the intestine has a 
high rate of cure (45-50%) with radical surgery. The most frequent metastatic involvement in 
CRC, after lymph nodes invasion, is seen in the liver. 
Several studies have analyzed the pre-operative prognostic factors in patients undergoing 
liver resection for liver metastases of CRC in order to select patients for surgical treatment. 
However, intraoperative and post-operative factors have been poorly studied and that could 
report on the aggressiveness of the tumour and the curative efficacy of the surgery 
performed. The purpose of surgery is resection of all liver lesions with a tumour-free 
margin, provided R0 resection (complete resection with no microscopic residual tumour) 
may be achieved with low morbidity and mortality (Choti et al. 2002; Marin et al. 2009; 
Lordan & Karanjia 2007) without endangering the life of the patient due to either liver 
insufficiency or post-operative complications. According to most authors, it should be noted 
that surgery, however extensive it is, does not prolong survival if residual microscopic or 
gross tumour is left (Harmantas et al. 1996; Kronawitter et al. 1999). 
Since Woodington and Waugh reported the first favourable results of surgical treatment for 
CRC liver metastases (Woodington & Waugh, 1964), a disease previously considered 
incurable, to date, a 5- and 10-year survival rates of 35-58% and 20-25% respectively have 
been achieved, while survival without treatment is less than 2% (Ohlsson et al. 1998; Fong et 
al. 1999).  
The key for indicating the most adequate treatment is the study conducted by a 
multidisciplinary team (Söreide et al. 2008; Artigas et al. 2007). The difficulty for assessing 
the indication stems from the fact that the presence of extrahepatic tumour, the possibility of 
achieving a tumour-free margin and the actual number of liver metastases are frequently 
known during the laparotomy. Different studies have analyzed the traditional pre-operative 
factors predicting survival in order to select patients in whom unnecessary surgery could be 
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avoided. These were factors related to the patient, the primary tumour and the liver 
metastases (Fong et al. 1999; Nordlinger et al. 1996). However, some authors do not 
contraindicate surgery in patients with poor prognostic criteria provided a R0 resection may 
be obtained, as a number of prognostic factors are known only after resection (Marín et al. 
2009). These factors include the histological study (number, resection margin size, 
microsatellites, type of growth, presence of tumour pseudocapsule, tumour differentiation 
grade, histological type, nuclear grade and number of mitoses/mm2) and the 
immunohistochemical study of the resected specimen. The latter may combine the markers 
of cell proliferation and cell cycle control, p53 and Ki67. There is increasing evidence 
supporting the concept that in human cancer, a minority of cells (tumour stem cells) has 
acquired characteristics of uncontrolled growth and the ability to form metastases (Reya et 
al. 2001; Dalerba et al. 2007; Jordan et al. 2006). This hypothesis is supported by different 
experimental observations made initially in acute myeloid leukaemia (Bonnet D & Dick J 
1997) and subsequently in human solid tumours, such as breast (Al-Hajj 2003), brain (Singh 
et al. 2004; Galli et al. 2004), colorectal (O' Brien et al. 2004; Ricci-Vitiani et al. 2007), head 
and neck (Prince et al. 2007) and pancreatic cancer (Li et al. 2007). However, this concept 
continues to be highly controversial and data reported on colorectal cancer are not yet 
conclusive (Ricci-Vitiani et al. 2007; Hill 2006).  
It is therefore interesting to know both the qualitative and quantitative stem cell population 
in the tumour using markers, such as CD44, CD133, and CD166. The tissue microarray 
(TMA) technique allows for monitoring and simultaneous evaluation of a great number of 
samples or tumour series in a single experiment, ensuring homogeneity of the techniques 
between specimens and validation of the results obtained with various histological, 
immunohistochemical and in-situ hybridization (FISH) techniques (Battifora 1986; Kononen 
et al 1998; Milanes-Yearsley et al 2002). 
In addition, over the last decade, a revolution in the approach to CRC liver metastases has 
occurred. Firstly, there was the advent of new chemotherapy drugs that have allowed better 
control of the disease, higher response rates and longer survival rates. Secondly, this has 
opened up a greater possibility of surgical rescue in more patients. Aggressive surgical 
management is called extreme liver surgery: ante-situ, in-situ and ex-situ liver resections are 
included (Mehrabi et al. 2011; Hoti et al. 2011; Oldhafer et al. 2001). 
2. Current diagnostic tools 
Imaging of the liver of CRC patients requires high sensitivity and reliable characterization of 
the lesions, allowing differentiation of malignant from benign tumours. Accurate and timely 
detection of hepatic metastases has long-range therapeutic and prognostic implications, 
since untreated liver metastases have a poor prognosis (5-year survival rate of 0–3%) while 
the resection with curative intent offers a much better one (5-year survival rate from 35% to 
58%) (El Khodary et al. 2011). An understanding of the segmental anatomy of the liver is 
imperative for localization and appropriate management of hepatic neoplasms. The 
classification proposed by Couinaud (Couinaud 1957 ) and later modified by Bismuth 
(Bismuth 1982) provides the surgically relevant information and is easily applicable to cross-
sectional imaging techniques, such as computed tomography (CT), magnetic resonance 
imaging (MRI) and ultrasonography (US).  
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The imaging assessment of potentially resectable CRC liver metastases, needed for a careful 
pre-operative selection of patients, should address the following five critical issues:  
1. Evaluation of possible liver metastases. Number, size and segmental location of 
tumours must be determined, as well as their differential diagnosis with benign lesions.  
2. Possible hilar lymph node involvement. As they represent metastases from the liver 
metastases, this lymphatic involvement carries a poor prognosis (survival rates after 
resection are 3-12%), although the pre-operative diagnosis is difficult.  
3. Vascular invasion. Obviously, assessment of vascular invasion is critical when deciding 
the appropriate surgical strategy.  
4. Liver volumetry. Measuring the volume of the future remnant liver when considering 
extended resections is recommended, since insufficient residual volume of liver 
parenchyma is a contraindication to surgery.  
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superfluous (Lucey et al. 2006).  
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US is a rapid and non-invasive method for screening patients with suspected liver 
metastases but, although it is highly efficient in distinguishing patients with diffuse hepatic 
metastases that involve all the liver, it is more operator dependent than other imaging 
methods, fails to show parts of the liver in certain patients and its sensitivity (50-70%) and 
specificity are surpassed by other imaging studies.  
The detection of hepatic metastases is substantially improved by contrast-enhanced US 
(CEUS) compared to conventional B-mode sonography, increasing the sensitivity per lesion 
from 71% to 87% (Oldenburg & Albrecht 2008). US contrast agents consist of microbubbles 
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Metastases behave characteristically in three phases: arterial, portal venous and delayed (El 
Khodary et al. 2011). CEUS sensitivity and specificity in staging liver metastases (80–95% 
and 84–98%, respectively) approach those of CT and MRI. In addition, CEUS is useful to 
improve the detection rate of metastases smaller than 1 cm or of those lesions that are 
isoechoic with respect to adjacent liver parenchyma, thus improving the performance of 
sonography in around 13.7% of the cases (Chami et al. 2008).  
In general, if an examination of the liver by US is insufficient, then examination by CEUS 
will also be insufficient. CEUS has limited ability to observe certain parts of the liver, 
especially in obese patients and/or in cases of steatosis and it is not possible to 
simultaneously examine multiple lesions in the arterial and early portal phases. 
Hypervascular metastases and haemangiomas on one hand and metastases and small cysts 
on the other can be difficult to differentiate (Larsen 2010).  
Intraoperative diagnosis is based on IOUS and on diagnostic laparoscopy. IOUS has higher 
sensitivity than transabdominal US, MDCT and MRI, and allows identification of metastases 
0.5 cm in size and defining the relationship between lesion, vessels and biliary structures. 
With a sensitivity of 98% and a specificity of 95%, IOUS is generally considered the gold 
standard for detecting liver lesions and is regarded as a routine investigation, modifying the 
planned surgical intervention in 18-30% of the patients. In addition, Doppler and spectral 
Doppler facilitate the technique of surgical resection. Laparoscopy, which is not routinely 
used in the pre-operative evaluation of the advanced disease, allows an assessment of the 
peritoneal and pelvic spread of the primitive cancer and, with the combined use of 
laparoscopic ultrasound (LIOUS), enables detection of small metastases, varying the initial 
surgical plan in 20–30% of the cases (Guglielmi et al. 2005). Contrast enhanced IOUS (CE-
IOUS) shows some benefit over pre-operative imaging and IOUS since it seems to improve 
the ability to characterize already detected lesions and facilitate the detection of new 
metastatic lesions (Fioole et al. 2008; Leen et al. 2006; Nakano et al. 2008; Torzilli et al. 2005).  
2.2 Computed Tomography 
MDCT has a sensitivity of 70–85% and a specificity of 90%, especially for lesions bigger than 
1.5–2 cm. Sensitivity is lower for small subglissonian metastases, even though multi-slice CT 
allows identification of hepatic lesions of 0.5 cm in size (Guglielmi et al. 2005). Fast data 
acquisition and breath-hold scanning allows imaging of the liver twice. This bi-phasic 
contrast-enhanced scan during the arterial-dominant phase and the portal-venous perfusion 
phase after bolus-like contrast administration, prior to the equilibrium phase, is accepted as 
standard for the optimised display of the complex vascularization of the liver and potential 
hepatic lesions. Slice thicknesses of 2 or 4 mm are the most effective for detection of focal 
liver lesions, with an identical detection rate of 96% for both. 3-D data sets can be produced 
improving multiplanar imaging, which allows evaluation of subcapsular lesions, 
demonstration of vascular anatomy and better characterisation of the lesions. Together with 
improvements in bolus-tracking, MDCT scanning during the various vascular contrast and 
equilibrium phases allows performing CT-angiography of the liver and mesenteric vessels, 
which can be important in patients undergoing hepatic resection or transarterial chemo or 
radio-embolisation. MDCT portal venogram is useful in evaluation of the portal system. 
Additionally, quantitative perfusion studies can also be done. Thus, MDCT can be used for 
evaluating the liver lesion, liver parenchyma and hepatic vessels in the same sitting. 
 
Liver Tumors 148 
Metastases behave characteristically in three phases: arterial, portal venous and delayed (El 
Khodary et al. 2011). CEUS sensitivity and specificity in staging liver metastases (80–95% 
and 84–98%, respectively) approach those of CT and MRI. In addition, CEUS is useful to 
improve the detection rate of metastases smaller than 1 cm or of those lesions that are 
isoechoic with respect to adjacent liver parenchyma, thus improving the performance of 
sonography in around 13.7% of the cases (Chami et al. 2008).  
In general, if an examination of the liver by US is insufficient, then examination by CEUS 
will also be insufficient. CEUS has limited ability to observe certain parts of the liver, 
especially in obese patients and/or in cases of steatosis and it is not possible to 
simultaneously examine multiple lesions in the arterial and early portal phases. 
Hypervascular metastases and haemangiomas on one hand and metastases and small cysts 
on the other can be difficult to differentiate (Larsen 2010).  
Intraoperative diagnosis is based on IOUS and on diagnostic laparoscopy. IOUS has higher 
sensitivity than transabdominal US, MDCT and MRI, and allows identification of metastases 
0.5 cm in size and defining the relationship between lesion, vessels and biliary structures. 
With a sensitivity of 98% and a specificity of 95%, IOUS is generally considered the gold 
standard for detecting liver lesions and is regarded as a routine investigation, modifying the 
planned surgical intervention in 18-30% of the patients. In addition, Doppler and spectral 
Doppler facilitate the technique of surgical resection. Laparoscopy, which is not routinely 
used in the pre-operative evaluation of the advanced disease, allows an assessment of the 
peritoneal and pelvic spread of the primitive cancer and, with the combined use of 
laparoscopic ultrasound (LIOUS), enables detection of small metastases, varying the initial 
surgical plan in 20–30% of the cases (Guglielmi et al. 2005). Contrast enhanced IOUS (CE-
IOUS) shows some benefit over pre-operative imaging and IOUS since it seems to improve 
the ability to characterize already detected lesions and facilitate the detection of new 
metastatic lesions (Fioole et al. 2008; Leen et al. 2006; Nakano et al. 2008; Torzilli et al. 2005).  
2.2 Computed Tomography 
MDCT has a sensitivity of 70–85% and a specificity of 90%, especially for lesions bigger than 
1.5–2 cm. Sensitivity is lower for small subglissonian metastases, even though multi-slice CT 
allows identification of hepatic lesions of 0.5 cm in size (Guglielmi et al. 2005). Fast data 
acquisition and breath-hold scanning allows imaging of the liver twice. This bi-phasic 
contrast-enhanced scan during the arterial-dominant phase and the portal-venous perfusion 
phase after bolus-like contrast administration, prior to the equilibrium phase, is accepted as 
standard for the optimised display of the complex vascularization of the liver and potential 
hepatic lesions. Slice thicknesses of 2 or 4 mm are the most effective for detection of focal 
liver lesions, with an identical detection rate of 96% for both. 3-D data sets can be produced 
improving multiplanar imaging, which allows evaluation of subcapsular lesions, 
demonstration of vascular anatomy and better characterisation of the lesions. Together with 
improvements in bolus-tracking, MDCT scanning during the various vascular contrast and 
equilibrium phases allows performing CT-angiography of the liver and mesenteric vessels, 
which can be important in patients undergoing hepatic resection or transarterial chemo or 
radio-embolisation. MDCT portal venogram is useful in evaluation of the portal system. 
Additionally, quantitative perfusion studies can also be done. Thus, MDCT can be used for 
evaluating the liver lesion, liver parenchyma and hepatic vessels in the same sitting. 
 
Colorectal Liver Metastasis: Current Management 149 
It is important to take account of the time elapsed between the radiological study and the 
operation. One recent study showed that the utility of MDCT as a pre-operative tool to 
evaluate CRC liver metastases is inversely proportional to the time interval between 
imaging and surgery, which may explain conflicting reports of the accuracy of MDCT in the 
literature (Yang et al. 2010).  
Hepatic volumetry, necessary to evaluate the feasibility of major hepatectomies, especially 
in the case of atypical resections, is provided by MDCT software able to highlight different 
liver segments and to create vascular maps for arterial and portal afferences, and for hepatic 
vein drainage. The volume of each single segment can be calculated and a simulation of 
surgical resection can be performed. Information can be displayed using coloured maps or 
three-dimensional movies (Laghi et al. 2005).  
2.3 Magnetic Resonance Imaging 
MDCT is usually preferred because it is more widely available and because it is a well-
established technique for surveying the extrahepatic abdominal organs and tissues. 
However, MRI has an advantage in the characterization of focal lesions and is also preferred 
for patients who cannot receive intravenous iodinated contrast material or when concerns 
about the risk of radiation from repeated exposure to CT, as in children or young adults, 
exists. In general, MRI sensitivity varies from 85-90% and its specificity is up to 95%, 
although a comparison of the performance of MDCT vs. MRI needs to be reassessed 
periodically, considering the rapid evolution of both technologies and the increase in 
therapeutic options available.  
Contrast media are of two types: the extracellular agents (gadolinium chelates) and the liver 
specific agents. Gadolinium is used for lesion detection and characterisation while liver 
specific agents are used as functional agents. The most commonly used substance in contrast-
enhanced dynamic MRI is extracellular gadolinium-chelate complex, which provides the 
greatest diagnostic sensitivity and specificity rates among cross-sectional techniques currently 
in use. The current standard MRI liver protocol includes a T2-weighted sequence, a T1-
weighted sequence and a three-phase technique after administration of gadolinium (arterial-
dominant, portal venous and hepatic venous or interstitial). Like CT, the detection of CRC 
liver metastases using MRI is maximized during the portal venous phase.  
The administration of organ-specific contrast agents with hepatocyte specificity 
(mangafodipir trisodium [MnDPDP], gadobenate dimeglumine [Gd-BOPTA]) or 
reticuloendothelial system specificity (superparamagnetic iron oxide [SPIO] particles, 
captured by Kupffer cells) allows an increase in the sensitivity and specificity of the method 
(Bluemke et al. 2000; Vidiri et al. 2004), but data about their benefits are controversial. 
Furthermore, these agents are generally costly and not widely available. 
Diffusion-weighted MR imaging (DWI) is a recently introduced technique to depict 
differences in molecular diffusion caused by the random motion of molecules. It provides 
excellent tissue contrast based on molecular diffusion, which is different from ordinary T1- 
and T2-weighted images, without the need for a contrast agent (El Khodary et al. 2011). An 
additional benefit of DWI is the ability to derive quantitative indices, which may be 
important in the assessment of disease response to novel therapeutics, including anti-
vascular and anti-angiogenic therapy, since conventional assessment based on measuring 
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lesion size is insensitive to early, treatment-related changes (Koh et al. 2006). In summary, 
DWI is a simple and sensitive method for screening focal hepatic lesions and is useful for 
differential diagnosis (Koike et al. 2009).  
2.4 Positron Emission Tomography 
FDG PET is a highly sensitive and specific imaging study detecting hepatic metastases from 
CRC (92–100% and 85–100% respectively), although for some authors the strength of these 
data is moderate (Lucey et al. 2006). Several studies have also shown the utility of FDG PET 
in identifying additional metastatic lesions when initial CT showed single hepatic 
metastases and, thus, changed the management strategy. Nevertheless, false negative and 
false positive findings in FDG PET for hepatic metastases are not negligible (Udayasankar et 
al. 2008) and its positive predictive value (PPV) is not high, leading to some authors to 
confirm histologically the FDG PET findings suggesting non-resectability (Valls et al. 2009).  
Two meta-analyses have demonstrated high diagnostic values of PET in the evaluation of 
hepatic metastases (Bipat et al. 2005; Wiering et al. 2005), as well as a recent review (Patel et 
al. 2011) confirming the superior sensitivity of FDG PET for detecting liver metastases on a 
per patient basis, but not on a per lesion basis. Other papers have shown FDG PET/CT to be 
slightly less sensitive than MRI with liver-specific contrast agents or dedicated sequences for 
small lesions (Coenegrachts et al. 2009), but more sensitive than MDCT alone (Kong et al. 
2008; Selzner et al. 2004), although its role is not yet clear owing to the small number of 
studies (Niekel et al. 2010). In the context of CRC metastases, the role of FDG PET/CT is to 
avoid unnecessary surgery, based on its ability to detect extrahepatic foci of disease (nodal 
metastases, lung nodules) that are not depicted or characterized as malignant by other 
imaging methods (Sørensen et al. 2007). In addition, this technology is not suitable for liver 
resection planning. In patients evaluated with FDG PET prior to surgery, a lower risk of 
“non-therapeutic laparotomy” (Pawlik et al. 2009) and improved survival (Fernandez et al. 
2004) has been observed, reflecting better patient selection.  
A recent meta-analysis reviewing more than 3,000 patients found that sensitivity of CT, MR 
imaging and FDG PET on a per lesion basis were 74.4%, 80.3% and 81.4%, respectively, 
while on a per patient basis, the sensitivities were 83.6%, 88.2% and 94.1%, respectively. 
Specificity estimates were comparable. No differences were seen for lesions measuring at 
least 10 mm. Data about FDG PET/CT were too limited for comparisons with other 
modalities (Niekel et al. 2010).  
In brief, although every modality has benefited from advances in technology, MDCT 
scanning remains a dominant imaging modality not only for lesion detection and pre-
operative planning, but also for treatment monitoring and post-treatment surveillance. 
High-resolution CT with contrast combined with FDG PET/CT may obviate the need for 
additional studies and may improve patient management (Bipat et al. 2007; Doan et al. 2010; 
Vauthey 2006). Dynamic gadolinium-based contrast-enhanced MRI should be reserved for 
problem solving. MRI has the highest sensitivity for lesion detection, but because of its low 
sensitivity in detecting extrahepatic disease in the peritoneum and chest, it is not a desirable 
primary imaging modality (Vauthey 2006) except for evaluating patients who have not 
previously undergone therapy (Lucey et al. 2006; Niekel et al. 2010). Ultimately, the 
modality used must be tailored not only to the patient and the clinical situation, but also to 
the imaging expertise within the institution.  
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3. Current criteria for resectability 
Improvements in pre-operative imaging techniques, patient selection and surgical 
techniques, as well as the introduction of new cytotoxic and biologic agents for pre-
operative and post-operative chemotherapy have improved the resectability rate and almost 
doubled the 5-year survival rate for patients with CRC liver metastases, from about 30% two 
decades ago to nearly 60%. In this setting, with the care of these patients rapidly evolving, 
the standards of care needed to be redefined. The criteria for resectability of these 
metastases have changed dramatically. Features such as the number of lesions (1 to 3 
unilobar metastases), the size of the lesion (less than 5 cm), preferably presenting at least 12 
months after resection of the primary tumour, resectable with a minimum margin of 1 cm in 
width and without hilar adenopathy or extrahepatic disease, are no longer considered as 
determinant factors regarding resectability and, thereby, are invalid to deny a patient the 
opportunity of lengthy survival.  
Regarding the number of metastasis, Altendorf-Hofmann did not find long-term differences 
in the survival rates between patients with 1 to 3 metastasis and those with 4 or more, if a R0 
resection had been obtained (Altendorf-Hofmann et al. 2003). Moreover, some studies have 
shown that the degree of response to chemotherapy is a stronger predictor factor for long-
term survival than the number of metastasis. Regarding tumour size and prognosis, reports 
have been conflicting. Evidence shows that size is not a resectability factor, but a factor 
related to tumour aggressiveness. 
It has been shown that the actual width of the surgical margin has no effect on survival as 
long as the margin is microscopically negative (Figueras et al. 2007; Lordan 2007; Pawlik et 
al. 2005). A margin greater than 10mm is considered to be optimum, although this has 
changed too (Casanova et al. 2004). Although surgeons should continue to plan hepatic 
resection to preserve a "safety zone" and should avoid routine use of "minimum margin" 
surgery, a predicted margin of less than 1 cm should no longer be considered an exclusion 
criterion for resection.  
Historically, extrahepatic disease has been almost universally accepted as a 
contraindication to liver resection. Recently, however, some series have shown a 5-year 
survival rate of 12% to 37% after liver resection in selected patients with extrahepatic 
disease, independent of the location of that disease (lung, primary colorectal recurrence, 
retroperitoneal or hepatic pedicle lymph nodes, peritoneal carcinomatosis, miscellaneous) 
(Elias et al. 2003, 2005). In most cases, incidental peritoneal disease found at laparotomy 
would contraindicate hepatic resection. In general, resection in such patients should only 
be considered after documentation of stable/responsive disease with systemic 
chemotherapy and when an R0 resection of both intrahepatic and extrahepatic disease is 
feasible. From an anatomic and prognostic perspective, it seems appropriate to 
recommend that patients with combined liver and extrahepatic disease be reported 
separately from those meeting the traditional resectable criteria, and be designated as 
borderline resectable (Vauthey 2007).  
Positive hilar lymph nodes are associated with a poor outcome and have been traditionally 
considered as a contraindication to hepatic resection of CRC liver disease. Recent papers 
have reported long-term survival in some patients with hilar nodal metastases and have 
concluded that this patient population may still benefit from hepatic resection and 
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lymphadenectomy, provided that involved nodes are in the hepatoduodenal-retropancreatic 
area and not in the common hepatic artery/celiac-axis region (Adam et al. 2008; Jaeck 2003). 
Although patients with microscopic involvement may derive a benefit from hepatic 
resection, gross involvement of the hilar nodes should be considered a relative 
contraindication to resection. 
At present, the criteria for resectability include any patient in whom all disease can be 
removed with a negative margin and who has adequate hepatic reserve. That is to say, 
instead of resectability being defined by what is removed, now it is sustained by what will 
remain after resection, including patients with extrahepatic disease (Pawlik et al. 2008). 
Interestingly, none of the traditional adverse prognostic indicators of recurrence, such as 
carcinoembryonic antigen more than 200 ng/mL, short disease-free interval, node-positive 
primary, tumour size more than 5 cm, multiple tumours, or synchronous presentation, 
precluded long-term survival, except for a positive resection margin (Vauthey 2007).  
In 2006, the Consensus Conference on Colorectal Liver Metastases of the American Hepato-
Pancreato-Biliary Association (AHPBA) established that CRC liver metastases should be 
defined as resectable when the disease can be completely resected, two adjacent liver 
segments can be spared with an adequate vascular inflow and outflow and biliary drainage, 
and the volume of the liver remaining after resection (future liver remnant [FLR]) will be 
adequate (at least 20% of the total estimated liver volume for normal parenchyma, 30–60% if 
the liver is injured by chemotherapy, steatosis or hepatitis, or 40–70% in the presence of 
cirrhosis, depending on the degree of underlying hepatic dysfunction) (Vauthey 2006). 
When hepatic metastatic disease is not optimally resectable based on insufficient remnant 
liver volume, pre-operative chemotherapy, portal vein embolization or staged liver resection 
can be considered. Also, ablative techniques may be considered alone or in conjunction with 
resection. All original sites of disease need to be amenable to ablation or resection (Abdalla 
et al. 2006; Adam et al. 2006; Donadon et al. 2007; Garden et al. 2006).  
Resection should be offered to all patients who are suitable candidates and neoadjuvant 
chemotherapy should be considered in patients who are deemed unresectable at initial 
evaluation (Doan et al. 2010). Novel chemotherapeutic regimens combining 5-FU, folinic 
acid and oxaliplatin and/or irinotecan have been associated with improved response rates 
(approximately 50%), allowing 10-30% of the patients with initially unresectable disease 
to be successfully treated with liver surgery (Adam et al. 2004). In addition, combination 
with biologic agents that target angiogenesis and the epidermal growth factor receptor 
(EGFR), bevacizumab and cetuximab, achieves response rates of up to 70%, increasing 
these figures (Vauthey 2006). Re-evaluation for resection should be done after 2 or 3 
months of pre-operative chemotherapy and every 2 months thereafter. Tumour 
progression before surgery is associated with a poor outcome, even after potentially 
curative hepatectomy. Tumour control before surgery is crucial to offer a chance of 
prolonged remission in patients with multiple metastases (Adam et al. 2004). Patients 
should be referred early for evaluation for resection. The peri-operative complication rate, 
including hepatobiliary complications, is higher with lengthy pre-operative chemotherapy 
and is likely related to the prolonged and sequential use of multiple regimens (de Haas et 
al. 2011).  
Once patients have been diagnosed and a decision made in a multidisciplinary setting that 
resection is appropriate, it is essential to ensure that patients undergo repeat high quality 
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abdominopelvic CT (or MRI) within a month of the date of surgery. Chest CT should also be 
performed at this time.  
4. Chemotherapy and surgery 
The high recurrence rate and the overall poor “true” survival after surgical resection of CRC 
liver metastases led to the incorporation of the use of chemotherapy. This treatment can be 
administered in different strategies: neoadjuvant, peri-operative, adjuvant and conversion 
or downstaging. The latter is administrated to patients with unresectable disease with the 
goal of downsizing the tumour, re-staging it and re-considering its resection.  
Chemotherapy seems to improve outcomes compared with surgery alone. Current 
chemotherapeutic regimens lead to improved survival in patients with unresectable liver 
metastases. Resection of the primary tumour and the liver lesions is the optimal 
management of stage IV CRC with liver metastases. For patients with extensive liver 
metastases, FOLFOX (folinic acid, 5-fluorouracil and oxaliplatin) and FOLFIRI (irinotecan 
instead of oxaliplatin) have improved resection rates and survival. Upfront chemotherapy in 
the asymptomatic patient compared with resection of the primary tumour does not appear 
to affect survival significantly. However, given that 60% of the patients were alive after 2 
years, resection of the primary lesion for palliative reasons and local control must be 
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Fig. 1. *Pre-operative therapy depends on the multidisciplinary team and the analyses of the 
individual case. In some cases, the first option can be resection without pre-operative 
chemotherapy. **Portal vein embolization (PVE) can be associated to these approaches 
according to future liver remnants (FLR) volume and the status of the liver (normal, 
postchemotherapy and cirrhotic). 
The efficacy of the peri-operative chemotherapy on survival benefit for resectable liver 
metastases has not been justified. However, the timing and the indication of the surgery are 
dramatically changing with the development of chemotherapeutic agents. The 
overwhelming majority of patients with resectable metastases receive some sort of 
chemotherapy, although it is not known if the adjuvant regimen is better than the 
neoadjuvant. The EORTC 40983 study did not demonstrate a clear advantage of pre-
operative chemotherapy in patients with initially resectable metastasis, but it could not 
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answer either if neoadjuvant, adjuvant or peri-operative chemotherapy is superior. 
Detractors claim that chemotherapy delays surgery while supporters point out that surgery 
is facilitated and that the treatment provides information on tumour biology (Nordlinger et 
al. 2008). The surgeon’s main concern is to operate on patients with livers affected by 
chemotherapy, which are usually more rigid, more difficult to manage and tend to bleed 
more easily. The same study demonstrated that no patient progressed from a resectable 
disease to an unresectable one, that short cycles of treatment provided minimal liver 
toxicity, that morbidity was similar in both groups and that survival improved in the 
chemotherapy sub-group. However, the problem persists over the timing of administering 
chemotherapy and the management of “ghost lesions” after complete response that cannot 
be detected with IOUS.  
5. Rescuing more patients 
In 1986, Ekberg provided several contraindications for the surgery of liver metastases of 
colorectal origin (4 or more nodules, a size greater than 5 cm, presence of extrahepatic 
disease and the inability to resect with a margin greater than 1 cm). Others studies 
corroborated these findings. A thorough analysis of these papers could have reduced their 
influence realising that they had short series or that their statistical analysis was 
univariate. As previously stated, these criteria are deemed obsolete. So the question is: can 
all disease be resected while leaving a functional liver remnant? (Charnsangavej et al. 
2006). There exist some innovative strategies that increase the volume of the hepatic 
remnant. Portal vein embolization (PVE) or ligation causes atrophy of the ipsilateral 
hemiliver and hypertrophy of the contralateral side. PVE appears to be particularly 
valuable in patients who present with underlying liver disease. The concomitant 
administration of chemotherapy may decrease both the tumour load and post-operative 
recurrences. Furthermore, aggressive approaches in selected cases can provide the only 
possible cure.  
5.1 Downstaging chemotherapy 
Downstaging chemotherapy is indicated for metastatic disease and for syncronicity in 
nonresectable disease. Intravenous or HAI downstaging chemotherapy showed a 
resectability of 20% (Fusai & Dadvison 2003). The advent of oxaliplatin and irinotecan 
reached response rates of up to 50% increased over 65% with the addition of bevazucimab 
and cetuximab. Although there are no reports of outcomes of liver resection after HAI, its 
complication rates are so high (57%) that it is dismissed as a first option.  
When treating these patients, the question arises as to whether to continue treatment until 
reaching the maximal effect or stopping once the disease becomes resectable. In general, pre-
operative chemotherapy should be stopped once the intrahepatic disease has been 
downsized to the point where hepatic resection is feasible. Surgery should be considered 
after 3 or 4 cycles in order to reduce liver toxicity, and therefore surgical morbidity, and to 
avoid a complete clinical response, difficult to trace intraoperatively. In most patients 
receiving chemotherapy, a complete response on CT scan does not mean cure (Benoist et al. 
2006) due to the fact that in over 80% of the cases there are viable cancer cells in the initial 
site of the metastasis. Current management of these ghost lesions is to remove all of them if 
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possible, considering the future liver remnant. In general, all the original sites of disease 
noted on the pre-therapy imaging need to be resected or ablated. 
Since post-operative morbidity affects long-term survival (Laurent et al. 2003), length of 
chemotherapy treatment must be taken into account. In recent years more and more 
patients with stable long-term disease (more than 20 months) are considered for surgical 
treatment. Irinotecan and oxaliplatin have been associated with the development of 
steatohepatitis. Among patients receiving these drugs, the rates of complications and 
death after major liver resection are likely to be higher compared to patients not receiving 
chemotherapy, although this is not completely clear. Albeit systemic treatment is very 
effective in reducing tumour burden and facilitates the surgical therapy in previously 
unresectable patients, the recurrence rate is high because of the presence of residual 
microscopic disease. 
5.2 Portal vein embolization 
Based on objective date, consensus has been reached on what is an adequate liver remnant 
and what are the “safe” resection percentages depending on the quality and health of the 







Fig. 2. Minimum FLR volume needed for safe liver resection in patients with normal, 
intermediate disease or cirrhotic liver (Zorzi et al. 2007). 
When the future liver remnant (FLR) is insufficient PVE should be considered. PVE also 
constitutes a dynamic pre-operative test on the capacity of the liver to respond to the 
surgical aggression. If a hypertrophy greater than 5% is achieved after PVE, there is a low 
risk of a terrible post-operative liver insufficiency (Ribero et al. 2007). Chemotherapy does 
not seem to affect the hypertrophy induced by PVE. A few studies using bevazucimab 
recommend a 6 week waiting period between the last dose and the hepatectomy, although 
its influence on the hypertrophy is unclear.   
Future Liver Remnant 
Normal Liver >20% 
Liver injury >30% 
Cirrhosis >40% 
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PVE is well tolerated with minimum side effects such as fever, nausea, and transient 
abnormality of liver function test. The complication rate is below 5% (Abdallah et al. 2001). 
Azoulay et al. reported that PVE increased the feasibility of liver resection by 19% and that 
the actuarial survival rate was 40% at 5 years, similar to that of patients resected without 
PVE (Azoulay et al. 2000). 
5.3 Two-stage hepatectomy 
Two-stage hepatectomy is one of the methods to increase the resectability of liver tumours. 
Its objective is to eliminate the entire tumour burden. The first stage can also be performed 
together with laparoscopic colorectal resection. It consists of combining two sequential and 
planned liver resections when it is impossible to resect all liver metastases in a single 
procedure, while preserving at least 30% of functional liver volume to avoid post-operative 
liver failure. Frequently, it is associated with peri-operative systemic chemotherapy and 
PVE, although it is not a rule (Jaeck et al. 2004) (Figure 3). 
The first hepatectomy attempts to resect the majority of liver tumours and to get 
hypertrophy of the remnant liver with or without PVE. The second hepatectomy is 
performed at least 4 weeks later to allow time for growth and hypertrophy of the FLR. The 
design of the technique must be meticulous well in advance of the first resection as an 
important strategy to achieve complete removal, admitting that around 30% of patients will 
not be rescued on the second hepatectomy.  
Usually, on the first hepatectomy the future remnant liver is cleared out of tumours with 
non-anatomic resections and/or radiofrequency ablation or at most a single segment 
resection. As mentioned, it can be associated to the removal of the primary colorectal 
tumour, preferably through a laparoscopic approach or using a “J” incision if it is located on 
the right colon. After 2 to 4 weeks after the clearance of the FRL, percutaneous PVE is 
performed. Alternatively, PVE can be done during the first hepatectomy through the 
ligation and alcoholization of the right portal vein, which is the side more often embolized. 
The second hepatectomy can be done on the fourth of fifth week after PVE, when an 
adequate hypertrophy of the non-embolized hemi-liver is achieved.  
Some authors recommend pre-operative chemotherapy during the entire process. This 
should be determined by the criteria of the multidisciplinary team according to each 
individual case (Adam et al. 2000). We carry out this procedure by performing PVE in the 
first hepatectomy with or without the removal of the primary tumour. After a 4 week 
waiting period and a CT confirming an adequate FRL, a second hepatectomy is performed. 
If during the second stage hepatectomy new liver metastases or extrahepatic lesions are 
discovered, such as localized peritoneum implants, the procedure can still be performed if a 
R0 resection can be achieved. A recent series reports a 5 year overall survival rate of 32% for 
patients on whom the procedure had been completed (Narita et al. 2011). 
Two factors affect the success of two-stage hepatectomy: patient selection and optimal 
chemotherapy regimen. This procedure may be the only therapy able to provide long-term 
survival and a possible cure for patients with initially unresectable multiple and bilobar 
CRC liver metastases.  
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Fig. 3. Multiple and bilobar metastases, right hydronephrosis and rectum cancer involving the 
right ovarium in a 37 year old woman. After chemotherapy treatment, first stage surgery 
consisted of tumour clearance of the left liver, anterior colorectal resection, right oophorectomy 
and right PVE (lower pictures). Five weeks later an extended right hepatectomy was performed.  
5.4 Synchronicity: Colorectal tumour and liver metastases 
On the international registry of liver metastasis from CRC, LiverMet Survey, a 51.7% of 
synchronicity has been recorded in January 2011 (table 1). This frequent sort of presentation, 
together with the expansion of the criteria of resectability and the laparoscopic approach for 
the colorectal and liver surgery, have created a new insight within the multidisciplinary teams.  
 
Sinc/Metac Number of patients 1 year 3 year 5 year 10 year 
Sincronic 6112 90% 58% 39% 22% 
Metacronic 5724 90% 60% 43% 26% 
Table 1. LiverMet Survey, January 2011. Survival rates in 11836 patients after hepatectomy 
(with permission). 
As mentioned, colon resection can be done on the first stage, or a liver approach can be done 
first after a downstaging of the liver tumour/tumours. What should be done first depends on 
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the primary tumour (mainly in cases of rectal cancer that require an ultralow resection or are 
T3 or T4) and on the volume of liver parenchyma that needs to be removed. If the patient has 
been downstaged to resectability, the liver should be approached first (if possible) and the 
colorectal tumour should be operated 4 to 6 weeks later (Figure 4).  
 
Fig. 4. Large liver metastasis involving the three hepatic veins (upper pictures) in a 61 year 
old patient with rectal cancer. After 3 months of chemotherapy (lower pictures) the patient 
underwent left hepatectomy, segment (Sg) 1 and Sg 8 segmentectomies and right hepatic 
vein reconstruction. Six weeks later the rectal cancer was resected. 
5.5 Ante-situ, in-situ and ex-situ procedures: Extreme liver surgery  
Liver transplantation has brought with it advances in techniques that can be applied to 
nontransplant hepatic surgery. The lessons learned from reducing adult-sized livers for 
implantation in children, living related donor liver transplantation and split liver 
transplantation can all be applied in the nontransplant setting. Tumours that were 
considered unresectable with standard techniques can now be considered for resection 
using in-situ, ante-situ and ex vivo or bench liver surgery. In the last technique, the liver is 
completely removed from the patient and perfused with preservation solution. A bloodless 
transection of hepatic parenchyma can then be performed allowing complex reconstruction 
of hepatic veins or portal structures after which the liver is reimplanted in the patient. The 
ex vivo technique was first performed by Pichlmayr and colleagues in 1988 and has been 
applied sparingly in selected patients since then (Hemming et al. 2000). 
The common basis for in-situ, ante-situ and ex-situ resection is the total vascular exclusion 
(TVE) of the liver, and the perfusion of the organ by preservation hypothermic solution. 
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The principles are the same for the three techniques, which differ only in the extent to 
which liver is mobilized from its vascular connections, hylum and caval vein. Generally, a 
veno-venous bypass is used to avoid venous congestion during prolonged caval and 
portal crossclamping and a hypothermic preservation solution is instilled through the 
portal vein (Fortner et al. 1978). In a study population about liver resection under TVE, 
Azoulay et al. concluded that standard TVE of any duration with hypothermic perfusion 
of the liver, in this issue in-situ procedure, was associated with a better tolerance to 
ischemia. Furthermore, compared with TVE ≥ 60 minutes, it was associated with better 
post-operative liver and renal functions and lower morbidity (Azoulay et al. 2005). The 
main indications of the three techniques are tumours that involve vascular structures of 
the hylum, venous confluence or inferior vena cava (IVC), or are in close proximity to 
them. The technique can be used for benign, primary or metastatic tumours. The decision 
about what technique to use depends on the tumour location and its relationship with the 
three hepatic veins and caval vein. It is important to notice that the ex-situ technique is 
losing support due to its high morbidity and mortality. The location of the lesion or 
lesions in or near the suprahepatic IVC represents a true challenge due to the 
impossibility of using conventional resection techniques. Furthermore, optimal peri-
operative anaesthetic management is crucial in this setting, and the anaesthesia team 
should be familiar with the hepatic transplant procedure.  
The involvement of the inferior vena cava does not necessarily preclude resection (Figure 5). 
Liver resection with reconstruction of the IVC can be performed in selected cases. The resected 
IVC may then be replaced with an autogenous vein graft or a prosthetic material. The 
mortality rate of resection IVC is 4.5-25% and morbidity up to 40% (Azoulay et al. 2005). The 
increased risk associated with the procedure appears to be balanced by the possible benefits, 
particularly when the lack of alternative approaches is considered (Hemming et al. 2004).  
In conclusion, liver resections, due to the adoption of several advanced techniques, such as 
vascular exclusion, veno-venous bypass, hypothermic perfusion of the liver (in-situ, ante-
situ or ex-situ), have become more common and, when IVC is involved, resection of the vein 
is no longer considered a contraindication. 
 
Fig. 5. Huge liver metastasis in a 64 year old patient with colon cancer. First surgery was an 
extended right hepatectomy plus Sg 1 segmentectomy, after PVE of right and Sg 4 portal 
veins. A left hemicolectomy was performed 7 weeks later. 
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6. Repeat resections 
The first large series of liver resections for secondary tumours was reported in 1978 (Foster 
1978). By improvement in surgical techniques, peri-operative patient’s care and management 
of complications, the morbidity and mortality associated with liver resection were reduced. 
This has been a very important factor to increase the aggressiveness of the surgical approach.  
 
Fig. 6. LiverMet database, with permission. 
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Liver recurrence of CRC is common (Figure 6) but only 5-27% of the patients are candidates 
for potentially curative repeated hepatectomy. About 70% of recurrences will be observed 
within the first 12 months after resection and 92% will be apparent within 24 months 
(Langenhoff et al. 2009). In medically fit patients, repeat hepatectomy has emerged as a safe 
and effective procedure under the same criteria of selection of the first hepatectomy. 
Although the prognostic variables provide rough indicators of prognosis, they should not be 
used as absolute contraindications to surgery. The multidisciplinary team should plan the 
strategy individually. Each new re-hepatectomy needs a particular and specific evaluation: 
disease-free interval, number of metastases, quality of life, general health condition, 
resectable extrahepatic disease, assessment of residual liver volume, etc. by the 
multidisciplinary team (Figure 7). 
 
 
Fig. 7. A 63 year old patient with right hepatectomy plus Sg 4a resection; 24 months later a 
recurrence involving the only hepatic vein (left hepatic vein) appeared. Tumour was 
removed and the left hepatic vein was reimplanted in the caval vein using graft prosthesis 
(less than 60 minutes of total vascular exclusion). 
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The LiverMet Survey includes 12448 liver resections of which 14.5% are repeated 
hepatectomies (Figure 8, Table 2). Patients likely to benefit of this approach represent a 
small and highly selected group. Maybe, an accurate genetic, immunohistochemical and 
histological profile of the patient’s tumour will be able to conclude who will benefit from 
this aggressive treatment.          
 
Fig. 8. LiverMet Survey: number of hepatectomies. 
 
Repeat hepatectomies Patients % over initial resection 3-years SV 5-years SV 
LiverMetsurvey (2011) 1794 15 58 37 
Adam et al. (2003)  199 32 54 35 
Fernandez - Trigo et al. (1995) 170 No reported  28 
Petrowsky et al. (2002) 126 8 51 34 
Nordlinger et al. (1994) 116 6 33  
Ishiguro et al. (2006) 111 No reported 74 41 
Thelen et al. (2007) 94 12 55 38 
Yamamoto et al. (1999) 75 21 48 31 
Shaw et al. (2006) 66 9 68 44 
Adam et al. (1997)  64 26 60 41 
Yan, et al. (2007) 55 14  49 
Nishio et al. (2007) 54 10 53 46 
Table 2. Repeat hepatectomies series and survival rates. 
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Recurrence after repeat hepatectomy has been reported in 60–80% of patients (Smith & 
McCall 2009). A few have resectable disease limited to the liver and may be candidates for a 
third or even fourth hepatic resection. In our group there are two patients with five 
hepatectomies. Reports of large repeated hepatectomy series show that 9-30% of patients 
who underwent a second hepatectomy for colorectal liver metastases had a third resection 
(Fong et al 1999; Söreide et al. 2008; Yamamoto et al. 1999; Petrowsky et al. 2002) and 4% of 
them had a fourth resection (Adam et al. 2003; Yamamoto et al. 1999). The safety of multiple 
repeated hepatic resections has been demonstrated in recent reports, and long-term 
survivors have been documented (Adam et al. 2003; Nordlinger et al, 1994; Yamamoto et al. 
1999; Petroswsky et al. 2002). LiverMet Survey published the largest series (n = 251) of third 
hepatectomies for recurrent CRC liver metastases with a survival benefit of 29% at 5 years. 
Adam et al. published a large series of patients who underwent a third liver resection with 
zero mortality and a morbidity rate of 5%, not significantly different from those who have 
had only one or two liver resections. In addition, patients with a third liver resection had a 
survival benefit of 32–38% at 5 years (Adam et al. 2003; Yamamoto et al. 1999). Major 
hepatectomy is possible in a minority of these patients, who represent a small and highly 
selected group (Petrowsky et al. 2002). 
7. Inmunohistochemical markers based on tissue microarrays 
The ideal marker predictor of outcome should include the following characteristics: of low 
cost and easy measure, reproducibility across institutions, and measurable both before 
and after treatment. Most importantly, this factor would predict major differences in 
outcome that significantly impact treatment. A clinical example is K-ras status as a 
predictor of response to therapy with cetuximab, a monoclonal antibody against the 
EGFR. In a prospective randomized controlled trial, patients with advanced CRC were 
randomized to receive treatment with or without cetuximab. When stratified for K-ras 
status, patients with wild type K-ras tumours demonstrated a significant survival 
advantage compared to those with mutated K-ras tumours, who derived no benefit from 
the agent. Therefore, patients with mutated K-ras do not receive cetuximab therapy and 
are spared the toxicity associated with a treatment with no proven benefit. To date, there 
is no specific clinical risk score or biomarker that specifically prognosticates or guides 
therapy for patients with resectable CRC liver metastases to this degree. This marker may 
combine the immunohistochemical markers of cell proliferation and cell cycle control, p53 
and Ki67. 
Surface antigen CD133 is a cell membrane glycoprotein that is considered as a cell surface 
marker expressed in stem cells of hematopoietic immature cells, but not in mature blood 
cells. CD133 has also been shown to be a marker of immature neuronal stem cells (Karoui et 
al. 2006). Two antibodies, CD133/1 or AC133 and CD133/2 (AC141), recognize it. CD133+ 
cells in colon cancer are helpful markers for detection of tumour initiating cells (Karoui et al. 
2006) (Figure 9). 
CD44 is considered as a cell membrane marker or epithelial cell adhesion molecule 
(EpCAM). Its phenotype EpCAMhigh-CD44+ is becoming established as a good marker for 
immature stem cells of human colon mucosa in certain series (Ieta et al. 2008) (Figure 10).  
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hepatectomies for recurrent CRC liver metastases with a survival benefit of 29% at 5 years. 
Adam et al. published a large series of patients who underwent a third liver resection with 
zero mortality and a morbidity rate of 5%, not significantly different from those who have 
had only one or two liver resections. In addition, patients with a third liver resection had a 
survival benefit of 32–38% at 5 years (Adam et al. 2003; Yamamoto et al. 1999). Major 
hepatectomy is possible in a minority of these patients, who represent a small and highly 
selected group (Petrowsky et al. 2002). 
7. Inmunohistochemical markers based on tissue microarrays 
The ideal marker predictor of outcome should include the following characteristics: of low 
cost and easy measure, reproducibility across institutions, and measurable both before 
and after treatment. Most importantly, this factor would predict major differences in 
outcome that significantly impact treatment. A clinical example is K-ras status as a 
predictor of response to therapy with cetuximab, a monoclonal antibody against the 
EGFR. In a prospective randomized controlled trial, patients with advanced CRC were 
randomized to receive treatment with or without cetuximab. When stratified for K-ras 
status, patients with wild type K-ras tumours demonstrated a significant survival 
advantage compared to those with mutated K-ras tumours, who derived no benefit from 
the agent. Therefore, patients with mutated K-ras do not receive cetuximab therapy and 
are spared the toxicity associated with a treatment with no proven benefit. To date, there 
is no specific clinical risk score or biomarker that specifically prognosticates or guides 
therapy for patients with resectable CRC liver metastases to this degree. This marker may 
combine the immunohistochemical markers of cell proliferation and cell cycle control, p53 
and Ki67. 
Surface antigen CD133 is a cell membrane glycoprotein that is considered as a cell surface 
marker expressed in stem cells of hematopoietic immature cells, but not in mature blood 
cells. CD133 has also been shown to be a marker of immature neuronal stem cells (Karoui et 
al. 2006). Two antibodies, CD133/1 or AC133 and CD133/2 (AC141), recognize it. CD133+ 
cells in colon cancer are helpful markers for detection of tumour initiating cells (Karoui et al. 
2006) (Figure 9). 
CD44 is considered as a cell membrane marker or epithelial cell adhesion molecule 
(EpCAM). Its phenotype EpCAMhigh-CD44+ is becoming established as a good marker for 
immature stem cells of human colon mucosa in certain series (Ieta et al. 2008) (Figure 10).  
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Fig. 9. Immunohistochemical pathological study. Positive membrane staining for stem cell 
markers CD133, CS-130127, CD133 (32AT1672) in most cells of metastatic adenocarcinoma. 
Santa Cruz Biotechnology®, Inc (x100).  
 
 
Fig. 10. Immunohistochemical pathological study. Positive membrane staining for stem cell 
markers CD44, EpCAMhigh-CD44+ in most cells of metastatic adenocarcinoma. Santa Cruz 
Biotechnology®, Inc (x400).  
CD166 is considered as a marker for both cell membrane or epithelial cell adhesion molecule 
(EpCAM) and cytoplasm (Figure 11). It is a marker of mesenchymal stem cells whose role in 
carcinogenesis is not fully clear (Ieta et al. 2008). Its phenotype EpCAMhigh-CD166+ added to 
EpCAMhigh-CD44+ is starting to be considered as an additional marker of immature stem 
cells in human colon mucosa (Dalerba et al. 2007). 
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Fig. 11. Immunohistochemical pathological study. Positive membrane staining for stem cell 
markers CD166, 35264, CD166 LYO 1 mL EpCAMhigh-CD166+ in most cells of metastatic 
adenocarcinoma. Menarini Diagnostics® (x40).  
Borrego et al. (2010) analyzed, as did Kokudo et al. (2002), p53 expression. The 
immunohistochemical markers tested in their study (p53, Ki-67) were not poor prognostic 
factors, in agreement with Saw et al. (2002). By contrast, authors such as Tanaka et al. 2004 
reported that p53 or Ki-67 expression had a negative impact on survival. It should be 
noticed, however, that in Borrego-Estella et al.’s study survival was longer than 5 years in 
patients with high Ki-67 levels and in those with a high mitotic index (>10 mitosis/mm2), 
which is also another expression of the tumour proliferation index. However, no significant 
relationship was found between cell proliferation, as measured by Ki-67 and p53, whose 
changes express a loss of cell cycle control, and survival. 
For O’Brien et al. (2007), most CD133+ stem cells had a 200-fold greater oncogenic potential 
than CD133- cells for development of CRC. In addition, this subpopulation is able to 
maintain itself and to differentiate and become established again as a tumour when 
transplanted in certain solid organs of experimental animals. For Borrego-Estella et al. 
significant trends were found in their series with regard to membrane CD133 and CD166 
markers. According to O'Brien et al. and Ricci-Vitiani et al. 2007, in several CRC, CD44 was 
more determinant than CD133, because CD44 was expressed in tumour lines not expressing 
CD133.  
To compare the results of Borrego et al. with other groups is difficult since many authors 
(Fong et al. 1999; Pawlik et al. 2005) did not performed immunohistochemical studies. 
However, regarding immunohistochemical markers, more significant results were not 
achieved probably because the only technique performed was immunohistochemistry array, 
but not flow cytometry or other molecular biology techniques. 
Another interesting marker, microsatellite instability, is a measure of the inability of the 
DNA mismatch repair system to correct errors that occur during DNA replication. It is the 
alternative pathway to chromosomal instability with loss of heterozygosity in colorectal 
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carcinogenesis. Microsatellite instability has been suggested to be prognostic for survival 
and predictive for response to therapy in patients with colorectal cancer. 
In conclusion, many studies have analyzed pre-operative prognostic factors in patients 
undergoing liver resection for hepatic metastases from CRC in order to select patients for 
surgery. However, intraoperative and post-operative factors have been poorly analyzed. 
Future studies should establish post-operative prognostic factors through histological and 
immunohistochemical tests based on the tissue microarray technique.  
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1. Introduction 
Hepatic resection still remains the golden standard treatment for patients with primary and 
metastatic liver cancer and offers the best chance for cure and survival (Agrawal & Belghiti, 
2011). However the vast majority of the patients with malignant liver tumors are not 
suitable for hepatectomy due to number or distribution of the hepatic lesions relative to 
future liver remnant volume. Aiming to overcome these limitations various local tumor 
ablation techniques were developed. Among them radiofrequency ablation (RFA) gained 
popularity in the past decade and became the most used local ablation technique 
worldwide. The principles of RFA are well described and discussed elsewhere (Rhim et al, 
2001; Ahmed & Goldberg, 2004; Chen et al, 2004). In brief - needle electrode/-s and high 
frequency electric current generator are used during RFA, in order to heat and coagulate 
neoplastic tissue (Figure 1).  
 
Fig. 1. Schematic view of the RFA process with the LeVeen needle electrode. 
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A sufficient rim of healthy liver parenchyma should also be destroyed as a safety margin. 
The size and geometry of created ablation zone depends mainly on the ablation protocol, 
electrodes used, tissue impedance and proximity of large vessels. Various RFA devices and 
electrodes are present on the market (Pereira et al, 2004), and they should be carefully 
evaluated before starting a clinical RFA program. Whenever possible the RFA devices 
should be tested in animal laboratory in order to become more familiar with the chosen 
technique before its clinical application. Clinical RFA of liver tumors currently is being 
performed percutaneously or during operation. Intraoperative RFA can be performed either 
as a sole procedure or (more frequently) as an adjunct to hepatic resection in order to control 
the functionally unresectable disease in the remnant liver (Figure 2). This chapter will 
discuss the rationale and technical aspects of intraoperative RFA in the treatment of patients 
with liver tumors. 
 
Fig. 2. Follow-up computed tomografy of patients after combined RFA and right 
hepatectomy (A) or left hepatectomy (B) for colorectal liver metastases. 
2. Indications for RFA 
Before considering RFA as a treatment option it should be remembered that hepatic 
resection still remains the standard treatment for patients with malignant liver tumors and 
offers the best chance for cure and survival. The volume of the liver remnant after resection 
is the most important factor when hepatic surgery is considered in a patient with liver 
cancer. Currently any hepatic involvement by a cancer is considered resectable if during 
surgery sufficient amount of tumor-free liver parenchyma can be spared, with preserved or 
reconstructed inflow, outflow and bile drainage. Otherwise RFA alone or in combination 
with resection can be performed to control the malignant disease in the liver. 
2.1 Hepatocellular carcinoma 
HCC in patients with viral hepatitis and/or cirrhosis is the most common indication for 
RFA. The limited hepatic functional reserve of a cirrhotic patient frequently is a cause of 
functional unresectability. In these patients RFA was proven as an effective treatment 
modality as well as a useful bridge to transplantation in transplant-candidates. Compared to 
various other local treatment modalities in both randomized and non-randomized studies 
RFA is more effective in terms of less recurrence of HCC or improved safety. However 
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offers the best chance for cure and survival. The volume of the liver remnant after resection 
is the most important factor when hepatic surgery is considered in a patient with liver 
cancer. Currently any hepatic involvement by a cancer is considered resectable if during 
surgery sufficient amount of tumor-free liver parenchyma can be spared, with preserved or 
reconstructed inflow, outflow and bile drainage. Otherwise RFA alone or in combination 
with resection can be performed to control the malignant disease in the liver. 
2.1 Hepatocellular carcinoma 
HCC in patients with viral hepatitis and/or cirrhosis is the most common indication for 
RFA. The limited hepatic functional reserve of a cirrhotic patient frequently is a cause of 
functional unresectability. In these patients RFA was proven as an effective treatment 
modality as well as a useful bridge to transplantation in transplant-candidates. Compared to 
various other local treatment modalities in both randomized and non-randomized studies 
RFA is more effective in terms of less recurrence of HCC or improved safety. However 
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compared to liver resection RFA demonstrates significantly more recurrences and shorter 
time to recurrence (Sutherland et al, 2006). Important local factors, which influence the 
effectiveness of RFA of HCC, are the size and growth pattern of the tumor. For medium and 
large HCC, an infiltrating growth pattern (portal invasion, irregular margins, extranodal 
growth) is associated with higher risk of local recurrence than a noninfiltrating growth 
pattern (well-circumscribed margins or surrounded by a capsule). However some authors 
reported safe and effective, mainly intraoperative RFA of large HCC up to 8cm (Poon et al, 
2004). For small HCC the presence or absence of a capsule did not influence the risk of local 
recurrence. There is an evidence from multivariate meta-analysis that RFA approach 
(percutaneous or intraoperative) influences significantly the effectiveness of ablation for 
both primary and metastatic liver malignancies regardless of the size of the tumor (Table 1, 
Mulier et al, 2005).  
 
 Percutaneous RFA RFA by laparotomy/laparoscopy 
< 3 cm (small) 16.0 3.6 
3-5 cm (medium) 25.9 21.7 
> 5 cm (large) 60.0 50.0 
Table 1. Local recurrence rates (in %) after RFA according to the approach. 
The possibilities for more precise placement of the electrodes and for obtaining both inflow 
and outflow vascular control are among the most important factors contributing to the 
superiority of surgical RFA (Julianov et al, 2008, Julianov, 2009) (Figure 3).  
 
Fig. 3. Preoperative CT (A) and MRI (B) images of a patient with bilobar HCC. Follow-up 
CT (C) and MRI (D) five years after combined operation – RFA of a right-sided lesion which 
was adjacent to vena cava and resection of the dominant left-sided tumor, demonstrates 
control of the disease. 
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The route of application also influences the safety of the RFA. Although the morbidity is 
insignificantly higher in more invasive surgical approaches (by laparotomy/laparoscopy), 
the possibility to control complications during treatment, results in virtually no mortality 
from intraoperative RFA for both primary and metastatic liver cancer (Table 2, Mulier et al, 
2002). 
 
 percutaneous RFA RFA by laparotomy RFA by laparoscopy 
Morbidity 7.2 9.5 9.9 
Mortality 0.5 0 0 
Table 2. Morbidity and mortality rates (in %) after RFA according to the approach. 
Short- and intermediate-term survival rates after RFA for small HCC are as high as 100% 
and 98% for 1- and 2-years, with corresponding local recurrence-free rates of 98% and 96% 
respectively (Lencioni et al, 2003). However with time progression and for medium- and 
large-sized HCC the results worsened sharply. Except from the lower complete ablation 
rates obtained in larger lesions, this situation is explained by the frequent presence of 
microscopic satellite tumor nodules in HCC. In small HCC microscopic tumor extends more 
than 1 cm beyond visible tumor borders in 60% of patients. In larger lesions this microscopic 
extension is more than 2 cm in 67% (Lai et al, 1993). It is important to note also that even in 
early HCC < 2 cm microscopic portal vein invasion is present in 25% of lesions (Kojiro, 
2002). According to the above data it is reasonable to recommend RFA with at least 1.5 cm 
security ablation margin for small HCC and with ≥2.5 cm margin for larger lesions, with 
concomitant inflow- and/or outflow control during ablation. In cases with bilobar/multiple 
tumors RFA can be recommended as an adjunct to surgical resection or as an alternative 
treatment option if the disease is deemed inoperable at laparotomy/laparoscopy. RFA can 
be a valuable treatment option for patients with unresectable HCC up to 8 cm. Surgical 
approach offers significantly better local control rates compared with percutaneous RFA 
independent of tumor size. Thus percutaneous RFA should be reserved for patients who 
refuse or cannot tolerate surgery.  
2.2 Liver metastases 
The liver is a common site for metastases from almost all solid malignancies. Hepatic 
resection is the standard treatment for liver metastases from various primary sites. However 
curative resection is frequently precluded by insufficient volume of the planned future liver 
remnant. Hepatectomy is not useful also in patients in poor general condition or in those 
who refuse liver resection. In these circumstances RFA was intensely explored as a 
treatment option for metastatic liver disease in unresectable cases. Currently RFA is used for 
treatment of unresectable liver metastases from different primaries including colorectal, 
neuroendocrine, sarcoma, breast etc. (Livraghi et al, 2003; Pawlik et al, 2006; Sutherland et 
al, 2006). Almost all of the published clinical data show that RFA can improve survival in 
patients with metastatic liver cancer compared with chemotherapy alone.  In our study in 
130 patients, RFA as an adjunct to surgical resection significantly improves both the local 
control and survival rate in primary and metastatic liver cancer (Julianov, 2009).  However 
there is no a randomized controlled trial comparing RFA with liver resection for metastatic 
liver disease. For many reasons such a trial does not seem ethical to be conducted in a near 
Liver Tumors 178 
The route of application also influences the safety of the RFA. Although the morbidity is 
insignificantly higher in more invasive surgical approaches (by laparotomy/laparoscopy), 
the possibility to control complications during treatment, results in virtually no mortality 
from intraoperative RFA for both primary and metastatic liver cancer (Table 2, Mulier et al, 
2002). 
 
 percutaneous RFA RFA by laparotomy RFA by laparoscopy 
Morbidity 7.2 9.5 9.9 
Mortality 0.5 0 0 
Table 2. Morbidity and mortality rates (in %) after RFA according to the approach. 
Short- and intermediate-term survival rates after RFA for small HCC are as high as 100% 
and 98% for 1- and 2-years, with corresponding local recurrence-free rates of 98% and 96% 
respectively (Lencioni et al, 2003). However with time progression and for medium- and 
large-sized HCC the results worsened sharply. Except from the lower complete ablation 
rates obtained in larger lesions, this situation is explained by the frequent presence of 
microscopic satellite tumor nodules in HCC. In small HCC microscopic tumor extends more 
than 1 cm beyond visible tumor borders in 60% of patients. In larger lesions this microscopic 
extension is more than 2 cm in 67% (Lai et al, 1993). It is important to note also that even in 
early HCC < 2 cm microscopic portal vein invasion is present in 25% of lesions (Kojiro, 
2002). According to the above data it is reasonable to recommend RFA with at least 1.5 cm 
security ablation margin for small HCC and with ≥2.5 cm margin for larger lesions, with 
concomitant inflow- and/or outflow control during ablation. In cases with bilobar/multiple 
tumors RFA can be recommended as an adjunct to surgical resection or as an alternative 
treatment option if the disease is deemed inoperable at laparotomy/laparoscopy. RFA can 
be a valuable treatment option for patients with unresectable HCC up to 8 cm. Surgical 
approach offers significantly better local control rates compared with percutaneous RFA 
independent of tumor size. Thus percutaneous RFA should be reserved for patients who 
refuse or cannot tolerate surgery.  
2.2 Liver metastases 
The liver is a common site for metastases from almost all solid malignancies. Hepatic 
resection is the standard treatment for liver metastases from various primary sites. However 
curative resection is frequently precluded by insufficient volume of the planned future liver 
remnant. Hepatectomy is not useful also in patients in poor general condition or in those 
who refuse liver resection. In these circumstances RFA was intensely explored as a 
treatment option for metastatic liver disease in unresectable cases. Currently RFA is used for 
treatment of unresectable liver metastases from different primaries including colorectal, 
neuroendocrine, sarcoma, breast etc. (Livraghi et al, 2003; Pawlik et al, 2006; Sutherland et 
al, 2006). Almost all of the published clinical data show that RFA can improve survival in 
patients with metastatic liver cancer compared with chemotherapy alone.  In our study in 
130 patients, RFA as an adjunct to surgical resection significantly improves both the local 
control and survival rate in primary and metastatic liver cancer (Julianov, 2009).  However 
there is no a randomized controlled trial comparing RFA with liver resection for metastatic 
liver disease. For many reasons such a trial does not seem ethical to be conducted in a near 
Expanding Local Control Rate in Liver Cancer Surgery – The Value of Radiofrequency Ablation 179 
future (Julianov & Karashmalakov, 2011). It is clear that RFA still cannot replace hepatic 
resection in the treatment of the liver metastases. For example - incomplete necrosis rates 
after percutaneous RFA for colorectal liver metastases reach 40% even in the treatment of 
small lesions <3 cm by most experienced hands (Livraghi et al., 2003). Moreover, the MD 
Anderson Cancer Center group reports stressing and still poorly explained data: no 5-year 
disease-free survivors in the RFA-treated group of 30 patients with solitary colorectal liver 
metastasis, even among patients with lesions < 3 cm. The comparison with the results of the 
liver resection in the same report clearly demonstrates that resection determines the 
outcome—5-year overall- and disease-free survival 27% and 0% for RFA versus 71% and 
50% for resection, respectively (Aloia et al, 2006). Regarding the route of application of RFA 
(percutaneous or surgical) there is evidence that short-term benefits of lower invasiveness of 
percutaneous RFA for liver tumors do not outweigh the longer-term higher risk of local 
recurrence. As mentioned above – surgical RFA results in superior local control, 
independent of tumor size, and percutaneous RFA should be reserved for patients who 
cannot tolerate laparoscopy or laparotomy (Mulier et al, 2005).  
3. Technique of intraoperative RFA 
3.1 General considerations 
Irrespective whether RFA is planned or not, any operation for liver tumor begins with 
through exploration of abdominal cavity for presence of previously unrecognized 
extrahepatic disease. Exploration of the liver with intraoperative ultrasound (IOUS) is a key 
step of the operation. All of the current imaging studies, including PET-CT, have well 
known limits to detect small hepatic and extrahepatic lesions compared with intraoperative 
staging, which includes IOUS. The latter fact ultimately adds unpredictable bias in 
estimating “new” lesions in any study of percutaneous RFA of liver metastases (Elias et al, 
2005). In our study, as in many others IOUS demonstrates significantly higher sensitivity 
compared with other diagnostic methods for detection of hepatic lesions (Table 3; Julianov, 
2008). More than 90% of the missed lesions are < 1cm and frequently had subcapsular 
location. 
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Table 3. Sensitivity of different diagnostic methods for detection of hepatic tumors. 
Resectable extrahepatic disease is not longer considered as a contraindication for liver 
surgery. However in most cases the presence of unresectable extrahepatic disease is a 
contraindication for a liver-directed procedure. Currently the exception from this rule can be 
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made for some patients with peritoneal carcinomatosis, if cytoreductive surgery plus 
intraperitoneal chemotherapy can be performed simultaneously with the liver-directed 
surgical treatment. In every case any attempt should be made initially for R0 resection even 
as a staged procedure. Survival rates following two-step hepatectomy for liver metastases 
still are better than those of combined RFA+liver resection procedures. RFA is 
recommended in some cases before portal vein embolisation to control small centrally 
placed lesion in the planned future liver remnant. When R0 hepatectomy deemed 
impossible RFA+resection can be considered. The aim of the procedure is to resect as much 
as possible of the lesions, treating smaller and centrally placed ones with RFA in order to 
preserve sufficient amount of residual healthy liver. However in patients with unresectable 
recurrence after liver resection, in high-risk patients with severe comorbidities or in those 
refusing hepatic resection RFA is a treatment option as a sole procedure (Figure 4).  
 
Fig. 4. Follow-up CT after intraoperative RFA of recurrent colorectal liver metastases after 
previous resection (A),  and of colorectal metastases in a high-risk patient (B)  . 
In selected patients with synchronous bilobar metastases and resectable extrahepatic disease 
simultaneous RFA plus liver and extrahepatic resection can be safely performed (Julianov et 
al, 2004, 2006). A substantial survival advantage can be expected in patients in whom local 
control is achieved with RFA/RFA+resection, compared with those patients treated with 
chemotherapy only. In our study of patients with liver metastases there were no 2-year 
survivors between patients deemed unresectable at operation and further treated with 
chemotherapy only. For comparison - the 3-year survival rate for patients treated with liver 
resection alone was 71% vs. 34% for those treated with combined RFA+resection or RFA 
alone. However the mean number of liver metastases was 2.5 in the resection group vs. 5 in 
the combined treatment group (Julianov, 2009). 
3.2 Technique of intraoperative RFA in different situations 
When performing intraoperative RFA some principal rules should be followed. IOUS 
guidance is mandatory for proper positioning of the RFA probe. A free-hand puncture 
technique usually allows more freedom to manipulate when compared to the puncture 
through guide, attached to the US-transducer. Mobilization of the liver is not mandatory but 
is sometimes necessary in order to achieve more comfortable positioning of the RFA 
electrode, to isolate the liver from adjacent organs/structures in order to protect them from 
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thermal injury, or for the purposes of outflow vascular control. The most deep and closest to 
the major vessel part of the lesion is treated first, to eliminate further cooling effect (“heat 
sink”) of the blood flow on ablation process. During RFA we always apply Pringle-
maneuver, starting at 5 minutes after beginning of each ablation cycle till its end. Finally the 
probe is cauterized before removing it from the liver, in order to minimize the risk of 
needle-tract seeding of viable tumor cells. 
RFA near major blood vessels. Proximity of a major vessel was identified as an independent 
limiting factor for successful hepatic RFA (Mulier et al, 2005). In animal experiments with 
RFA a rim of viable tissue has been always observed around the large vessels >5mm (Lu et 
al, 2002). Thus vascular control becomes important adjunct to RFA procedure, when tumors 
near major vessels are treated in both normal and cirrhotic livers (Rossi et al, 2000; De Baere 
et al, 2002; Washburn et al, 2003). Pringle-maneuver is sufficient vascular control technique 
for lesions located near inflow vessels. However inflow occlusion does not eliminate the 
“heat sink” when the tumor located near major hepatic vein is treated. In this situation the 
backflow cooling from the hepatic vein can be simply controlled by finding with IOUS the 
respective vein confluence to the inferior vena cava, and compressing the vein with the 
transducer until its lumen disappears on IOUS-screen (Julianov, 2008, 2009). Even the 
lesions adjacent to the vena cava can be successfully treated if proper vascular control 
techniques are used during RFA (Julianov et al, 2008; Figure 3). 
RFA near hilar bile ducts. RFA for a lesion near the hepatic hilum is considered dangerous 
because of the high risk from thermal injury and subsequent stricture of hilar bile ducts. 
However successful and safe RFA of a hepatic tumor near the hepatic hilum can be 
performed (Figure 5).  
 
Fig. 5. Computed tomography of a patient with liver metastasis from gastrointestinal 
stromal tumor (A). RFA with cooling of bile ducts was performed (B). 
For this purpose the left and right main duct should be protected. One option is to place the 
stents in both ducts through ERCP. Another option proven in both experimental and clinical 
setting is to cool the bile ducts during ablation. Our preferred option is to cool the biliary tree 
by perfusion of cold 5% isotonic glucose solution in the bile ducts using catheters inserted 
through small incision of the common bile duct, as proposed by D. Elias (Elias et al, 2001). 
Large-volume RFA. For large lesions, more than a single positioning of the RFA probe is 
frequently necessary to control the tumor with appropriate safety margin. In such cases it is 
important to plan the whole RFA procedure with all positions of the electrode before 
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starting the ablation. RFA causes changes in the coagulated liver parenchyma, which will 
affect further proper positioning of the probe under US-guidance (Figure 6). The geometry 
of overlapping ablations can vary widely, and they should be planned with respect of the 
size of the target lesion. A well-designed protocol for RFA of larger lesions should be used 
in order to ensure high success rate of complete ablation (Chen et al, 2004). 
 
Fig. 6. IOUS images. Isoechoic liver metastasis with hypoechoic rim before treatment (A). 
The lesion is punctured with the LeVeen needle electrode and ablation started (B). The RFA 
cycle is finished (C). 
To date the physiologic response of large-volume RFA (Figure 7), has not reported to be 
different from the more limited “usual” ablation volumes in clinical practice. However the 
safety limit of clinical RFA of the liver remains unknown. 
 
Fig. 7. Computed tomography of a patient with colorectal liver metastases before (A) and 
one week after large-volume RFA (B). Posttreatment follow-up CT of a patient two weeks 
(C) and 6 months (D) after large volume RFA.  
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In animal model of RFA a 40% of the liver volume is ablated without mortality in healthy 
livers whereas in cirrhotic liver up to 20% can be ablated safely, without significant systemic 
inflammatory response (Ng et al, 2006). It is not clear whether these data are applicable in 
clinical setting. In our experience, the posttreatment course of patients with even very large 
volumes of hepatic RFA does not show any specific difference from more “usual” cases. 
3.3 Complications after RFA 
The postoperative care after RFA does not require specific treatment, irrespective whether 
RFA is performed as a sole procedure or simultaneously with various hepatic and/or 
extrahepatic resections. However the possibility of a potential life-threatening complication 
after RFA should always be kept in mind (Figure 8).  
 
Fig. 8. Computed tomography of a patient after simultaneously performed bowel and liver 
resection plus RFA. Hepatic abscesses occurred at resection- and RFA sites (arrows). 
Although RFA of the liver is a well-tolerated and safe procedure, complications and rarely 
death may occur after RFA-treatment. The most common complications after RFA of the 
liver are bleeding, abscessus and biloma formation and they sometimes may be fatal (Enne 
et al, 2003). The life-threatening complications from the thermal injury of organs adjacent to 
the liver were reported mainly for percutaneous RFA. Surgical approaches permit 
protection and isolation of endangered organs from inadvertent burn injury during hepatic 
RFA. In patients with cirrhosis, delayed portal vein thrombosis can occur after RFA near the 
main portal vein branches. Rare complication as a gas gangrene after RFA was also reported 
(Kvitting et al, 2006). Any complication after hepatic RFA require immediate treatment and 
when necessary interventions (surgical or image-guided) should be regarded as life saving 
and performed without delay. This approach permits avoiding mortality even in most 
critical situations (Julianov, 2008)   
4. Conclusions 
The two crucial questions must be always addressed when considering RFA as a treatment 
option in a patient with primary or metastatic liver cancer: 1. Whether RFA is equal in 
curability to surgical resection for resectable malignant liver tumor, and 2. What additional 
survival benefit does RFA has over modern systemic therapies in the treatment of 
unresectable disease? The long-term results from clinical studies to date showed 
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significantly better survival obtained from surgical resection for all types of resectable 
malignant liver tumors. Thus RFA cannot be regarded as an equally effective alternative of 
liver resection. On the other hand, if compared with systemic treatment alone there is 
enough clinical data to demonstrate that when local control is achieved by RFA it offers 
survival advantage (and even cure) for patients with unresectable disease. Unfortunately 
these facts are frequently misinterpreted and lead to misuse or abuse with RFA. In a survey 
from Germany 25.9% of patients undergoing RFA had a resectable tumor (Birth et al, 2004). 
This is partly because of the public pressure on physicians to refer their patients for 
minimally invasive treatment, rather than for major surgery, becomes heavier today. As a 
consequence many radiologists and gastroenterologists start to treat with percutaneous RFA 
patients with resectable tumors. On the other hand, surgeons that have no experience with 
hepatic surgery start to perform RFA as an alternative to resection in resectable cases, rather 
than referring these patients to the experienced liver surgeon. As the philosopher Abraham 
Maslow once said, “If the only tool you have is a hammer, then you tend to see every 
problem as a nail.” However, when RFA is properly used in patients with primary and 
metastatic liver cancer its clinical benefits in terms of prolonged survival and even cure are 
indisputed. Today the RFA-device clearly is a necessary tool in the armamentarium of a 
liver surgeon. 
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Primary liver cancer is the fifth most common cancer worldwide and the third most 
common cause of cancer mortality. More than 500 000 new cases are currently diagnosed 
yearly, with an age-adjusted worldwide incidence of 5.5–14.9 per 100 000 population (Jemal 
et al., 2011). Doxorubicin remains the first line of treatment for liver cancer ever since its 
discovery in 1971 (Yoshikawa & Kitaoka, 1971). Unfortunately, clinical effectiveness of this 
class of drugs is limited by cumulative cardiotoxicity which occurs in significant percentage 
of patients at cumulative dose in the range 450-600 mg/m2 (Ganz et al., 1993).  Therefore, 
various strategies have been developed to reduce cardiotoxicity of doxorubicin and its 
analogues (Haley & Frenkel, 2008). Commercialized doxorubicin has high cytotoxicity, good 
solubility and high affinity to nuclear (Viale & Yamamoto, 2008). There is no need to 
improve its ability to penetrate cell membrane and accumulation into cell nuclear. The aim 
of delivery techniques is to alter its in vivo distribution, enhance its deposition in the liver 
tumor sites and reduce its cardiotoxicity. Formulations of doxorubicin should have the 
ability to specifically release the drug in response to the tumor micro-environment. 
Doxorubicin can insert in the double strand of DNA and preferentially bind to double-
stranded 5’-GC-3’ or 5’-CG-3’ to form tightly coupled complex without chemical bond 
links (Vicent, 2007). Once the DNA was digested, the doxorubicin can be released. 
Cationic polymers are often used as carriers for the DNA drugs’ delivery because they can 
combine DNA to form nanoscale particles by the interaction between their positive charge 
and the negative charge on the DNA chain (Bodley et al., 1989). Upon these two aspects, 
we developed a nanoscale formulation of doxorubicin. Doxorubicin was complexed into 
polyGC double-strand DNA fragments to form the DOX-polyGC intercalation. After that, 
the DOX-polyGC intercalation was combined by a bio-degradable cationic polymer, 
cationic gelatin, to form nanoscale particles. Cationic gelatin can be effectively digested by 
gelatinase (GA) that is a mixture of two kinds of matrix metalloproteinase (MMP) highly 
expressed by the tumor tissue (Eliyahu, 2005). This makes the complex composed by 
cationic gelatin, DNA and doxorubicin (CPX1) can be specifically digested and release the 
doxorubicin in tumor sites (Figure 1). To avoid the accumulation into the liver which also 
produces gelatinase in a relatively high level (Emonard & Grimaud, 1990), a pH-sensitive 
material, histamine-modified alginate (His-alginate) was used to cover CPX1 to form 
CPX2. His-alginate has a pKa of about 6.9 which shows a cationic state when pH < 6.9 and 
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an anionic state when pH > 6.9. His-alginate combined CPX1 at physiological pH (7.2)  
via its anion interact with the cation on the surface of CPX1. In tumor micro-environment, 
the pH varied from 6.2-6.7 according to different physical states. At such a pH, His-
alginate turned it anionic state to a cationic one and dissociated from CPX2. To enhance 
the ability of CPX2 to escape from the reticuloendothelial system, PEG 2000 was 
conjugated to His-alginate to form PEG-His-alginate (PHA). The construct scheme was 
shown in Figure 1. 
 
Fig. 1. Fabrication scheme of CXP1 and CPX2. 
2. Materials and methods 
2.1 Materials synthesis  
Poly-GC and Poly-AT were synthesized by Invitrogen (Shanghai, China) with a length of 20 
bases. Cationic gelatin was synthesized by using Ethylenediamine-modification according to 
the reported methods (Matsumoto et al., 2006). The conversion rate of carboxyl groups to 
amino groups was measured by the TNBS method to characterize the product (Eklund, 1976). 
PEG-His-modified alginate was synthesized according the following methods: A total of  
500 mg of alginate (Sigma) was dissolved in 20 ml of 10 mM N,N,N’,N’-
tetramethylethylenediamine (TEMED) / HCl buffer solution (pH 4.7). A total of 1.0 g of EDC 
was added to this solution and stirred at 40 ◦C for 24 h. Then, different1.5 g histidine were 
added and stirred for another 24 h at 40 ◦C. The resulting His-alginate were dialyzed for 4 days 
against Milli Q water and lyophilized. The resulted His-alginate was examined for its pKa 
value. The following Pegylation was achieved by conjugating a 2000 Da mPEG-NH2 to the 
His-alginate using a Pegylation kit (YARE Chem, Shanghai, China). Rhodamine-labled  
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PEG-His-alginate and FITC-labled cationic gelatine was synthesized by using fluorescence-
label kits (DAZHI Biotech, Nanjing, China) injected into liver tumor bearing mice.  
2.2 Cells and animals  
Hepa 1-6 is a mouse hepatoma cell line derived from the BW7756 mouse hepatoma which 
arose in C57/L mouse (ATCC). Hepa 1-6 cells were cultured in DMEM supplemented with 
10% FCS. Female ICR mice (18-20g) of the same background were purchased from the 
experimental animal center of Nanjing Medical University. All animals received human care 
according to Chinese legal requirements. To generate the allograft model of liver cancer, 
Hepa 1-6 cells (1×107 cells/ml, 10 μl) were injected into the hepatic lobe of anesthetized mice 
using a microinjector (Cheng et al., 2011). 
2.3 Preparation of CPX1 and CPX2  
PolyGC-DOX intercalation was obtained by mixing 2 mg/ml DOX with DNA solutions with 
different concentrations to find the DOX/DNA ratio at which free DOX can insert into DNA 
chain completely. The fluorescence (exciting: 480 nm; emission: 590nm) of DOX quenched 
when inserting in the DNA. By detecting the fluorescence of DOX, the formation of the 
intercalation could be determined. CPX1 was formed by mixing PolyGC-DOX intercalation 
with cationic gelatin solution at different DNA/Gelatin weight ratio. CPX2 was obtained by 
mixing CPX1 solution with the some volume of 2mg/ml PEG-His-alginate solution by 
gently agitation for 1 hour. The physical stability of each complex was studied by agarose 
gel electrophoresis (0.8% agarose in TAE buffer). The diameters and zeta potential of the 
complex were analyzed by photon correlation spectroscopy by using 90 Plus Particle Sizer 
(Brookhaven Instruments, Holtsville, NY). The DOX fluorescence of CPX1 was also 
examined to investigate whether the combination between the intercalation and cationic 
gelatin release the DOX from DNA chain. 
2.4 Dox release from the complexes  
CPX1 and CPX2 were digested by gelatinase and Dnase I in PBS buffers with different PH 
values, and the resulted solution was examined by DOX fluorescence quantification.  
The digestion abilities of mouse plasma, the supernatant of the tumor homogenate (THS) 
and liver homogenate (LHS) on CPX1 and CPX2 were also examined. CPX1 and CPX2 
solutions were mixed with mouse plasma or the tissue homogenate supernatants for 2 
hours. After that, the mixtures were examined by quantification of the DOX fluorescence. 
To further confirm the tumor-specific drug-release ability of CPX2, in vivo experiments was 
performed. Rhodamine labeled PEG-His-alginate (PHA) and FITC-labeled cationic gelatin 
was used to form CPX2. Hoechst 33258 was used to substitute for DOX because Hoechst 
33258 also possess high DNA-affinity like DOX and it show blue fluorescence which could 
be discriminated from the red fluorescence of PHA and green fluorescence of C-gelatin. 
PolyAT was used to substitute for polyGC because Hoechst 33258 specifically binds AT in 
DNA (Jong et al., 1991). This PHA-C-gelatin-polyAT-Hoechst complex was injected into the 
tumor and liver separately. One hour later, sections of the liver and tumor was examined 
under microscope. 
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2.5 Bio-distribution of doxorubicin  
CPX1 and CPX2 solutions and free DOX solution were separately injected into liver tumor 
bearing mice via tail vain at a dose of 20 mg/kg body weight. Different organs were 
harvested from the experimental mice bearing implanted tumors. Doxorubicin in the organ 
was extracted according a reported method and quantified by the examination of its 
fluorescence intensity at 590 nm (Bigotte, 1985).  
2.6 Toxicology investigation  
Healthy mice were given CPX1, CPX2 or free DOX to examine their toxicity. CPX1, CPX2 
and DOX were intravenously injected into animals at the doses of 20 mg DOX/kg body 
weight and 30 mg DOX/kg body weight. The changes of their body weights were examined 
every day for one week. The mortality of the animals was also calculated. For histological 
examination, different tissues were harvested at the 4th day after the drugs were given and 
sectioned and analyzed by hematoxylin and eosin staining. Animal plasma activity of 
alanine transaminase (ALT) and creatine kinase (CK) were determined for the evaluation of 
the functions of livers and hearts.  
2.7 Anti-cancer activity  
Animals bearing implanted liver tumors were intravenously given CPX1, CPX2 and free 
DOX at a dose of 10 mg DOX/kg body weight every two days from day 5 after the allograft 
model establishment. All tumors were separated, weighed and sectioned for pathological 
analyze on day 21. For the calculation of survives, testing animals bearing tumors were 
divided into 4 group, 10 animals each. CPX1 and CPX2 at a dose of 10 mg DOX/kg body 
weight were given intravenously every two days with free doxorubicin and saline as 
controls.  
2.8 Statistical analysis 
Results are expressed as the mean ± standard error of the mean (S.E.M). The differences 
between groups were analyzed by Mann-Whitney U test and, if appropriate, by Kruskal-
Wallis ANOVA test. Survival curves were analyzed by the Kaplan-Meyer log-rank test. 
Changes in body weight were compared by use of the Wilcoxon matched-pair signed-rank 
test. A value of P <0.05 was considered significant. 
3. Results 
3.1 Preparation of CPX1 and CPX2 
The anthracycline class of drugs, including doxorubicin, has fluorescence properties that 
become quenched after intercalation into DNA. Fluorescence spectroscopy was used to 
examine the binding of doxorubicin to DNA and the drug encapsulation efficiency of 
CPX1 and CPX2. A series of weight ratio of DOX/polyGC was tested. DOX could be 
completely combined by polyGC at the weight ratio of 2:1. Cationic gelatin could combine 
with DOX-polyGC intercalation at a weight ratio of polyGC/C-gelatin = 1:2. In CPX1, 
weight ratio of DOX/polyGC/C-gelatin = 2:1:2. Its zeta potential was +18 mV. PEG-His-
alginate was added to the solution of CPX1 at the C-gelatin/PEG-His-alginate ratio of 1:1 
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to form CPX2. The zeta potential of CPX2 was -1.2 mV. Figure 2A show the fluorescence 
intensity of doxorubicin, DOX-polyGC, CPX1 and CPX2. Figure 2B show the particle sizes 




Fig. 2. Preparation of CPX1 and CPX2. A) Fluorescent intensity of free DOX,  
DOX-polyGC intercalation (weight ratio : DOX:polyGC = 2:1),  
CPX1 (weight ratio: C-gelatin : polyGC : DOX = 2:1:2) and  
CPX2 (weight ratio: PEG-His-alginate : C-gelatin : polyGC : DOX = 2:2:1:2) at 590nm;  
B) Size distribution of CPX2 in saline. 
3.2 DOX release from the complexes 
The most important property of the complex is to response to PH and gelatinase. PHA-C-
gelatin-polyAT-Hoechst complex was used in vivo instead of CPX2 to test the drug release 
property of CPX2 in response to tumor acidic microenvironments. Results shown in Figure 
3A demonstrated that the three kinds of fluorescence were completely overlapped in liver 
sections. In liver tumor sections, blue “drug” could be seen in a separated area from the 
green and red fluorescence.  
The ability of gelatinase and Dnase I (DA1) to free DOX from CPX1 and CPX2 in PBS 
buffers with different pH values was tested. The results in Figure 3B demonstrated that 
DOX in CPX1 could be released under both PH values of 7.2 and 6.5 while CPX2 could 
only be digested when PH was 6.5. CPX1 and CPX2 were incubated with tumor tissue 
homogenate supernatant (THS) and then were examined for the released DOX. Serum and 
normal liver tissue homogenate supernatant (LHS) was used as the control. The results 
were shown in Figure 3C and Figure 3D. DOX in CPX1 or CPX2 was not released in serum 
while THS could efficiently release free DOX from CPX1 and CPX2. LHS could only 
release free DOX from CPX1. CPX2 remained stable in LHS. Figure 3E demonstrated that 
more than 60% DOX was released from both CPX1 and CPX2 within 2 hours when 
incubated with THS. When incubated with LHS, CPX1 was also destructed and released 
DOX very quickly while CPX2 remained stable and kept the DOX from release for more 
than 20 hours.  
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Fig. 3. Release of DOX from CPX1 and CPX2. A) Tumor-specific drug release of CPX2.  
0.2 mg Hoechst 33258 contained in multi-fluorescence-labeled CPX2 (polyGC was 
substituted by polyAT) was injected into the tumor or animal liver after the animals were 
anesthetized 1 hour before the tissues were separated, sectioned and analyzed by 
microscope. B) Fluorescent intensity of CPX1 and CPX2 digested by 5 U/ml gelatinase (GA) 
and 0.5 U/ml Dnase I (DA1) in PBS buffer with PH value of 7.2 or 6.5 for 2 hours at 37 C at 
590nm; C) Fluorescent intensity of CPX1 digested by plasma, THS or LHS for 2 hours at  
37 C at 590nm; D) Fluorescent intensity of CPX2 by plasma, THS or LHS for 2 hours at  
37 C at 590nm; E) DOX release rates from the complexes in THS or LHS. In all experiments, 
the concentration of DOX contained in CPX1 and CPX2 in the solution is 0.2mg/ml. 
3.3 Bio-distribution of doxorubicin 
Free DOX, CPX1 and CPX2 were administrated into mice via tail vein at a dose of 20 mg 
DOX per kg body weight. Different tissues and organs were harvested 48 hours later. The 
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concentration of DOX in these tissues was measured. Data in Figure 4A indicated that CPX2 
efficiently enhanced the accumulation of DOX in tumor tissue and reduced the deposition of 
the drug in heart and the other organs. As a control, CPX1 not only enhanced the drug 
concentration in tumor but also in liver. The concentration of DOX delivered by CPX1 was 2 
times higher than free DOX. Figure 4B and Figure 4C described the variation of DOX 
concentrations in tumor and liver after CPX1, CPX2 or free DOX was administrated. CPX2 
dramatically increased the deposition of DOX in tumor and decreased the liver 
concentration of the drug. CPX1 could increase the concentration of DOX in both tumor and 
liver.  
 
Fig. 4. A) Bio-distribution of free DOX or delivered by CPX1 and CPX2 given i.v. at a dose of 
20 mg/kg body weight; B) DOX concentrations in tumor after free DOX, CPX1 or CPX2 
were injected i.v. at the dose of 20 mg/kg body weight; C) DOX concentrations in liver after 
free DOX, CPX1 or CPX2 were injected i.v. at the dose of 20 mg/kg body weight. 
3.4 Toxicology investigation 
Daily injection of doxorubicin exhibited serious toxicity which resulted in loss of weight, 
cardiac toxicity and death. CPX1 and CPX2 remarkably reduced the toxicity of doxorubicin, 
which caused less weight loss than free DOX (Figure 5A). 30 and 20 mg/kg body weight of 
DOX caused 100% and 60% death in 5 days. The same dose of DOX in the form of CPX1 
caused 50% and 20% death in up to 8 days while 20 mg/kg body weight DOX in the form of 
CPX2 cause no death and the extreme high dose of 30 mg/kg body weight only caused 10% 
death (Figure 5B).  
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Fig. 5. Toxicology analysis. A) Body weight changes of animals received i.v. injections of saline, 
free DOX, CPX1 or CPX2 at a dose of 20 mg/kg body weight; B) Mortality caused by free 
DOX, CPX1 or CPX2 at different doses; C) H & E stained heart, liver and lung tissue sections of 
animal treated by 20 mg/kg body weight free DOX or delivered by CPX1 and CPX2.  
Treatment with free doxorubicin caused massive myocardial degeneration (Figure 5C), 
which resulted in the increase of the plasma level of CK and LDH (Table 1) and heart failure 
which induced significant pulmonary congestion (Figure 5C). This toxicity was greatly 
reduced when DOX was delivered by CPX1 and CPX2 (Figure 5C and Table 1). CPX1 
showed more hepatotoxicity than free doxorubicin at the same dose, which resulted in the 
necrosis of hepatocytes (Figure 5C) and increase in plasma levels of ALT (Table 1) while 
CPX2 did not cause this toxicity. CPX2 also reduced the nephrotoxicity of doxorubicin 
which was demonstrated by the decrease of BUN level (Table 1).  
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 ALT (IU) AST (IU) CK (U/ml) LDH (U/l) BUN (U/l) 
Healthy mice 26.9 32.1 0.23 489.2 10.3 
Mice given DOX 29.5 29.7 1.28 562.9 12.7 
Mice given CPX1 42.3 34.1 0.26 461.3 10.9 
Mice given CPX2 28.3 30.5 0.24 462.7 10.2 
Table 1. Serological analysis of mice treated with free DOX, CPX1 and CPX2. 
3.5 Anti-cancer activity of CPX1 and CPX2 
The anti-tumor activity was evaluated in a mouse orthotopic allograft liver cancer model 
using a hepatoma cell line, Hepa 1-6. Figure 6A shows the photograph of tumors 
separated from animals 16 days after they received free DOX, CPX1, CPX2 and saline in 
vein. From the results of histological analyze of tumor sections (Figure 6B), massive 
cancer cell remissions could be observed from the sections of tumors treated with CPX1 
and CPX2. CPX2 exhibited the most efficiency on prevention of cancer cell’s expansion.  
 
Fig. 6. Anti-tumor activity. A) Representative Tumors separated from animals received 
intravenous injections of saline, free DOX, CPX1 or CPX2. B) Sections of tumor tissues taken 
from animal received intravenous injections of saline, free DOX, CPX1 or CPX2. C) Mean 
weights of tumors separated from animals received of saline, free DOX, CPX1 or CPX2 
intravenously. D) Survive rates of animals implanted tumors received treatments with saline, 
free DOX, CPX1 or CPX2 in more than 4 weeks. *p＜0.05 compared with saline treated group. 
Liver Tumors 196 
The mean weight of the tumors isolated from the liver was shown in figure 6C. CPX2 
exhibited more than 1 times higher anti-tumor activity than free DOX. Results of the 
examination of animal survive shown in Figure 6D. Animals bearing tumors and received 
saline as control died within 4 weeks. Free doxorubicin kept 30% animals from death 
within 5 weeks while CPX2 rescued 90% of them in more than 4 weeks. 
4. Discussion 
Doxorubicin, as a chemotherapy drug, has been commonly used in the treatment of 
hepatocellular carcinoma, but is thwarted by a key obstacle-cumulative cardiotoxicity. To 
improve its anti-cancer activity and reduce its toxicity, a number of doxorubicin formations 
such as pegylated liposomal doxorubicin, doxorubicin-eluting-bead has been performed in 
liver cancer clinical trials recently. Among them, anthracycline-DNA complexes as 
therapeutic reagents have been used for the treatment of liver cancer for a long history, due 
its easy-fabrication, no change in the structure of the drug molecules and its anti-cancer 
activity (Trouet, 1979a). Clinical trials were also carried out to evaluate their enhancement in 
the performances in effectiveness and toxicology compared to free anthracycline (Trouet, 
1979b). However, except a few of in vitro reports about successfully reducing the toxicity of 
the anthracycline by using the complexes, there is no convincing results demonstrating the 
advantages of using the complexes instead of free anthracycline (Dorr et al., 1991). One of 
the most important reasons underlies the ineffectiveness of the intercalation between DNA 
and anthracycline is that there is abundant Dnase in circulation and body fluids which 
digests un-protected DNA molecular with extremely high efficiency (Paik & Kim, 1970). The 
anthracycline-DNA complexes were destroyed soon after their injection into the body. The 
anthracycline in complexes was released very quickly and did not change their 
pharmaceutical properties any more.  
Protection of DNA from destroying by Dnase is necessary for gene delivery technology 
(Tranchant et al., 2004). Non-viral gene delivery practices take the advantage of using 
cationic polymers to combine DNA, which prevents the exposure of DNA molecules to 
Dnases (Wagner, 2004). DNA complexed with cationic polymers could totally resist the 
degradation of Dnase I or serum Dnases in reported in vivo and in vitro tests (Paleos et al., 
2009). These researches instruct us cationic polymers could be used to combine the 
intercalation of anthracycline-DNA to form an anthracycline-DNA-cationic polymer ternary 
complex. Such a complex can avoid the unexpected early release of anthracycline into serum 
by protecting DNA from the digestion of Dnases. In our experimets, cationic gelatin was 
used to combine DNA-DOX intercalation. This simple process generated regular 
nanocomplexes that could be observed. It is difficult to release DOX in short time using 
Dnase I alone to digest the complex, which suggested that DNA is well protected by cationic 
gelatin. Additionally, in the present study, synthesized GC oligonucleotide was used to 
substitute the natural DNA fragments, which increased the drug-loading capacity of DNA. 
Moreover, the combination between DOX and polyGC is more stable than DOX-natural 
DNA intercalation fragments which may release DOX when combined by some kind of 
cationic polymer. No DOX release was observed in the study when DOX-polyGC was 
combined by cationic gelatin. 
A lot of cationic polymers are used as gene carriers, such as polyether imide (PEI), 
polylysine (PLL), cationic polysaccharides and other polycation materials (Bodley et al., 
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1989). To ensure the sufficient release of anthracycline in tumor sites, the cationic polymer 
used to form the anthracycline-DNA-cationic polymer ternary complex must be 
biodegradable, especially in tumor. Cationic gelatin is a derivate of gelatin by conjugating 
ethylenediamine, spermine or other compounds with multiple amino groups to the 
gelatin molecules. Cationic gelatin is a proved effective DNA carrier for gene delivery in 
vitro and in vivo. It can protect DNA and even RNA from the degradation of Dnases 
(Kushibiki et al., 2003). More importantly, cationic gelatin can be easily digested by 
gelatinase (Ganea et al, 2007). Gelatinase belong to the matrix metallopeptidase (MMP) 
family. It is composed of MMP-2 and MMP-9 (Eliyahu, 2005). Recent investigations 
suggest that gelatinase is involved in the genesis, development and metastasis of most 
kinds of tumors, which is highly expressed in solid tumors (Deryugina & Quigley, 2006). 
That means cationic gelatin could be effectively digested in tumor. To address this, tumor 
homogenate supernatant was tested for its ability to digest cationic gelatin in CPX1 and 
release DOX. Compared to plasma, THS exhibited much higher efficiency of releasing the 
DOX from CPX1. This implies CPX1 can be destroyed and DOX can be released 
specifically in tumor sites. 
However, only gelatinase-response is not sufficient to enable the tumor-specific drug release 
ability of the delivery system because gelatinase is relatively high-expressed in liver 
(Emonard & Grimaud, 1990). In our experiments, CPX1 notablely enhanced the liver 
accumulation of DOX and caused serious hepatotoxicity which weakened the efficacy of the 
drug. To avoid this, a pegylated PH-responsive alginate was introduced in the system. After 
the surface of CPX1 was covered with this polymer (Formed CPX2), it could resist the 
digestion of gelatinase under physiological conditions. The environment intra tumor is acid 
which could trigger a change of the charge on the polymer from negative to a positive one, 
which resulted in the dissociation of the polymer form CPX1 and the digestion of CPX1 by 
gelatinase in the tumor. Because of the pegylation, CPX2 acquired stronger enhanced 
permeability and retention (EPR) effect that increased the distribution of the drug in tumor 
than CPX1 and greatly reduced the liver accumulation.  
Cardiotoxicity is the main drawback of anthracycline, which restraints more effective 
application of this drug to liver cancer patients (Ferreira et al., 2008). Myocardial 
degeneration is the most commonly encountered side-effects of anthracycline (Combs & 
Acosta, 1990). It can cause serious heart failure and even death (Ferrans, 1978). In our study, 
CPX2 efficiently reduced the accumulation of DOX in heart, which greatly alleviated the 
cardiotoxicity of DOX. It completely rescued animals from death caused by high doses of 
DOX. Additionally, controlled-release and tumor site specifically release of DOX also eased 
the acute toxicity-induced loss of body weight.  
5. Conclusion 
In our present study, a PH-/enzyme responsive complex composed by self-assemble of 
doxorubicin, CpG DNA fragments, cationic gelatin and a PH-sensitive alginate was 
developed. This complex increased the accumulation of doxorubicin in tumor, reduced its 
deposition in heart and could specifically release doxorubicin in tumor sites, which resulted 
in the enhanced anti-cancer activity and decreased cardiotoxicity of doxorubicin. When 
tested in animal model of implanted tumor, the complex exhibited high effective in 
preventing the growth of the tumors and dramatically alleviated toxicity compared to free 
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doxorubicin. All results suggest that this easy- manufactured, cost-effective nanoscale 
formulation of doxorubicin hold great promise to be used to clinical practices.  
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